

CITATION REPORT

List of articles citing

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

DOI: 10.1158/1078-0432.ccr-04-0220

Clinical Cancer Research, 2004, 10, 5367-74.

Source: <https://exaly.com/paper-pdf/37308103/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2283	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. 2011 , 121, 2750		11
2282	A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high-risk features and poor outcome. 2010 , 4, 167		0
2281	p16 expression correlates with basal-like triple-negative breast carcinoma. 2013 , 7, 317		9
2280	Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?. 2011 , 5, 217		1
2279	Growth and molecular interactions of the anti-EGFR antibody Cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: New prospects in the treatment of triple-negative/basal-like breast cancer. 1992 , 33, 1165		3
2278	EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. 1994 , 21, 413		4
2277	An early peak of relapse after surgery for breast cancer. 2004 , 6, 255-7		5
2276	KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. 2005 , 13, 205-20		372
2275	Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. 2005 , 24, 147-52		53
2274	p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. 2005 , 47, 458-66		77
2273	The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. 2005 , 18, 1305-20		125
2272	Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. 2005 , 18, 1321-8		153
2271	KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. 2005 , 18, 1623-31		121
2270	TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. 2005 , 18, 1641-8		35
2269	High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells. 2005 , 115, 403-11		44
2268	p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. 2005 , 447, 688-94		177
2267	Myoepithelial cells in the control of mammary development and tumorigenesis: data from genetically modified mice. 2005 , 10, 211-9		30

2266	Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. 2005 , 93, 237-46	92
2265	The current understanding of the molecular determinants of inflammatory breast cancer metastasis. 2005 , 22, 615-20	14
2264	The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?. 2005 , 206, 451-7	175
2263	Squamous cell carcinoma of the breast. 2005 , 23, 7827-35	127
2262	A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. 2005 , 12, 1059-69	35
2261	Breast cancer gene expression profiling: clinical trial and practice implications. 2005 , 6, 49-58	10
2260	Prognostic relevance of basal cytokeratin expression in operable breast cancer. 2005 , 69, 478-85	83
2259	Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 4003-11	12.9 143
2258	Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. 2005 , 23, 7350-60	696
2257	Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. <i>Clinical Cancer Research</i> , 2005 , 11, 8006-14	12.9 255
2256	Molecular prediction of tamoxifen resistance in breast cancer. 2005 , 7, 1	78
2255	Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. 2005 , 7, R1028-35	116
2254	Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. 2005 , 7, 143-8	191
2253	Genomic analysis of human breast cancer in families and populations. 2005 , 7, 1	78
2252	Dynamic imaging of plasticity and escape in tumor cell invasion. 2005 , 7, 1	78
2251	Comparative genomic hybridization using oligonucleotide arrays and total genomic DNA. 2005 , 7, 1	78
2250	Hypoxia promotes invasion and metastasis of breast cancer cells by increasing lysyl oxidase expression. 2005 , 7, 1	1
2249	Brn-3b transcription factor in breast tumorigenesis: regulation of genes associated with growth and migration of cancer cells. 2005 , 7, 1	78

2248	Mammary development fate and breast cancer risk. 2005, 7, 1	78
2247	Molecular profiling of early breast cancer in relation to detection of micrometastases and outcome. 2005, 7, 1	1
2246	Real-time PCR-based expression profiling of BRCA1-induced genes in primary breast tumors. 2005, 7, 1	78
2245	Breast tumors induced by high-dose radiation display similar genetic profiles. 2005, 7, 1	78
2244	Stromal and epithelial TGF- β signaling in mammary tumorigenesis. 2005, 7, 1	78
2243	The extracellular matrix composition and responsiveness to breast carcinoma therapy. 2005, 7, 1	78
2242	Determining the factors affecting breast cancer infectivity by oncolytic adenovirus. 2005, 7, 1	78
2241	HER2 and ER α downregulate estrogen-responsive element-mediated transcription activity of ER β -positive cells in response to estrogen stimulation. 2005, 7, 1	1
2240	Establishment and characterization of two breast cancer xenografts in immunodeficient mice for studies on hormone-dependent and hormone-independent tumor growth, progression and invasion. 2005, 7, 1	2
2239	Functional genomic approaches to breast cancer. 2005, 7, 1	78
2238	Cell differentiation and dominant signaling pathway signatures in the molecular classification of human breast cancer cell lines. 2005, 7, 1	3
2237	Potential mechanisms whereby estrogens induce breast cancer in women. 2005, 7, 1	1
2236	Potentiated phospho-protein networks in cancer cells. 2005, 7, 1	1
2235	Identification of molecular apocrine breast tumours by microarray analysis. 2005, 7, 1	8
2234	Identification of novel sequence alterations and the functional analysis of the BRCA1 promoter/5'-UTR in families from Upper Silesia, Poland. 2005, 7, 1	78
2233	Comparison of the expression profile in breast cancer and ovarian cancer. 2005, 7, 1	1
2232	Targeting estrogen to kill ER-positive and ER-negative breast cancer. 2005, 7, 1	78
2231	High-throughput experimental verification of predicted tissue-specific and tumor-specific splice isoforms. 2005, 7, 1	78

2230	The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. 2005, 7, 1	0
2229	Cigarette smoking and breast cancer risk among non-drinking women. 2005, 7, 1	78
2228	Screening for germline rearrangements in BRCA1 and BRCA2 in Norwegian families with breast or breast/ovarian cancer. 2005, 7, 1	78
2227	Genome-wide expression profiling of microdissected human breast tumor cells: tumor classification predictive of metastases and clinical outcome. 2005, 7, 1	78
2226	Gene expression profiling in breast cancer challenges the existence of intermediate histological grade. 2005, 7, 1	78
2225	Molecular approaches to understanding pregnancy-induced protection against breast cancer. 2005, 7, 1	78
2224	Cooperation between extracellular signaling and intracellular Ras activation leads to immortalization and epithelial-to-mesenchymal transition of variant human mammary epithelial cells. 2005, 7, 1	78
2223	Immortalization-associated gene signature in breast cancer. 2005, 7, 1	78
2222	Genetic determinants of breast cancer characteristics and outcome in women under 50 years of age. 2005, 7, 1	78
2221	Identification of differentially expressed genes in canine mammary tumor cell lines using a newly developed canine-specific cDNA microarray. 2005, 7, 1	78
2220	Genetic and epigenetic changes in early carcinogenesis. 2005, 7, 1	78
2219	Biological features and xenograft models of a very early human premalignant breast lesion. 2005, 7, 1	78
2218	Myoepithelial cell layer disruption and human breast cancer invasion. 2005, 7, 1	1
2217	HER2 upregulates fatty acid synthase and acetyl-CoA carboxylase at a translational level in breast cancer cells. 2005, 7, 1	78
2216	Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy. 2005, 7, 1	78
2215	Chromosomal imbalances mapped by array-based comparative genomic hybridization in an integrated approach to combat breast cancer in Denmark. 2005, 7, 1	1
2214	DNA copy number changes in breast cancer samples using array-CGH profiling. 2005, 7, 1	78
2213	Genomic and transcriptional events associated with poor clinical responses to conventional therapies. 2005, 7, 1	78

2212	Expression profiling of peripheral blood cells for early detection. 2005, 7, 1	78
2211	HIN-1, an inhibitor of cell growth, invasion, and AKT1 activation. 2005, 7, 1	78
2210	Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2. 2005, 7, 1	78
2209	Mapping the location of recurring amplicons in array-CGH data. 2005, 7, 1	78
2208	Predicting survival from gene expression data by generalized partial least squares regression. 2005, 7, 1	2
2207	Large-scale single nucleotide polymorphism analysis of candidates for low-penetrance breast cancer genes. 2005, 7, 1	1
2206	Molecular distinctions among ERBB2-overexpressing breast cancers. 2005, 7, 1	78
2205	In vitro models for tumor protein d52 function in cancer cells. 2005, 7, 1	78
2204	Protein expression and gene amplification of primary cyclins (A, B1, D1, D3and E) and secondary cyclins (C and H) in relation to prognosis in breast cancer patients. 2005, 7, 1	0
2203	TP53 mutations among molecular subtypes of HER2-positive tumors. 2005, 7, 1	78
2202	Comparison of methods for pharmacogenomics: SNaPshot, SNPstream UHT, Nanogen, and RFLP. 2005, 7, 1	78
2201	Targeting the cell cycle for prognosis and therapy of breast cancer. 2005, 7, 1	78
2200	Expression profiling as a prognostic and predictive factor in breast cancer. 2005, 7, 1	78
2199	Lack of evidence for nuclear IGFBP5 in mammary epithelial cells. 2005, 7, 1	78
2198	Expression of wild-type and mutated TP53in breast carcinomas. 2005, 7, 1	78
2197	Cancer gene mutation discovery and detection using array-based resequencing. 2005, 7, 1	78
2196	The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. 2005, 7, 1	78
2195	High-resolution representational oligonucleotide microarray analysis and fluorescence in situ hybridization analysis of aneuploid and diploid breast tumors. 2005, 7, 1	78

2194	A single nucleotide polymorphism in the HDM-2 gene regulates the p53 apoptotic response and influences the age of onset of cancers in humans: the SNP 309 HDM-2 polymorphism. 2005, 7, 1	78
2193	Microcell-mediated transfer of chromosome 6 into the breast cancer cell line MDA-MB-231: a specific set of genes is involved in the reversion of the tumorigenic phenotype. 2005, 7, 1	78
2192	Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer. 2005, 7, 1	78
2191	Detection of minimal disease in breast cancer. 2005, 7, 1	78
2190	Association of NCOA3 (AIB1) polymorphisms with breast cancer risk. 2005, 7, 1	1
2189	A critical need for molecular markers of breast cancer risk and risk reduction. 2005, 7, 1	78
2188	TP53 and additional pathways in therapy resistance. 2005, 7, 1	78
2187	Hypermethylation of cyclin D2 and DAP kinase is associated with the lobular subtype of breast cancer. 2005, 7, 1	78
2186	Development of a rapid screening approach for candidate gene sets in cancer. 2005, 7, 1	78
2185	Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy. 2005, 7, 1	78
2184	High-density screening of the Zbtb7 gene in breast cancer patients. 2005, 7, 1	1
2183	Effects of oestrogen on gene expression in the epithelium and stroma of the normal human breast. 2005, 7, 1	78
2182	Role of HER2 in local relapse and metastasis. 2005, 7, 1	78
2181	Development of CDK inhibitors as cancer therapeutics. 2005, 7, 1	1
2180	Expression profiling of Wnt pathway genes in breast cancer. 2005, 7, 1	78
2179	Gene expression studies in radiation-sensitive cell lines. 2005, 7, 1	78
2178	Breast tumors induce the recruitment of AC133+KDR+ endothelial precursor cells mobilized by plasma vascular endothelial growth factor. 2005, 7, 1	2
2177	Identification of drug targets for the treatment of Basal-like tumors. 2005, 7, 1	1

2176	BRCA1 directly modulates gene expression required for estrogen biosynthesis: a possible mechanism of tissue-specific tumor suppression. 2005, 7, 1	78
2175	The search for low-penetrance breast cancer genes. 2005, 7, 1	2
2174	Molecular characterization of breast cell lines: a tool for breast cancer studies. 2005, 7, 1	78
2173	SNPS in putative regulatory loci controlling gene expression in cancer. 2005, 7, 1	78
2172	Characterization of extracellular matrix composition in breast carcinoma. 2005, 7, 1	78
2171	The anti-estrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF7 breast cancer cells refractory to long-term estrogen deprivation through downregulation of ER and IGF signalling. 2005, 7, 1	78
2170	Proteomic approaches to early detection of breast cancer. 2005, 7, 1	78
2169	Reproducibility of molecular portraits in early stage breast cancer. 2005, 7, 1	78
2168	Gene expression signature of hereditary breast cancer. 2005, 7, 1	78
2167	ATM mutations associated with breast cancer. 2005, 7, 1	78
2166	The future of breast cancer prevention. 2005, 7, 1	78
2165	A model of the BRCA1/BRCA2 network. 2005, 7, 1	78
2164	The interaction of the ER with ERBB2 and PI3K results in elevated levels of AKT and p90RSK in tamoxifen-resistant MCF-7 cells. 2005, 7, 1	4
2163	Gene expression profiling to identify parity-induced changes in the human mammary gland. 2005, 7, 1	1
2162	Envisioning new targets and new approaches for molecular-based cancer therapeutics. 2005, 7, 1	78
2161	High prevalence of a BRCA1 gene founder mutation, 5083del19, in unselected breast/ovarian cancer patients from Southern Italy: genotype/phenotype correlations. 2005, 7, 1	2
2160	Lymph node metastases display gene expression profiles of their primary breast carcinomas. 2005, 7, 1	78
2159	Comparative expressed sequence hybridisation revealed distinct chromosomal regions of differential gene expression in breast cancer subtypes. 2005, 7, 1	78

2158	ER α in normal and malignant breast. 2005, 7, 1	78
2157	RNA integrity number: towards standardization of RNA quality assessment for better reproducibility and reliability of gene expression experiments. 2005, 7, 1	1
2156	Essential functions of the Janus kinase 2 (Jak2) during mammary gland development and tumorigenesis. 2005, 7, 1	78
2155	Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families. 2005, 7, 1	78
2154	Promoter composition predicts gene classes in microarray expression analyses of breast cancer. 2005, 7, 1	78
2153	Predicting response/resistance to endocrine therapy for breast cancer. 2005, 7, 1	78
2152	The role of the tumor microenvironment in breast cancer progression. 2005, 7, 1	78
2151	Ex vivo isolation of adult stem cells from normal and tumour mouse mammary parenchyma. 2005, 7, 1	78
2150	6-(1-oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone exerts anti-angiogenic activity via inhibition of vascular endothelial cell growth factor and hypoxia-inducible factor 1 alpha in hypoxia-exposed MCF breast cancer cells. 2005, 7, 1	78
2149	Low-dose ionizing radiation significantly increases the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study (IBCCS). 2005, 7, 1	78
2148	Discovering genetic profiles by array-CGH in familial breast tumors. 2005, 7, 1	78
2147	A breast cancer progression model: the importance of three-dimensional tissue architecture and metalloproteinases. 2005, 7, 1	1
2146	Regulation of epithelial cell polarity during carcinogenesis. 2005, 7, 1	1
2145	Imprint as a reliable diagnostic tool in breast cancer and possible usefulness for research purposes. 2005, 7, 1	78
2144	Altered signaling in anti-estrogen-resistant human breast cancer cells. 2005, 7, 1	78
2143	Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). 2005, 7, 1	78
2142	Morphogenesis of the mammary gland and the role of keratin expression. 2005, 7, 1	78
2141	Outcome signature genes in breast cancer: is there a unique set?. 2005, 7, 1	5

2140	Quality control of DNA with on-chip electrophoresis for oligonucleotide-array comparative genomic hybridization. 2005, 7, 1	78
2139	DNA polymorphisms of several genes and predisposition to breast cancer. 2005, 7, 1	1
2138	Stem cells in human breast development and cancer. 2005, 7, 1	78
2137	Expression of STAT1 target genes and interferon gamma in human mammary carcinoma tissue. 2005, 7, 1	78
2136	Who gets cancer?. 2005, 7, 1	78
2135	Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer. 2005, 7, 1	1
2134	Chromosome-wide pharmacogenetics: localisation and linkage disequilibrium of genes coding for ROS metabolism and signalling. 2005, 7, 1	78
2133	Insulin-like growth factor regulation of mammary gland development and tumorigenesis. 2005, 7, 1	78
2132	Tailored therapies based upon tumor subtype biology. 2005, 7, 1	78
2131	Functional characterization of genes involved in the development of breast cancer. 2005, 7, 1	78
2130	IL-8 is a novel marker for breast cancer. 2005, 7, 1	1
2129	Mutant p53 exerts its gain of function through activation of the NF- κ B pathway. 2005, 7, 1	78
2128	Evaluation of the arrayed primer extension resequencing assay for TP53mutation detection. 2005, 7, 1	78
2127	Genetic polymorphisms in the 5' flanking region of glutathione S-transferase P1 affect promoter methylation. 2005, 7, 1	78
2126	Apoptotic chemotherapies. 2005, 7, 1	78
2125	Genomic profiling of breast cancer. 2005, 7, 1	78
2124	Deletions at the chromosome 3 common eliminated region 1 on 3p21.3 in human breast tumors. 2005, 7, 1	78
2123	Identification of clinically relevant gene sets and pathways using functional models of breast tumor suppression. 2005, 7, 1	78

2122	Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients. 2005 , 7, 1	78
2121	Detection of circulating cancer cells in peripheral blood as a prognostic factor in early breast cancer. 2005 , 7, 1	78
2120	Alpha-1 antitrypsin genotypes in breast cancer patients. 2005 , 7, 1	2
2119	ZBTB7 HapMap in a worldwide population study. 2005 , 7, 1	1
2118	Evading p53 action during tumor development and therapy. 2005 , 7, 1	78
2117	Epigenetic silencing of tropomyosin alters transforming growth factor beta control of cell invasion and metastasis. 2005 , 7, 1	78
2116	Postoperative serum proteomic profiles and identification of biomarkers with prognosis value in high-risk early breast cancer patients. 2005 , 7, 1	78
2115	Polymorphisms in the CRK gene and their association with breast cancer risk. 2005 , 7, 1	78
2114	Gene expression profiling in whole-blood samples from postmenopausal women exposed to hormone replacement therapy. 2005 , 7, 1	78
2113	Targeting new therapies in combination with hormonal therapies for ER-positive breast cancer. 2005 , 7, 1	78
2112	Methylation profiling of carcinogenesis-associated genes in sporadic breast cancer. 2005 , 7, 1	78
2111	Application of microarray analyses to identify genes involved in radiation-induced fibrosis. 2005 , 7, 1	1
2110	Dissection of molecular pathways of cancer by high-throughput biochip technologies and RNA interference. 2005 , 7, 1	1
2109	Subclassification and molecular characterization of early stage breast carcinomas using Applied Biosystems Human Genome Survey Microarrays. 2005 , 7, 1	1
2108	DNA damage response pathways in cancer causation and treatment. 2005 , 7, 1	78
2107	Magnetic resonance spectroscopy of breast cancer tissue used for tumor classification and lymph node prediction. 2005 , 7, 1	1
2106	Sex-hormone binding globulin receptor-mediated growth inhibition in breast cancer cells: a proteomics approach. 2005 , 7, 1	78
2105	Hereditary breast cancer spectrum of pathogenic mutations and unknown variants of BRCA1 and BRCA2 genes in the Czech Republic: efficiency of testing and clinical follow-up. 2005 , 7, 1	78

2104	Genes, genomes, and cancer. 2005 , 7, 1		78
2103	Abstract withdrawn. 2005 , 7, 1		78
2102	Abstract withdrawn. 2005 , 7, 1		78
2101	The challenges in translating present knowledge of the molecular biology of breast cancer into clinical use. 2005 , 7, 1		0
2100	Update on HER2-directed therapy. 2005 , 7, 1		1
2099	International Agency for Research on Cancer workshop on 'Expression array analyses in breast cancer taxonomy'. 2006 , 8, 303		6
2098	Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. 2006 , 8, R56		103
2097	Genetics of soft tissue tumors. 2006 , 1, 435-66		28
2096	Cancer du sein. 2006 ,		
2095	RefSeq refinements of UniGene-based gene matching improve the correlation of expression measurements between two microarray platforms. 2006 , 5, 89-98		5
2094	Proteomics of breast cancer: principles and potential clinical applications. 2006 , 5, 1772-86		58
2093	MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling. 2006 , 169, 362-71		37
2092	Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. <i>Clinical Cancer Research</i> , 2006 , 12, 1533-9	12.9	282
2091	Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. 2006 , 24, 5652-7		824
2090	Metaplastic Breast Carcinomas: Are They of Myoepithelial Differentiation? Immunohistochemical Profile of the Sarcomatoid Subtype Using Novel Myoepithelial Markers. 2006 , 16, 359		
2089	CD44 Expression is Associated With Increased Survival in Node-Negative Invasive Breast Carcinoma. 2006 , 16, 359		
2088	Lobulitis is a Frequent Finding in Prophylactically Removed Breast Tissue From Women at Hereditary High Risk of Breast Cancer. 2006 , 16, 359-360		
2087	Significance, detection and markers of disseminated breast cancer cells. 2006 , 13, 1033-67		221

2086	The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. 2006 , 94, 1703-9		67
2085	Metaplastic breast cancer: clinical significance. 2006 , 191, 657-64		116
2084	Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. 2006 , 42, 3149-56		164
2083	Deconstructing the molecular portrait of basal-like breast cancer. 2006 , 12, 537-44		119
2082	C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu. 2006 , 37, 205-11		24
2081	Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. 2006 , 37, 1217-26		259
2080	Isolation of mouse mammary epithelial progenitor cells with basal characteristics from the Comma-Dbeta cell line. 2006 , 293, 414-25		70
2079	The canonical Notch/RBP-J signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. 2006 , 293, 565-80		117
2078	Carcinosarcoma of the Breast. 2006 , 218-229		1
2077	Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. <i>American Journal of Surgical Pathology</i> , 2006 , 30, 1097-104	6.7	206
2076	Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. 2006 , 208, 495-506		248
2075	EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. 2006 , 209, 445-53		203
2074	Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. 2006 , 210, 420-30		61
2073	Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. 2006 , 49, 22-34		257
2072	Metaplastic breast carcinomas are basal-like tumours. 2006 , 49, 10-21		244
2071	Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma. 2006 , 49, 248-55		15
2070	Cytokeratin profiles of male breast cancers. 2006 , 49, 365-70		20
2069	Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. 2006 , 95, 1334-41		53

2068	Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. 2006 , 19, 264-71	806
2067	Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. 2006 , 19, 307-19	75
2066	Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. 2006 , 19, 617-21	175
2065	Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. 2006 , 19, 999-1009	127
2064	Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. 2006 , 19, 1506-11	103
2063	Basal-like breast cancer and the BRCA1 phenotype. 2006 , 25, 5846-53	368
2062	Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. 2006 , 23, 1951-8	10
2061	Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. 2006 , 95, 243-55	90
2060	Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. 2006 , 99, 85-90	111
2059	Systemische Chemotherapie beim metastasierten Mammakarzinom. 2006 , 12, 683-698	
2058	Hétérogénéité moléculaire des cancers du sein: quelles implications pour la sélection des patientes en vue d'une chimiothérapie adjuvante?. 2006 , 8, 235-242	
2057	A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. 2006 , 10, 515-27	2386
2056	Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer. 2006 , 7, 141-5	12
2055	Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. 2006 , 209, 645-52	106
2054	Co-regulation of B-Myb expression by E2F1 and EGF receptor. 2006 , 45, 10-7	135
2053	Classification of breast cancer using genetic algorithms and tissue microarrays. <i>Clinical Cancer Research</i> , 2006 , 12, 6459-68	12.9 88
2052	Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. 2007 , 60, 1006-12	78
2051	Genome-scale identification of membrane-associated human mRNAs. 2006 , 2, e11	76

2050	Basal-like breast carcinomas: clinical outcome and response to chemotherapy. 2006 , 59, 729-35	213
2049	The impact of expression profiling on prognostic and predictive testing in breast cancer. 2006 , 59, 225-31	93
2048	Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. 2006 , 5, 2572-9	67
2047	The epidermal growth factor family has a dual role in deciding the fate of cancer cells. 2006 , 66, 623-30	10
2046	Steroid hormone receptor status of mouse mammary stem cells. 2006 , 98, 1011-4	244
2045	The expression of p63 and cytokeratin 5 in mixed tumors of the canine mammary gland provides new insights into the histogenesis of these neoplasms. 2006 , 43, 424-9	38
2044	Biphasic metaplastic sarcomatoid carcinoma of the breast. 2006 , 17, 605-13	138
2043	Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. 2006 , 66, 4872-9	129
2042	Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 4185-91	12.9 88
2041	Demystifying basal-like breast carcinomas. 2007 , 60, 1328-32	41
2040	Breast cancer heterogeneity: a mixture of at least two main types?. 2006 , 98, 948-51	90
2039	Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. 2006 , 24, 3039-47	150
2038	MYC amplification in breast cancer: a chromogenic in situ hybridisation study. 2007 , 60, 1017-23	50
2037	Application of visualization tools to the analysis of histopathological data enhances biological insight and interpretation. 2006 , 34, 921-8	28
2036	Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. 2006 , 95, 616-26	106
2035	Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. 2006 , 3, 621-32	100
2034	Breast cancer in African-American women: differences in tumor biology from European-American women. 2006 , 66, 8327-30	142
2033	Vascular Endothelial Growth Factor Expression in the Basal Subtype of Breast Carcinoma. 2006 , 125, 512-518	35

2032	The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. 2007 , 67, 10230-40		68
2031	NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. 2007 , 97, 659-69		70
2030	PLD1 is overexpressed in an ER-negative MCF-7 cell line variant and a subset of phospho-Akt-negative breast carcinomas. 2007 , 97, 809-17		39
2029	Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer. 2007 , 103-120		
2028	Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. 2008 , 61, 327-32		87
2027	Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. 2007 , 18, 1477-83		66
2026	Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. 2007 , 4, e90		132
2025	Cancer du sein. 2007 ,		2
2024	p63, cell adhesion and survival. 2007 , 6, 255-61		38
2023	Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins. <i>Clinical Cancer Research</i> , 2007 , 13, 3164-73	12.9	83
2022	Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. 2007 , 11, 1287-98		23
2021	Gene-expression analysis and the basal-like breast cancer subtype. 2007 , 3, 55-63		29
2020	Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. 2007 , 6, 1973-82		71
2019	Differences in risk factors for breast cancer molecular subtypes in a population-based study. 2007 , 16, 439-43		349
2018	What can breast cancer molecular sub-classification add to conventional diagnostic tools?. 2007 , 18 Suppl 9, ix33-6		4
2017	BRCA1, a potential predictive biomarker in the treatment of breast cancer. 2007 , 12, 142-50		125
2016	EGFR and Src are involved in indole-3-carbinol-induced death and cell cycle arrest of human breast cancer cells. 2007 , 28, 435-45		44
2015	Breast Cancer. 2007 ,		

2014	Radiation effects on development of HER2-positive breast carcinomas. <i>Clinical Cancer Research</i> , 2007 , 13, 46-51	12.9	58
2013	HER-2/neu overexpression in invasive ductal breast cancer: An association with other prognostic and predictive factors. 2007 , 15, 15-18		2
2012	A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. 2007 , 67, 11732-41		108
2011	The phenotypic spectrum of basal-like breast cancers: a critical appraisal. 2007 , 14, 358-73		64
2010	Use of immunohistochemistry in diagnosis of breast epithelial lesions. 2007 , 14, 93-107		36
2009	Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. 2007 , 14, 419-30		97
2008	Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study. <i>American Journal of Surgical Pathology</i> , 2007 , 31, 501-8	6.7	53
2007	Basal-Like Breast Cancers. 2007 , 12, 143-153		7
2006	The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas. 2007 , 67, 6574-81		115
2005	Use and assessment of diagnostic and predictive markers in breast pathology. 2007 , 13, 126-134		2
2004	Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. 2007 , 143, 109-18		113
2003	Identification of a basal-like subtype of breast ductal carcinoma in situ. 2007 , 38, 197-204		166
2002	Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. 2007 , 38, 830-41		131
2001	Chromogenic and fluorescent in situ hybridization in breast cancer. 2007 , 38, 1105-22		77
2000	A perspective on DNA microarrays in pathology research and practice. 2007 , 171, 375-85		42
1999	The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. <i>Clinical Cancer Research</i> , 2007 , 13, 2329-34	12.9	1534
1998	Triple-negative breast cancer: therapeutic options. 2007 , 8, 235-44		664
1997	Classification moléculaire des cancers du sein: vers une classification prédictive. 2007 , 297-305		

1996	Immunohistochemical markers as predictive tools for breast cancer. 2008 , 61, 689-96	45
1995	Are triple-negative tumours and basal-like breast cancer synonymous?. 2007 , 9, 404; author reply 405	83
1994	Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. 2007 , 9, R61	112
1993	Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. 2007 , 9, R65	454
1992	Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis. 2007 , 9, R29	59
1991	Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. 2007 , 9, R24	130
1990	FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. 2007 , 9, R23	211
1989	Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. 2007 , 9, R16	101
1988	Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. 2007 , 9, R4	230
1987	Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. 2007 , 8, R76	880
1986	Transcriptomic signatures in breast cancer. 2007 , 3, 466-72	9
1985	Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management. 2007 , 7, 269-80	11
1984	American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. 2007 , 25, 5287-312	1760
1983	Triple-negative breast cancer: clinical features and patterns of recurrence. <i>Clinical Cancer Research</i> , 2007 , 13, 4429-34	12.9 2961
1982	Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia. 2007 , 1, 97-119	29
1981	Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. <i>Clinical Cancer Research</i> , 2007 , 13, 90-101	12.9 180
1980	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. 2007 , 7, 34-42	115
1979	[Towards an integrated cellular and molecular: definition of breast cancers]. 2007 , 23, 626-32	1

1978	BRCA1 germline mutation in a woman with metaplastic squamous cell breast cancer. 2007 , 30, 316-8	10
1977	Moesin expression is a marker of basal breast carcinomas. 2007 , 121, 1779-85	63
1976	Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. 2007 , 109, 1721-8	1505
1975	Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. 2007 , 110, 1687-96	73
1974	Malignant adenomyoepithelioma of the breast with matrix production may be compatible with one variant form of matrix-producing carcinoma: a case report. 2007 , 203, 599-604	14
1973	c-KIT expression in columnar cell lesions of the breast accompanied by benign and malignant breast diseases. 2007 , 203, 765-9	6
1972	A mouse model of basal-like breast carcinoma with metaplastic elements. 2007 , 211, 389-98	118
1971	BRCA1 dysfunction in sporadic basal-like breast cancer. 2007 , 26, 2126-32	466
1970	Triple negative tumours: a critical review. 2008 , 52, 108-18	640
1969	Expression profiling technology: its contribution to our understanding of breast cancer. 2008 , 52, 67-81	34
1968	Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. 2007 , 7, 791-9	365
1967	Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers. 2007 , 20, 208-14	116
1966	Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. 2007 , 20, 474-81	179
1965	Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer. 2007 , 20, 864-70	118
1964	Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). 2007 , 20, 1200-7	64
1963	Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAx families. 2007 , 20, 1298-306	44
1962	Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. 2007 , 50, 434-8	132
1961	Evaluation of oestrogen receptor expression in breast cancer by quantification of mRNA. 2007 , 51, 829-36	14

1960	Predictive markers in breast cancer--the future. 2008 , 52, 91-8	21
1959	Increased phosphorylation of Akt in triple-negative breast cancers. 2007 , 98, 1889-92	53
1958	Frequency of the basal-like phenotype in African breast cancer. 2007 , 115, 1391-9	33
1957	Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 2007 , 7, 841-9	12
1956	Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. 2007 , 7, 134	284
1955	A new molecular breast cancer subclass defined from a large scale real-time quantitative RT-PCR study. 2007 , 7, 39	14
1954	Nectin-4 is a new histological and serological tumor associated marker for breast cancer. 2007 , 7, 73	102
1953	EGFR associated expression profiles vary with breast tumor subtype. 2007 , 8, 258	208
1952	The evolution of targeted biologic therapies. 2007 , 16 Suppl 2, S1-3	
1951	The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. 2007 , 16 Suppl 2, S72-7	86
1950	Cytokeratin KRT8/18 expression differentiates distinct subtypes of grade 3 invasive ductal carcinoma of the breast. 2007 , 178, 94-103	14
1949	Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. 2007 , 11, 981-1011	175
1948	Treatment of hereditary breast cancer. 2007 , 34, 384-91	12
1947	Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. 2007 , 14, 2994-3003	36
1946	Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. 2007 , 64, 3219-32	20
1945	Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. 2007 , 106, 181-9	94
1944	P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. 2007 , 450, 73-80	62
1943	The emerging picture of the mouse mammary stem cell. 2007 , 3, 114-23	34

1942 New multitargeted treatments with antiangiogenic and antitumor activity: focus on sunitinib. **2007**, 2, 17-29

1941 Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines. **2008**, 107, 303

9

1940 Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women. **2008**, 107, 405-14

24

1939 Epidemiology of basal-like breast cancer. **2008**, 109, 123-39

651

1938 Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. **2008**, 110, 245-56

57

1937 Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. **2008**, 111, 27-44

257

1936 alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. **2008**, 111, 411-7

57

1935 New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. **2008**, 112, 453-9

29

1934 Immunohistochemical profiles of brain metastases from breast cancer. **2008**, 90, 223-8

29

1933 Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. **2008**, 62, 667-72

74

1932 [Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?]. **2008**, 29 Suppl 2, 363-9

1931 [Aquaporin 1 expression in invasive breast carcinomas]. **2008**, 29 Suppl 2, 357-62

11

1930 Analysis of the clinicopathologic features and prognosis in triple-negative breast cancer. **2008**, 5, 387-390

1929 Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. **2008**, 15, 153-8

29

1928 Is triple negative a prognostic factor in breast cancer?. **2008**, 15, 303-8

80

1927 "New" molecular taxonomy in breast cancer. **2008**, 10, 777-85

13

1926 Basal-like subtype and BRCA1 dysfunction in breast cancers. **2008**, 13, 395-400

29

1925 Cancer du sein mElastatique. **2008**, 10, 136-148

1

1924	Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. 2008 , 453, 123-32		111
1923	The ubiquitin E3 ligase activity of BRCA1 and its biological functions. 2008 , 3, 1		78
1922	The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. 2008 , 214, 25-37		138
1921	Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. 2008 , 215, 398-410		116
1920	Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. 2008 , 97, 30-4		36
1919	Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. 2008 , 113, 1521-6		102
1918	Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?. 2008 , 113, 2422-30		137
1917	Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. 2008 , 113, 2638-45		438
1916	How basal are triple-negative breast cancers?. 2008 , 123, 236-40		336
1915	DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. 2008 , 47, 490-9		79
1914	A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 67, 80-92	7	46
1913	Tissue microarrays: emerging standard for biomarker validation. 2008 , 19, 19-25		52
1912	'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials. 2008 , 20, 35-9		33
1911	Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. 2008 , 70, 35-42		45
1910	Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. 2008 , 72, 1056-63		33
1909	Molecular diagnosis in breast cancer. 2008 , 14, 202-213		8
1908	Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. 2008 , 116, 515-25		27
1907	Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. 2008 , 21, 1413-20		3

1906	Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). 2008 , 21, 1060-1; author reply 1061-2	10
1905	Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters. 2008 , 21, 1183-91	37
1904	Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. 2008 , 99, 327-34	122
1903	An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. 2008 , 40, 499-507	1885
1902	Increased expression of osteopontin in patients with triple-negative breast cancer. 2008 , 38, 438-46	43
1901	Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. 2008 , 52, 370-80	35
1900	Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa. 2008 , 52, 445-56	58
1899	[Immunohistochemical characterisation of breast cancer: towards a new classification?]. 2008 , 84, 138-45	2
1898	The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis. 2008 , 8, 268	45
1897	Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. 2008 , 8, 28	28
1896	The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. 2008 , 8, 307	92
1895	Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. 2008 , 8, 309	56
1894	A resampling-based meta-analysis for detection of differential gene expression in breast cancer. 2008 , 8, 396	14
1893	CD109 expression in basal-like breast carcinoma. 2008 , 58, 288-94	43
1892	Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. 2008 , 8, 249-56	118
1891	Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. 2008 , 8 Suppl 4, S171-8	13
1890	The prognostic importance of triple negative breast carcinoma. 2008 , 17, 341-6	81
1889	Optimizing the management of advanced breast cancer in the AsiaPacific region: Role of clinical trials and treatment guidelines. 2008 , 4, S24-S29	3

1888	Challenging patient populations in breast cancer: Taxane resistance and triple-negative receptor subtype. 2008 , 4, S40-S48	
1887	Tissue microarrays in clinical oncology. 2008 , 18, 89-97	92
1886	Molecular subtypes in breast cancer evaluation and management: divide and conquer. 2008 , 26, 1-10	150
1885	High throughput molecular diagnostics in bladder cancer - on the brink of clinical utility. 2008 , 1, 384-94	13
1884	Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities. 2008 , 8, 215-23	24
1883	Differences and molecular immunohistochemical parameters in the subtypes of infiltrating ductal breast cancer. 2008 , 130, 414-24	28
1882	Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. 2008 , 10, R101	168
1881	A functional Notch-survivin gene signature in basal breast cancer. 2008 , 10, R97	91
1880	Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. 2008 , 10, R99	103
1879	Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. 2008 , 10, R85	88
1878	Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. 2008 , 10, R89	93
1877	Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. 2008 , 10, R67	230
1876	The CD44+/CD24- phenotype is enriched in basal-like breast tumors. 2008 , 10, R53	408
1875	Prognostic ability of a panel of immunohistochemistry markers - retailoring of an 'old solution'. 2008 , 10, 102	14
1874	The molecular pathology of hereditary breast cancer. 2008 , 75, 85-94	64
1873	Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery. 2008 , 4, 271-87	24
1872	Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. 2008 , 39, 167-74	59
1871	Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast. 2008 , 39, 386-92	53

1870	The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?. 2008 , 39, 331-6	25
1869	Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?. 2008 , 39, 506-13	46
1868	Expression of BRCA1 protein in breast cancer and its prognostic significance. 2008 , 39, 857-65	115
1867	The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. 2008 , 39, 1431-7	41
1866	Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. 2008 , 39, 1809-15	54
1865	Basal cytokeratin expression in relation to biological factors in breast cancer. 2008 , 39, 1744-50	15
1864	Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women. 2008 , 195, 153-8	30
1863	AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. 2008 , 12, 33-40	55
1862	What is triple-negative breast cancer?. 2008 , 44, 2799-805	230
1861	Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis. 2008 , 141, 147-52	10
1860	Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer. 2008 , 34, 701-9	18
1859	Expression of apoptosis-related protein Bcl-2 correlates with breast carcinomas of luminal or basal-like subtype. 2008 , 1, 113-119	2
1858	Basal carcinoma of the breast revisited: an old entity with new interpretations. 2008 , 61, 553-60	89
1857	Basal-like breast cancer: a critical review. 2008 , 26, 2568-81	657
1856	EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. 2008 , 8, 417-34	76
1855	Development of therapeutic approaches to 'triple negative' phenotype breast cancer. 2008 , 12, 1123-37	16
1854	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. <i>Clinical Cancer Research</i> , 2008 , 14, 1368-76	12.9 917
1853	Breast carcinoma with basal phenotype: mammographic findings. 2008 , 191, 346-51	36

1852	Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. 2008 , 26, 671-9	14
1851	CK5 is more sensitive than CK5/6 in identifying the "basal-like" phenotype of breast carcinoma. 2008 , 130, 724-30	35
1850	Gene expression profiling of breast cancer. 2008 , 3, 67-97	56
1849	Triple-negative breast cancer: risk factors to potential targets. <i>Clinical Cancer Research</i> , 2008 , 14, 8010-812.9	336
1848	Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. 2008 , 19, 1561-5	50
1847	An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes. 2008 , 29, 1475-82	43
1846	Morphological and immunophenotypic analysis of basal-like carcinoma of the breast. 2008 , 1, 19-27	2
1845	Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. 2008 , 19, 465-72	80
1844	Commercialized multigene predictors of clinical outcome for breast cancer. 2008 , 13, 477-93	210
1843	Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. 2008 , 68, 989-97	823
1842	p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. 2008 , 19, 1261-1265	49
1841	Is 'basal-like' carcinoma of the breast a distinct clinicopathological entity? A critical review with cautionary notes. 2008 , 75, 119-31	32
1840	Research issues affecting preoperative systemic therapy for operable breast cancer. 2008 , 26, 806-13	54
1839	Breast cancer in young women: a new color or a different shade of pink?. 2008 , 26, 3303-5	6
1838	Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. 2008 , 36, e13	59
1837	Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. 2008 , 68, 2122-31	42
1836	Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. 2008 , 19, 1713-9	70
1835	Analysis of integrin beta4 expression in human breast cancer: association with basal-like tumors and prognostic significance. <i>Clinical Cancer Research</i> , 2008 , 14, 1050-8	12.9 91

1834	Identifying breast cancer druggable oncogenic alterations: lessons learned and future targeted options. <i>Clinical Cancer Research</i> , 2008 , 14, 961-70	12.9	36
1833	MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. 2008 , 19, 669-74		39
1832	Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. 2008 , 61, 615-20		73
1831	Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. 2008 , 19, 315-20		28
1830	Nestin is expressed in basal-like and triple negative breast cancers. 2008 , 61, 1045-50		51
1829	Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. <i>Clinical Cancer Research</i> , 2008 , 14, 1938-46	12.9	173
1828	Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. 2008 , 7, 944-51		57
1827	A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 7878-83	12.9	95
1826	Clinicopathologic and prognostic characteristics of triple-negative breast cancer. 2008 , 31, 610-4		23
1825	Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort. <i>Clinical Cancer Research</i> , 2008 , 14, 4168-74	12.9	35
1824	Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. 2008 , 17, 2078-86		86
1823	Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. <i>Clinical Cancer Research</i> , 2008 , 14, 1956-65	12.9	130
1822	High levels of expression of cytokeratin 5 are strongly correlated with poor survival in higher grades of mucoepidermoid carcinoma. 2008 , 61, 837-40		7
1821	Advances in breast cancer: pathways to personalized medicine. <i>Clinical Cancer Research</i> , 2008 , 14, 7988-99.9		134
1820	Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. <i>Clinical Cancer Research</i> , 2008 , 14, 370-8	12.9	230
1819	Are triple-negative and basal-like breast cancer synonymous?. <i>Clinical Cancer Research</i> , 2008 , 14, 618; author reply 618-9	12.9	42
1818	Impact of basal-like breast carcinoma determination for a more specific therapy. 2008 , 75, 95-103		25
1817	Clinical and pathologic aspects of basal-like breast cancers. 2008 , 5, 149-59		71

1816	Micropapillary carcinoma of the breast with necrosis-like cell death: a case report. 2008 , 32, 153-9			1
1815	Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. 2008 , 26, 2373-8			632
1814	Evaluation of morphologic features to identify "basal-like phenotype" on core needle biopsies of breast. 2008 , 16, 411-6			13
1813	Triple negative breast cancer: current understanding of biology and treatment options. 2008 , 20, 40-6			50
1812	Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 544-52	6.7		85
1811	Triple-negative breast cancer. 2008 , 20, 614-20			53
1810	Diagnostic, Theranostic, and Genomic Immunohistochemistry: Standardization Issues. 2008 , 15, 302-304			1
1809	Therapeutic strategies for triple-negative breast cancer. 2008 , 14, 343-51			58
1808	Treatment and survival outcome for molecular breast cancer subtypes in black women. 2008 , 247, 463-9			34
1807	Immunohistochemical Analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR Antigen Expression in Medullary Breast Cancer. 2008 , 94, 838-844			16
1806	Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status. 2008 ,			2
1805	[Breast cancer: new concepts in classification]. 2008 , 30, 42-7			5
1804	[Molecular features of breast cancer predictive of lymph node metastases]. <i>Revista Da Associação Médica Brasileira</i> , 2008 , 54, 203-7		1.4	5
1803	Osteopontin Expression According to Molecular Profile of Invasive Breast Cancer: A Clinicopathological and Immunohistochemical Study. 2008 , 23, 154-160			6
1802	Mammospheres and breast carcinoma. 49-67			
1801	[Basal-like breast cancers: clinicopathological features and outcome]. <i>Revista Da Associação Médica Brasileira</i> , 2009 , 55, 529-34		1.4	9
1800	Prognostic Significance of Basal Markers in Triple-negative Breast Cancers. 2009 , 12, 4			11
1799	Quantitative assessment of tissue biomarkers and construction of a model to predict outcome in breast cancer using multiple imputation. 2009 , 7, 29-40			12

1798	Impact of grade, hormone receptor, and HER-2 status in women with breast cancer on response to specific chemotherapeutic agents by in vitro adenosine triphosphate-based chemotherapy response assay. 2009 , 24, 1150-7		7
1797	Integrated functional, gene expression and genomic analysis for the identification of cancer targets. <i>PLoS ONE</i> , 2009 , 4, e5120	3-7	85
1796	Basal Cytokeratin Expression in Relation to Immunohistochemical and Clinical Characterization in Breast Cancer Patients with Triple Negative Phenotype. 2009 , 95, 53-62		14
1795	[Immunophenotype and evolution of breast carcinomas: a comparison between very young and postmenopausal women]. 2009 , 31, 54-60		11
1794	Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. 2009 , 106, 12909-14		94
1793	Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. 2009 , 18, 1807-14		89
1792	Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. 2009 , 27, 4515-21		284
1791	Tiling path genomic profiling of grade 3 invasive ductal breast cancers. <i>Clinical Cancer Research</i> , 2009 , 15, 2711-22	12.9	138
1790	Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. 2009 , 27, 3908-15		131
1789	Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. 2009 , 20, 862-7		242
1788	Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. 2009 , 62, 139-46		28
1787	Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. 2009 , 27, 4701-8		253
1786	Metformin induces unique biological and molecular responses in triple negative breast cancer cells. 2009 , 8, 2031-40		324
1785	Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome. 2009 , 101, 48-54		19
1784	Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. 2009 , 106, 2359-64		87
1783	Brain metastases and subtypes of breast cancer. 2009 , 20, 803-5		27
1782	Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. 2009 , 20, 628-35		158
1781	Possible Relationship between Basal-Like Breast Carcinoma and Age. 2009 , 4, 183-187		

1780	Distribution of Molecular Breast Cancer Subtypes in Middle Eastern-Saudi Arabian Women: A Pilot Study. 2009 , 33, 141-150		18
1779	Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas. 2009 , 34, 983-93		10
1778	Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. <i>American Journal of Surgical Pathology</i> , 2009 , 33, 1802-8	6.7	21
1777	Triple negative, basal-like and BRCA1-associated breast cancers – what’s the difference and should anyone care?. 2009 , 1, 59-61		
1776	A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. 2009 , 23, 1737-42		83
1775	Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?. 2009 , 18, 1467-77		12
1774	Pleomorphic lobular carcinoma of the breast: molecular pathology and clinical impact. 2009 , 5, 233-43		41
1773	What’s positive about ‘triple-negative’ breast cancer?. 2009 , 5, 1015-25		19
1772	Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables. 2009 , 63, 152-62		6
1771	Thyroid transcription factor-1 and "basal marker"--expressing small cell carcinoma of the breast. 2009 , 17, 368-72		26
1770	Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers. 2009 , 62, 896-902		22
1769	Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. 2009 , 20, 1639-46		216
1768	Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. 2009 , 20, 609-14		30
1767	Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. 2009 , 62, 624-8		26
1766	The macrophage colony-stimulating factor 1 response signature in breast carcinoma. <i>Clinical Cancer Research</i> , 2009 , 15, 778-87	12.9	138
1765	Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. <i>Clinical Cancer Research</i> , 2009 , 15, 5869-77	12.9	46
1764	Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?. 2009 , 17, 285-302		56
1763	Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. 2009 , 69, 3802-9		340

1762	Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?. 2009 , 18, 125-32		104
1761	High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. 2009 , 69, 663-71		119
1760	Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. <i>Molecular Cancer Research</i> , 2009 , 7, 1304-9	6.6	95
1759	High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. 2009 , 20, 1818-23		64
1758	Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. 2009 , 69, 3589-96		114
1757	Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. 2009 , 19, 204-10		82
1756	Histogenesis of metaplastic breast carcinoma and axillary nodal metastases. 2009 , 59, 116-20		13
1755	Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. 2009 , 9, 342		27
1754	A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. 2009 , 7, 77		28
1753	Genetic characterization of breast cancer and implications for clinical management. 2009 , 13, 4090-103		31
1752	Therapeutic options for triple-negative breast cancers with defective homologous recombination. 2009 , 1796, 266-80		22
1751	Chromosomal changes in aggressive breast cancers with basal-like features. 2009 , 193, 29-37		36
1750	p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. 2009 , 124, 991-7		36
1749	Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. 2009 , 124, 1457-62		58
1748	A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. 2009 , 124, 2124-34		50
1747	Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. 2009 , 115, 946-51		117
1746	Fragile histidine triad protein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. 2009 , 115, 899-908		36
1745	Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status. 2009 , 115, 4917-23		44

1744	Cytological criteria to predict basal phenotype of breast carcinomas. 2009 , 37, 809-14	7
1743	Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype?. 2009 , 48, 351-65	74
1742	Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. 2009 , 100, 89-94	40
1741	Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. 2009 , 454, 647-56	69
1740	Pattern of metastatic spread in triple-negative breast cancer. 2009 , 115, 423-8	369
1739	Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. 2009 , 117, 183-91	43
1738	Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. 2009 , 115, 325-33	79
1737	Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. 2009 , 117, 199-204	69
1736	Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. 2009 , 117, 273-80	176
1735	Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. 2009 , 116, 317-28	150
1734	Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers. 2009 , 118, 131-7	79
1733	Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. 2009 , 113, 357-70	285
1732	Patho-biological aspects of basal-like breast cancer. 2009 , 113, 411-22	61
1731	The immunohistochemically "ER-negative, PR-negative, HER2-negative, CK5/6-negative, and HER1-negative" subgroup is not a surrogate for the normal-like subtype in breast cancer. 2009 , 118, 661-3	7
1730	Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers. 2009 , 26, 372-8	27
1729	Breast cancer circulating tumor cells. 2009 , 3, 225-235	
1728	Molekulare Pathologie beim Mammakarzinom. 2009 , 2, 141-145	
1727	Basal phenotype in breast carcinoma occurring in women aged 35 or younger. 2009 , 15, 41-5	4

1726	Breast cancer with cartilaginous and/or osseous metaplasia. 2009 , 16, 234-7	4
1725	Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features. 2009 , 16, 179-85	20
1724	Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. 2009 , 16, 275-80	26
1723	Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction. 2009 , 16, 268-74	9
1722	Gene and chromosomal alterations in sporadic breast cancer: correlation with histopathological features and implications for genesis and progression. 2009 , 16, 186-201	24
1721	Clinical significance of basal-like subtype in triple-negative breast cancer. 2009 , 16, 260-7	48
1720	Clinicopathological characteristics of triple-negative breast cancers. 2009 , 16, 254-9	27
1719	Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents. 2009 , 64, 1039-46	16
1718	[Genome-wide expression profiling as a clinical tool: are we there yet?]. 2009 , 30, 141-6	3
1717	Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. 2009 , 218, 301-15	65
1716	Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas. 2009 , 55, 346-52	22
1715	Breast cancer in the elderly: a histological assessment. 2009 , 55, 441-51	10
1714	Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. 2009 , 55, 594-9	14
1713	Fragile gene product, Fhit, in oxidative and replicative stress responses. 2009 , 100, 1145-50	31
1712	Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma. 2010 , 21, 259-66	6
1711	Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. 2009 , 22, 291-8	136
1710	The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression. 2009 , 22, 1423-31	36
1709	Dual expression of alpha-tocopherol-associated protein and estrogen receptor in normal/benign human breast luminal cells and the downregulation of alpha-tocopherol-associated protein in estrogen-receptor-positive breast carcinomas. 2009 , 22, 770-5	11

1708	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. 2009 , 15, 907-13		1034
1707	Mammary development meets cancer genomics. 2009 , 15, 842-4		148
1706	T time in the brain. 2009 , 15, 844-6		32
1705	Do 'basal-like' breast cancers really exist?. 2009 , 9, 128-34		89
1704	The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. 2009 , 100, 405-11		150
1703	BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. 2009 , 101, 1168-74		51
1702	Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. 2009 , 101, 1338-44		66
1701	Breast cancer subtypes and molecular biomarkers. 2009 , 15, 485-489		7
1700	Endogenous NIS expression in triple-negative breast cancers. 2009 , 16, 962-8		20
1699	Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. 2009 , 16, 2270-9		15
1698	The role of molecular analysis in breast cancer. 2009 , 41, 77-88		41
1697	Obesity and risk of the less commonly diagnosed subtypes of breast cancer. 2009 , 35, 928-35		11
1696	Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling. <i>Cancer Letters</i> , 2009 , 283, 143-51	9.9	70
1695	Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues. 2009 , 87, 432-7		54
1694	Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma. 2009 , 40, 1224-33		32
1693	Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray. 2009 , 40, 1176-81		17
1692	Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. 2009 , 40, 1408-17		40
1691	IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. 2009 , 40, 1528-33		83

1690	Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort. 2009 , 3, 220-37	35
1689	Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. 2009 , 9 Suppl 2, S73-81	424
1688	Triple-negative/basal-like breast cancer: review. 2009 , 41, 40-7	204
1687	Molecular Biology. 2009 , 85-120	
1686	Does vimentin help to delineate the so-called 'basal type breast cancer'?. 2009 , 28, 118	28
1685	Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. 2009 , 11, R69	85
1684	An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. 2009 , 11, R66	152
1683	Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. 2009 , 11, 208	10
1682	Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. 2009 , 11, R31	220
1681	Immunohistochemical characterization of subtypes of male breast carcinoma. 2009 , 11, R28	65
1680	Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. 2009 , 11, R23	65
1679	Breast Cancer in the Post-Genomic Era. 2009 ,	3
1678	Triple-negative breast cancer--current status and future directions. 2009 , 20, 1913-27	416
1677	Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. 2009 , 106, 12903-8	174
1676	Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. 2009 , 93, 639-44	40
1675	Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept. 2009 , 45 Suppl 1, 11-26	50
1674	Triple negative breast cancers: clinical and prognostic implications. 2009 , 45 Suppl 1, 27-40	173
1673	Correlated expression of peroxisome proliferator-activated receptor γ with high histologic grade and basal type in invasive ductal carcinoma of the breast. 2009 , 2, 118-124	

1672	Pharmacotherapy of triple-negative breast cancer. 2009 , 10, 2081-93		26
1671	[Basal-like breast cancer: a review]. 2009 , 29, 180-6		5
1670	Triple-Negative Breast Carcinoma. 2009 , 2, 247-61		3
1669	Genetic alterations and oncogenic pathways associated with breast cancer subtypes. <i>Molecular Cancer Research</i> , 2009 , 7, 511-22	6.6	171
1668	Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. <i>Clinical Cancer Research</i> , 2009 , 15, 2302-10	12.9	371
1667	Triple negative breast carcinomas: similarities and differences with basal like carcinomas. 2009 , 17, 483-94		17
1666	Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome. 2009 , 16, 204-15		57
1665	Molecular Classification and Prognostication of Breast Cancer. 2009 , 14, 129-134		2
1664	Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. <i>American Journal of Surgical Pathology</i> , 2009 , 33, 163-75	6.7	95
1663	Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. <i>American Journal of Surgical Pathology</i> , 2009 , 33, 1093-7	6.7	59
1662	Low-Grade Fibromatosis-Like Spindle Cell Metaplastic Carcinoma: A Basal-Like Tumor with a Favorable Clinical Outcome. Report of Two Cases. 2009 , 95, 264-267		9
1661	Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. 2009 , 2, 8390		33
1660	Clinical proteomics of breast cancer. 2010 , 11, 528-36		15
1659	HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. 2010 , 251, 1107-16		42
1658	Developing mRNA-based biomarkers from formalin-fixed paraffin-embedded tissue. 2010 , 7, 205-211		6
1657	Triple-negative breast cancer: a short review. 2010 , 33, 637-45		99
1656	Epithelial-to-mesenchymal transition in metaplastic breast carcinomas with chondroid differentiation: expression of the E-cadherin repressor Snail. 2010 , 18, 526-31		17
1655	What is the difference between triple-negative and basal breast cancers?. 2010 , 16, 12-6		30

1654	Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?. 2010 , 16, 23-32	106
1653	Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. 2010 , 18, 113-8	31
1652	High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancers. 2010 , 1, 261-266	4
1651	[Triple-negative breast carcinoma--review of current literature]. 2010 , 54, 325-35	2
1650	Ca ²⁺ -binding protein S100A11: a novel diagnostic marker for breast carcinoma. 2010 , 23, 1301-8	21
1649	Characterization of molecular subtypes of Korean breast cancer: an ethnically and clinically distinct population. 2010 , 37, 51-9	
1648	Immunohistochemical profiling of node negative breast carcinomas allows prediction of metastatic risk. 2010 , 36, 889-98	4
1647	Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer. 2010 , 37, 41-9	34
1646	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. 2010 , 4, 117822341000400	130
1645	p53 as a marker of prognosis in African-American women with breast cancer. 2010 , 17, 1398-405	42
1644	The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. 2010 , 17, 2411-8	104
1643	BRCA-Aktivität beim triple-negativen Mammakarzinom. 2010 , 43, 1002-1007	
1642	Pleomorphic carcinoma of the breast in a 17-year-old woman. 2010 , 43, 43-7	3
1641	Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. 2010 , 457, 467-76	71
1640	Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy. 2010 , 136, 233-41	10
1639	Clinicopathological features and treatment strategy for triple-negative breast cancer. 2010 , 15, 341-51	36
1638	Research progress in triple-negative breast cancer. 2010 , 9, 239-242	3
1637	Clinicopathologic features and related prognosis factors analysis of the basal and non-basal phenotype of triple negative breast cancer. 2010 , 9, 249-252	1

1636	BRCA1 and EGFR as prognostic biomarkers in triple negative metastatic breast cancer patients treated with cisplatin plus docetaxel. 2010 , 9, 700-707	2
1635	Triple Negative Breast Cancer. 2010 , 3, 185-189	
1634	Predicting responses to chemotherapy in breast cancer: from bench to bedside. 2010 , 17, 92-6	
1633	Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer. 2010 , 6, 93-103	10
1632	Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin. 2010 , 27, 34-9	27
1631	A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. 2010 , 27, 926-31	66
1630	Breast cancer, neoadjuvant chemotherapy and residual disease. 2010 , 12, 461-7	14
1629	Current and emerging treatment options in triple-negative breast cancer. 2010 , 4, 5-13	3
1628	Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions. 2010 , 15, 149-68	66
1627	The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. 2010 , 119, 551-8	195
1626	Aquaporin 1 (AQP1) expression is a novel characteristic feature of a particularly aggressive subgroup of basal-like breast carcinomas. 2010 , 120, 67-76	57
1625	A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. 2010 , 120, 83-93	47
1624	CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. 2010 , 120, 95-109	47
1623	The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. 2010 , 121, 41-51	43
1622	Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. 2010 , 121, 53-64	207
1621	An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. 2010 , 121, 575-89	132
1620	Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations. 2010 , 122, 711-20	21
1619	Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. 2010 , 123, 97-108	148

1618	Subtypes of familial breast tumours revealed by expression and copy number profiling. 2010 , 123, 661-77	81
1617	A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (2010, 119, 653-61	56
1616	Combinatorial biomarker expression in breast cancer. 2010 , 120, 293-308	150
1615	Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. 2010 , 120, 491-8	63
1614	Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study. 2010 , 124, 653-66	26
1613	Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. 2010 , 121, 261-71	67
1612	Health disparities in breast cancer: biology meets socioeconomic status. 2010 , 121, 281-92	76
1611	Histologic diagnosis in young women with breast cancer. 2010 , 123 Suppl 1, 15-8	3
1610	Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer. 2010 , 37, 384-401	31
1609	Expression and prognostic significance of CK19 in canine malignant mammary tumours. 2010 , 184, 45-51	11
1608	Aggressive progression of breast cancer with microscopic pulmonary emboli possessing a stem cell-like phenotype independent of its origin. 2010 , 60, 228-34	7
1607	Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. 2010 , 10, 465-70	22
1606	Novel treatment approaches for triple-negative breast cancer. 2010 , 10 Suppl 1, E16-22	19
1605	Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. 2010 , 10, 136	44
1604	Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study. 2010 , 10, 223	50
1603	Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. 2010 , 10, 483	133
1602	Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. 2010 , 10, 507	41
1601	Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. 2010 , 10, 568	32

1600	Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. 2010 , 10, 653	34
1599	Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. 2010 , 6, 5	69
1598	Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: a pathological and immunohistochemical study. 2010 , 19, 137-41	16
1597	Management of triple negative breast cancer. 2010 , 19, 312-21	148
1596	Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. 2010 , 49, 78-90	23
1595	Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. 2010 , 116, 302-8	90
1594	Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. 2010 , 116, 1234-42	153
1593	Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. 2010 , 116, 1431-9	113
1592	African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. 2010 , 116, 4926-32	153
1591	Tumor suppressor function of Rab25 in triple-negative breast cancer. 2010 , 126, 2799-812	67
1590	Selected recent advances in the pathology of salivary neoplasms. 2010 , 16, 276-286	8
1589	The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. 2010 , 220, 45-57	184
1588	The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. 2010 , 220, 263-80	306
1587	Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. 2010 , 220, 562-73	165
1586	Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas. 2010 , 222, 64-75	29
1585	Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. 2010 , 222, 282-98	120
1584	Epidermal growth factor-dependent enhancement of invasiveness of squamous cell carcinoma of the breast. 2010 , 101, 1133-40	22
1583	Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. 2010 , 56, 560-72	52

1582	Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma. 2010 , 56, 860-7		146
1581	HER2 molecular subtype is a dominant subtype of mammary Paget's cells. An immunohistochemical study. 2010 , 57, 564-71		28
1580	Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. 2010 , 102, 369-75		80
1579	Topo2 β protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. 2010 , 103, 1794-800		21
1578	Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. 2010 , 10, 605-17		159
1577	Editorial: Molecular subtypes and clinical outcomes of breast cancer. 2010 , 5,		
1576	Reinventing diagnostics for personalized therapy in oncology. <i>Cancers</i> , 2010 , 2, 1066-91	6.6	3
1575	Clinical Outcomes in Patients with Triple-negative Breast Cancer and Brain Metastases. 2010 , 13, 160		1
1574	Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer. <i>PLoS ONE</i> , 2010 , 5, e15094	3.7	15
1573	hisBreast cancer Molecular subtypes and their clinicopathological characteristics amongst patients at the Aga Khan University hospital (Nairobi). 2010 , 5,		6
1572	Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients. 2010 , 65, 1033-6		32
1571	Breast. 2010 , 701-744		
1570	Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 876-87	12.9	321
1569	Basal-like subtype breast cancers in women older than 40 years of age. 2010 , 18, 42-7		1
1568	Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. 2010 , 70, 7970-80		128
1567	Cancers du sein métastatiques « triples négatifs ». Critères cliniques et biologiques additionnels nécessaires pour prendre une décision thérapeutique. Stratégies thérapeutiques, place des anti-angiogéniques et nouvelles thérapeutiques ciblées. 2010 , 233-242		
1566	ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells. 2010 , 9, 1503-14		15
1565	Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. 2010 , 107, 6340-5		151

1564	Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization?. 2010 , 21 Suppl 7, vii30-5		73
1563	Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 956-64	6.7	81
1562	Mammary gland growth factors: roles in normal development and in cancer. 2010 , 2, a003186		68
1561	Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 4702-10	12.9	120
1560	Premalignant breast neoplasia: a paradigm of interlesional and intralesional molecular heterogeneity and its biological and clinical ramifications. 2010 , 3, 579-87		24
1559	Will molecular classification replace traditional breast pathology?. 2010 , 18, 162S-166S		15
1558	Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. 2010 , 1, 812-21		167
1557	Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases. 2010 , 18, 27-35		17
1556	Breast cancer subtypes and the risk of local and regional relapse. 2010 , 28, 1684-91		903
1555	Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. 2010 , 70, 9391-401		143
1554	Cancer du sein en situation mEastatique. 2010 ,		
1553	Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. 2010 , 107, 22231-6		213
1552	Molecular stratification of triple-negative breast cancers. 2010 , 15 Suppl 5, 39-48		173
1551	Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells. 2010 , 102, 1432-46		39
1550	Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. 2010 , 23, 197-204		73
1549	Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. 2010 , 10, 199-207		60
1548	FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. 2010 , 70, 3870-6		168
1547	Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. 2010 , 10, 135-43		106

1546	Vascular invasion in triple-negative carcinoma of the breast identified by endothelial lymphatic and blood vessel markers. 2010 , 18, 324-9	7
1545	Claudin 1 in breast tumorigenesis: revelation of a possible novel "claudin high" subset of breast cancers. 2010 , 2010, 956897	57
1544	Invasive Lobular Carcinomas Do Not Express Basal Cytokeratin Markers CK5/6, CK14 and CK17. 2010 , 4, 49-55	8
1543	Prognostic significance of subtype classification for short- and long-term survival in breast cancer: survival time holds the key. 2010 , 7, e1000281	8
1542	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. 2010 , 7, e1000279	616
1541	Biomarker research in breast cancer. 2010 , 14, 771-83	3
1540	Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results. 2010 , 31, 76-8	4
1539	A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. 2010 , 28, 978-82	57
1538	Beyond triple-negative breast cancer: the need to define new subtypes. 2010 , 10, 1197-213	17
1537	Basal-like breast cancer displays distinct patterns of promoter methylation. 2010 , 9, 1017-24	32
1536	Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1 β regulation in human breast cancer. 2010 , 77, 289-300	11
1535	Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. 2010 , 79, 324-30	50
1534	Is capecitabine efficacious in triple negative metastatic breast cancer?. 2010 , 79, 331-6	10
1533	Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. 2010 , 70, 5465-74	58
1532	Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser ¹¹⁷ phosphorylation in epidermal growth factor receptor-expressing breast cancer. 2010 , 9, 3090-9	16
1531	MYC and Breast Cancer. 2010 , 1, 629-40	194
1530	The Met receptor tyrosine kinase and basal breast cancer. 2010 , 9, 1043-50	24
1529	[Proteomics and breast cancer: a search for novel diagnostic and theragnostic biomarkers]. 2010 , 97, 321-39	2

1528	[Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas]. 2010 , 97, 357-63	6
1527	PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. 2010 , 23, 1334-45	54
1526	Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. 2010 , 23, 1357-63	43
1525	Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estrogen receptor signaling remain the best predictors of relapse and survival in a series of 289 cases. 2010 , 9, 266-73	10
1524	EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. 2010 , 23, 644-53	87
1523	Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast. 2010 , 23, 951-60	47
1522	Classification models for breast cancer molecular subtyping: what is the best candidate for a translation into clinic?. 2010 , 6, 623-5	2
1521	Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. 2010 , 12, e22	25
1520	Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. 2010 , 28, 1145-53	734
1519	Microarray-Based Gene Expression Profiling for Molecular Classification of Breast Cancer and Identification of New Targets for Therapy. 2010 , 41, 364-372	23
1518	Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. 2010 , 23, 123-33	175
1517	DNA amplifications in breast cancer: genotypic-phenotypic correlations. 2010 , 6, 967-84	18
1516	Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy. 2010 , 10, 1125-36	30
1515	Triple-negative breast cancer. 2010 , 12 Suppl 2, S3	165
1514	Expresión de p63 y citoqueratina 5/6 en los diferentes tipos moleculares del carcinoma de mama. 2010 , 43, 79-85	
1513	Histological types of breast cancer: how special are they?. 2010 , 4, 192-208	255
1512	Triple-negative breast cancer: present challenges and new perspectives. 2010 , 4, 209-29	212
1511	Intratumoral expression level of epidermal growth factor receptor and cytokeratin 5/6 is significantly associated with nodal and distant metastases in patients with basal-like triple-negative breast carcinoma. 2010 , 134, 782-7	44

1510	Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. 2010 , 176, 1639-47		27
1509	Treatment options for patients with triple-negative breast cancer. <i>Journal of Hematology and Oncology</i> , 2010 , 3, 42	22.4	45
1508	Mapping the cellular and molecular heterogeneity of normal and malignant breast tissues and cultured cell lines. 2010 , 12, R87		142
1507	Triple-negative breast cancer: epidemiology and management options. 2010 , 70, 2247-58		81
1506	Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer. 2010 , 10 Suppl 2, S20-9		11
1505	Does the PI3K pathway play a role in basal breast cancer?. 2010 , 10 Suppl 3, S66-71		21
1504	Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. 2010 , 23 Suppl 2, S60-4		241
1503	Emerging targeted therapies for breast cancer. 2010 , 28, 3366-79		148
1502	Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and "triple-negative" breast cancers. 2010 , 41, 401-6		24
1501	Adenoid cystic carcinomas of the breast have low Topo II α expression but frequently overexpress EGFR protein without EGFR gene amplification. 2010 , 41, 1617-23		24
1500	Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer. 2010 , 163, 52-7		20
1499	Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: current status. <i>Cancer Letters</i> , 2010 , 294, 13-24	9.9	32
1498	Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. 2010 , 36, 206-15		196
1497	Targeting DNA repair in breast cancer: a clinical and translational update. 2010 , 36, 557-65		35
1496	BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. 2010 , 7, 403-17		518
1495	ORIGINAL ARTICLE: Immunohistochemical identification of basal-like breast carcinoma and its histopathologic correlation. 2010 , 3, 86-92		
1494	Breast Cancer Biology and Clinical Characteristics. 2010 , 21-46		9
1493	EGFR expression and gene copy number in triple-negative breast carcinoma. 2010 , 203, 222-9		55

1492	Breast cancer molecular profiling with single sample predictors: a retrospective analysis. 2010 , 11, 339-49	274
1491	The mammographic correlations with Basal-like phenotype of invasive breast cancer. 2010 , 17, 333-9	8
1490	Characteristic morphology of invasive micropapillary carcinoma of the breast: an immunohistochemical analysis. 2010 , 40, 781-7	28
1489	Biomarkers for Basal-like Breast Cancer. <i>Cancers</i> , 2010 , 2, 1040-65	6.6 37
1488	Triple-negative breast cancer: disease entity or title of convenience?. 2010 , 7, 683-92	588
1487	Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry. 2010 , 29, 39	11
1486	Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo. 2010 , 12, R49	32
1485	Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. 2010 , 12, R57	23
1484	Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. 2010 , 12, R10	27
1483	Metastatic behavior of breast cancer subtypes. 2010 , 28, 3271-7	1300
1482	A pathway-based classification of human breast cancer. 2010 , 107, 6994-9	258
1481	Triple-negative breast cancer: unique biology and its management. 2010 , 28, 878-83	11
1480	Therapeutic management of breast cancer in the elderly. 2011 , 12, 945-60	13
1479	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. 2011 , 103, 250-63	513
1478	p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. 2011 , 41, 172-9	49
1477	Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. 2011 , 105, 272-80	48
1476	Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. 2011 , 4, 222-6	47
1475	Glut-1 Expression Correlates with Basal-like Breast Cancer. 2011 , 4, 321-7	47

1474	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. 2011 , 24, 157-67	447
1473	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. 2011 , 20, 3289-303	140
1472	New treatment strategies in the management of breast cancer. 2011 , 9, 22-29	2
1471	Breast. 2011 , 225-247	1
1470	Deconstructing the molecular portraits of breast cancer. 2011 , 5, 5-23	841
1469	Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms. 2011 , 48, 85-97	99
1468	Expression of androgen receptor in breast cancer and its significance as a prognostic factor. 2011 , 22, 1288-1294	80
1467	Handbook of Practical Immunohistochemistry. 2011 ,	5
1466	Immunohistology of the Breast. 2011 , 763-819	0
1465	Current treatment options in triple negative breast cancer. 2010 , 32, 99-122	38
1464	Triple negative breast cancer: adjuvant chemotherapy effect on survival. 2011 , 56, 285-90	6
1463	A methyl-deviator epigenotype of estrogen receptor-positive breast carcinoma is associated with malignant biology. 2011 , 179, 55-65	13
1462	Statistical association of basal cell keratins with metastasis-inducing proteins in a prognostically unfavorable group of sporadic breast cancers. 2011 , 179, 1061-72	14
1461	Lipid-rich carcinoma of the breast clinicopathologic analysis of 17 cases. 2011 , 15, 225-32	17
1460	Paired distribution of molecular subtypes in bilateral breast carcinomas. <i>Cancer Genetics</i> , 2011 , 204, 96-103	10
1459	Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. 2011 , 47, 138-50	117
1458	Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. 2011 , 37, 18-24	20
1457	Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. 2011 , 64, 937-46	383

1456	Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. 2011 , 22, 1736-47	2402
1455	Molecular phenotypes of matched in situ and invasive components of breast carcinomas. 2011 , 42, 1438-46	8
1454	Chromosome aberrations associated with centrosome defects: a study of comparative genomic hybridization in breast cancer. 2011 , 42, 1693-701	10
1453	Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. 2011 , 13, R35	86
1452	Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. 2011 , 13, R9	62
1451	The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. 2011 , 13, R19	37
1450	Stratifying triple-negative breast cancer: which definition(s) to use?. 2011 , 13, 105	23
1449	Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. 2011 , 13, R47	124
1448	Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. 2011 , 13, R62	50
1447	Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. 2011 , 13, R133	33
1446	Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. 2011 , 103, 470-7	160
1445	CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. 2011 , 6, 638-49	82
1444	P-cadherin role in normal breast development and cancer. 2011 , 55, 811-22	50
1443	Clinical significance of morphologic characteristics in triple negative breast cancer. 2011 , 80, 301-6	12
1442	Triple-negative breast cancers: an updated review on treatment options. 2011 , 18, e173-9	54
1441	Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. 2011 , 3, 9-19	11
1440	Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer. 2011 , 2, 257-264	16
1439	The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes. 2011 , 26, 352-9	26

1438	Molecular phenotypes of unifocal, multifocal, and diffuse invasive breast carcinomas. 2010 , 2011, 480960		6
1437	Patterns of recurrence after breast-conserving treatment for early stage breast cancer by molecular subtype. 2011 , 14, 46-51		26
1436	MicroArray Technology - Expression Profiling of MRNA and MicroRNA in Breast Cancer. 2011 ,		0
1435	B-Crystallin is a Novel Oncoprotein Associated with Poor Prognosis in Breast Cancer. 2011 , 14, 14-9		26
1434	Clinicopathologic and immunohistochemical characteristics of triple negative invasive lobular carcinoma. 2011 , 52, 89-97		22
1433	Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk. 2011 , 66, 607-12		12
1432	Triple-negative breast cancers and the human mammary epithelial cell hierarchy. 2010 , 32, 49-61		2
1431	The implications of breast cancer molecular phenotype for radiation oncology. <i>Frontiers in Oncology</i> , 2011 , 1, 12	5-3	8
1430	[Brain metastases in breast cancer. Epidemiology and natural history. The Institut Curie experience]. 2011 , 98, 357-69		3
1429	Molecular profiling of triple negative breast cancer. 2010 , 32, 73-84		19
1428	[Molecular subtypes of breast cancer: prognostic implications and clinical and immunohistochemical characteristics]. 2011 , 34, 219-33		11
1427	Do Pre-Diagnostic Drinking Habits Influence Breast Cancer Survival?. 2011 , 97, 142-148		16
1426	Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. <i>PLoS ONE</i> , 2011 , 6, e17251	3-7	74
1425	Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. <i>PLoS ONE</i> , 2011 , 6, e25080	3-7	28
1424	Triple-Negative Breast Cancer: Clinical and Histological Correlations. 2011 , 6, 273-278		31
1423	Molecular heterogeneity of triple-negative breast cancer and its clinical implications. 2011 , 23, 566-77		62
1422	'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis. 2011 , 23, 19-23		5
1421	IMP3, a proposed novel basal phenotype marker, is commonly overexpressed in adenoid cystic carcinomas but not in apocrine carcinomas of the breast. 2011 , 19, 413-6		20

1420	Triple-negative breast cancer and new treatment developments. 2011 , 1, 1107-1118	
1419	Clinicopathological parameters and biological markers predicting non-sentinel node metastasis in sentinel node-positive breast cancer patients. 2011 , 25, 1063-71	19
1418	Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. 2011 , 25, 1481-7	32
1417	Epidemiology of triple negative breast cancers. 2010 , 32, 5-24	39
1416	Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition. 2011 , 102, 1882-8	17
1415	Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple-negative breast cancer. 2011 , 59, 776-80	65
1414	Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast. 2011 , 59, 264-73	14
1413	Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma. 2011 , 59, 950-6	20
1412	Epidermal growth factor receptor as a therapeutic target in veterinary oncology. 2011 , 9, 81-94	13
1411	The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions. 2011 , 7, 197-211	11
1410	Biologic activity of a dinuclear Pd(II)-spermine complex toward human breast cancer. 2011 , 77, 477-88	40
1409	Expression of midkine and endoglin in breast carcinomas with different immunohistochemical profiles. 2011 , 119, 103-10	10
1408	Analysis of Brca1-deficient mouse mammary glands reveals reciprocal regulation of Brca1 and c-kit. 2011 , 30, 1597-607	20
1407	MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes. 2011 , 30, 4118-28	92
1406	Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. 2011 , 104, 120-7	98
1405	An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. 2011 , 104, 1730-8	143
1404	PARP inhibitors--current status and the walk towards early breast cancer. 2011 , 20 Suppl 3, S12-9	30
1403	Triple-negative breast cancer: what the radiologist needs to know. 2011 , 46, 26-39	25

1402	"Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers. 2011 , 38, 254-62	18
1401	Predictive value of pathological and immunohistochemical parameters for axillary lymph node metastasis in breast carcinoma. 2011 , 6, 18	17
1400	Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer. 2011 , 6, 36	21
1399	Clinical trials in the era of personalized oncology. 2011 , 61, 365-81	43
1398	A challenging drug development process in the era of personalized medicine. 2011 , 16, 891-7	35
1397	Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. 2011 , 1815, 224-40	76
1396	Early and more advanced unifocal and multifocal breast carcinomas and their molecular phenotypes. 2011 , 11, 258-63	10
1395	Multifocality in "basal-like" breast carcinomas and its influence on lymph node status. 2011 , 18, 1671-7	17
1394	Predicting breast cancer recurrence following breast-conserving therapy: a single-institution analysis consisting of 764 Chinese breast cancer cases. 2011 , 18, 2492-9	21
1393	Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study. 2011 , 18, 3839-47	29
1392	Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. 2011 , 18, 2851-7	73
1391	Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients. 2011 , 50, 700-10	186
1390	Phenotype-genotype correlation in familial breast cancer. 2011 , 16, 27-40	28
1389	Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. 2011 , 125, 687-96	189
1388	Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. 2011 , 126, 1-14	76
1387	Nuclear and cytoplasmic expressions of ER α and ER β are predictive of response to therapy and alters prognosis in familial breast cancers. 2011 , 126, 395-405	44
1386	Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. 2011 , 128, 301-13	46
1385	Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. 2011 , 126, 185-92	90

1384	Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. 2011 , 127, 471-8	118
1383	Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. 2011 , 129, 421-32	40
1382	High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. 2011 , 129, 747-60	63
1381	Triple negative breast cancer: unmet medical needs. 2011 , 125, 627-36	226
1380	Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. 2011 , 126, 463-70	54
1379	Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo. 2011 , 130, 783-90	27
1378	PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. 2011 , 127, 861-9	88
1377	Common genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer subtypes. 2011 , 129, 593-606	44
1376	Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea. 2011 , 128, 171-7	18
1375	Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. 2011 , 130, 663-79	95
1374	A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments. 2011 , 130, 489-98	66
1373	Vascular proliferation is increased in basal-like breast cancer. 2011 , 130, 1063-71	39
1372	Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. 2011 , 22, 399-405	64
1371	Non-steroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. 2011 , 22, 965-75	44
1370	Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes. 2011 , 105, 547-53	12
1369	Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer. 2011 , 20, 247-59	12
1368	Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates. 2011 , 458, 65-72	26
1367	The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype. 2011 , 137, 271-8	20

1366	Characteristics of triple-negative breast cancer. 2011 , 137, 183-92	172
1365	Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. 2011 , 137, 1505-10	29
1364	A subset of breast cancer predisposes to brain metastasis. 2011 , 44, 15-20	35
1363	Carcinosarcoma of the breast: report of a case and review of the literature. 2011 , 8, 201-205	
1362	Prognostic factors affecting postmastectomy locoregional recurrence in patients with early breast cancer: are intrinsic subtypes effective?. 2011 , 35, 2196-202	13
1361	A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. 2011 , 67, 1225-37	47
1360	Quantitative proteomic profiling of breast cancers using a multiplexed microfluidic platform for immunohistochemistry and immunocytochemistry. 2011 , 32, 1396-403	25
1359	May metaplastic breast carcinomas be actually basal-like carcinoma? Further evidence study with its ultrastructure and survival analysis. 2011 , 28, 42-50	6
1358	Aspirin intake may prevent metastasis in patients with triple-negative breast cancer. 2011 , 28, 1308-10	4
1357	Overview of preoperative radiochemotherapy in breast cancer: past or future?. 2011 , 13, 446-50	4
1356	The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer. 2011 , 18, 292-8	25
1355	Estrogen receptor-alpha promoter methylation in sporadic basal-like breast cancer of Chinese women. 2011 , 32, 713-9	7
1354	Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?. 2011 , 11, 299	37
1353	Protein and lipid MALDI profiles classify breast cancers according to the intrinsic subtype. 2011 , 11, 465	46
1352	Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. 2011 , 11, 44	38
1351	Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines. 2011 , 4, 75	33
1350	Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. 2011 , 3, 528-44	130
1349	Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors. 2011 , 50, 71-81	47

1348	CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry. 2011 , 117, 1350-9	12
1347	Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. 2011 , 117, 3093-100	60
1346	The use of fine-needle aspiration biopsy samples for the assessment of basal phenotype in triple negative breast cancer patients: a correlative study. 2011 , 39, 1-7	2
1345	Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature. 2011 , 81, 336-44	10
1344	P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. 2011 , 24, 64-81	50
1343	The changing role of pathology in breast cancer diagnosis and treatment. 2011 , 78, 99-114	77
1342	Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. 2011 , 24, 924-31	207
1341	Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays. 2011 , 22, 2597-2603	28
1340	Shorter telomeres in luminal B, HER-2 and triple-negative breast cancer subtypes. 2011 , 24, 194-200	23
1339	Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. 2011 , 24, 774-85	84
1338	Therapeutic potential of PARP inhibitors for metastatic breast cancer. 2011 , 11, 1243-51	21
1337	Overexpression of c-KIT (CD117) in triple-negative breast cancer. 2011 , 31, 113-117	4
1336	FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. <i>Clinical Cancer Research</i> , 2011 , 17, 5275-86	12.9 138
1335	Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. 2011 , 135, 587-91	59
1334	Invasive Breast Cancer: Recognition of Molecular Subtypes. 2011 , 6, 258-264	25
1333	Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells. 2011 , 10, 550-7	32
1332	Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 7194-203	12.9 18
1331	Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells. 2011 , 10, 1460-9	71

1330	Prognostic factors in young Japanese women with breast cancer: prognostic value of age at diagnosis. 2011 , 41, 180-9	13
1329	The triple-negative subtype: new ideas for the poorest prognosis breast cancer. 2011 , 2011, 108-10	44
1328	Handbook of Metastatic Breast Cancer. 2011 ,	
1327	Triple-negative breast cancer: adjuvant therapeutic options. 2011 , 2011, 696208	43
1326	Management options in triple-negative breast cancer. 2011 , 5, 175-99	29
1325	The characterization of cell line crl-2335 as a Basal-like breast carcinoma model. 2011 , 5, 67-72	1
1324	Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. 2011 , 16, 1675-83	70
1323	ECatenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. 2011 , 24, 209-31	264
1322	ECatenin-independent WNT signaling in basal-like breast cancer and brain metastasis. 2011 , 32, 434-42	100
1321	Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies. 2011 , 25, 199-211	118
1320	A case report of lipid-rich carcinoma of the breast including histological characteristics and intrinsic subtype profile. 2011 , 4, 275-80	8
1319	Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer. 2011 , 10, 619-24	48
1318	Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. 2011 , 22, 848-856	69
1317	Molecular stratification of triple-negative breast cancers. 2011 , 16 Suppl 1, 61-70	247
1316	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. 2011 , 22, 1561-1570	131
1315	Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?. 2011 , 8, 272-9	25
1314	Basal phenotype breast cancer: implications for treatment and prognosis. 2011 , 7, 181-202	19
1313	The cell cycle profile test is a prognostic indicator for breast cancer patients treated with postoperative 5-fluorouracil-based chemotherapy. 2011 , 41, 739-46	

1312	Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients. 2011 , 29, 180-6	3
1311	Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer. 2011 , 80, 341-9	11
1310	Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. 2011 , 32, 1107-21	78
1309	Morphological aspects and immunophenotypic profiles of mammary carcinomas in benign-mixed tumors of female dogs. 2012 , 2012, 432763	7
1308	[Expression of cytokeratins 5/6 and cytokeratin 17 in invasive breast carcinoma]. 2012 , 69, 1031-8	3
1307	Molecular subtyping of male breast cancer by immunohistochemistry. 2012 , 25, 398-404	101
1306	Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. 2012 , 23, 2578-2584	40
1305	Targeting triple-negative breast cancer: optimising therapeutic outcomes. 2012 , 23, 2223-2234	120
1304	APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. 2012 , 31, 1160-76	51
1303	High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. 2012 , 42, 256-63	73
1302	Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. 2012 , 109, 2766-71	156
1301	Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective. 2012 , 23 Suppl 6, vi19-22	90
1300	Identification of novel interaction between annexin A2 and keratin 17: evidence for reciprocal regulation. 2012 , 287, 7573-81	21
1299	Delay to formalin fixation alters morphology and immunohistochemistry for breast carcinoma. 2012 , 20, 531-42	31
1298	Dietary intakes of total and specific lignans are associated with clinical breast tumor characteristics. 2012 , 142, 91-8	28
1297	Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer. 2012 , 35, 242-6	6
1296	The significance of immunohistochemical expression of maspin in basal-like breast cancer. 2012 , 32, 204-210	1
1295	Morphological and immunohistochemical characteristics of triple negative and basal breast carcinoma. 2012 , 32, 6-13	1

1294	Relationships between immunophenotype, Ki-67 index, microvascular density, Ep-CAM/P-cadherin, and MMP-2 expression in early-stage invasive ductal breast cancer. 2012 , 20, 550-60	14
1293	Molecular classification of estrogen receptor-positive/luminal breast cancers. 2012 , 19, 39-53	53
1292	Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodies. 2012 , 11, 1467-76	45
1291	Cancers du sein triples négatifs: Jusqu'où doit-on aller dans le bilan histologique?. 2012 , 565-570	
1290	Male breast cancer: immunohistochemical subtypes and clinical outcome characterization. 2012 , 83, 228-33	11
1289	Triple-negative breast cancer: are we making headway at least?. 2012 , 4, 195-210	60
1288	Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women. 2012 , 23, 2435-2441	29
1287	Reappraisal of immunohistochemical profiling of special histological types of breast carcinomas: a study of 121 cases of eight different subtypes. 2012 , 65, 1066-71	15
1286	Non-canonical HIF-2 β function drives autonomous breast cancer cell growth via an AREG-EGFR/ErbB4 autocrine loop. 2012 , 31, 2283-97	55
1285	Reduced expression of E-cadherin and β -catenin and high expression of basal cytokeratins in feline mammary carcinomas with regional metastasis. 2012 , 49, 979-87	15
1284	Understanding the biology of triple-negative breast cancer. 2012 , 23 Suppl 6, vi13-8	104
1283	Unresectable Metastatic Colorectal Cancer Treatment and Survival [Pauls Stradins Clinical University Hospital Experience. 2012 , 12, 15-19	
1282	Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement. 2012 , 13, 5047-52	30
1281	Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. 2012 , 6, 1-8	43
1280	Molecular basis of triple negative breast cancer and implications for therapy. 2012 , 2012, 217185	77
1279	Cadherin cell adhesion system in canine mammary cancer: a review. 2012 , 2012, 357187	14
1278	Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer. 2012 , 2012, 829315	10
1277	Metaplastic breast carcinomas and their relationship with basal-like phenotype. 2012 , 28, 134-41	6

1276	[Immunohistochemical characteristics of triple negative/basal-like breast cancer]. 2012 , 28, 238-44	2
1275	Ploidy, S-phase fraction, ER, PR, and EGFR expression in node-negative breast cancer Egyptian patients. 2012 , 32, 107-113	1
1274	TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. 2012 , 30, 2615-23	359
1273	Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer. 2012 , 82, 180-7	9
1272	Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China. 2012 , 7, 13-17	15
1271	Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature. 2012 , 25, 567-75	66
1270	Clinicopathologic features and prognosis of triple-negative breast cancer in patients 40 years of age and younger in Saudi Arabia. 2012 , 5, 101-6	11
1269	Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma. 2012 , 20, 334-9	12
1268	Basal breast cancer: a complex and deadly molecular subtype. 2012 , 12, 96-110	139
1267	Laminin 332 expression in breast carcinoma. 2012 , 20, 159-64	21
1266	[Towards a better knowledge of breast cancer physiopathology: the proteomics approach]. 2012 , 70, 553-65	1
1265	Carcinosarcoma of the Breast. 2012 , 257-269	
1264	Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. 2012 , 44, 303-12	31
1263	Pathology of Breast Cancer: from Classic Concepts to Molecular Pathology and Pathogenesis. 2012 , 12, 59-66	1
1262	The Value of Magnetic Resonance in Differentiation between Brain Glioma and Treatment Induced Injury. 2012 , 12, 24-28	0
1261	Breast Conserving Surgery in Early Stage Triple Negative Breast Cancer: Is There a Higher Risk of Locoregional Recurrence?. 2012 , 12, 11-14	
1260	Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer. <i>Revista Da Associação Médica Brasileira</i> , 2012 , 58, 532-536	1.4 3
1259	Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. 2012 , 38, 698-707	342

1258	Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35. 2012 , 18, 399-405	11
1257	Targeted therapies in breast cancer. 2012 , 142, w13550	9
1256	Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer. 2012 , 93, 391-8	39
1255	Molecular pathology of breast cancer: what a pathologist needs to know. 2012 , 138, 770-80	66
1254	Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes. 2012 , 61, 629-43	75
1253	Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma. 2012 , 72, 2657-71	43
1252	Current issues in diagnostic breast pathology. 2012 , 65, 771-85	24
1251	Cancers du sein triples négatifs: Une revue de la littérature. 2012 , 571-588	
1250	RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells. 2012 , 11, M111.011932	61
1249	Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCA1, but not BRCA1 familial breast cancers. 2012 , 14, R69	32
1248	Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. 2012 , 14, R83	98
1247	ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR. 2012 , 14, R148	68
1246	BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression. 2012 , 461, 305-12	30
1245	Keratin expression in breast cancers. 2012 , 461, 313-22	58
1244	Les signatures moléculaires sur paraffine dans le cancer du sein : le point de vue du pathologiste. 2012 , 14, 506-511	
1243	Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation. 2012 , 135, 93-102	29
1242	A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. 2012 , 136, 487-93	106
1241	Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. 2012 , 135, 555-69	38

1240	Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer. 2012 , 136, 407-17		60
1239	Local control, toxicity, and cosmesis in women >70 years enrolled in the American Society of Breast Surgeons accelerated partial breast irradiation registry trial. 2012 , 84, 323-30		25
1238	Study on the skip metastasis of axillary lymph nodes in breast cancer and their relation with Gli1 expression. 2012 , 33, 1943-50		11
1237	Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer. <i>Revista Da Associação Médica Brasileira</i> , 2012 , 58, 532-536	1.4	16
1236	Analysis of the concordance rates between core needle biopsy and surgical excision in patients with breast cancer. 2012 , 58, 532-536		1
1235	EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia. 2012 , 32, 142-9		10
1234	Using rule-based machine learning for candidate disease gene prioritization and sample classification of cancer gene expression data. <i>PLoS ONE</i> , 2012 , 7, e39932	3.7	72
1233	PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. 2012 , 2, 1036-47		418
1232	Tumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyond. 2012 , 9, 415-23		9
1231	The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast. 2012 , 43, 48-55		43
1230	Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer. 2012 , 43, 865-73		8
1229	CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. <i>Cancer Letters</i> , 2012 , 319, 49-55	9.9	44
1228	New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. 2012 , 38, 303-10		24
1227	Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. 2012 , 48, 2066-74		7
1226	Dissecting the heterogeneity of triple-negative breast cancer. 2012 , 30, 1879-87		304
1225	Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. 2012 , 118, 5937-46		138
1224	Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. 2012 , 12, 510		37
1223	Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib. 2012 , 10, 165		8

1222	A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas. 2012 , 7, 145	26
1221	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. 2012 , 5, 44	199
1220	An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis. 2012 , 5, 54	10
1219	Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer. 2012 , 5, 248	28
1218	Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. 2012 , 103, 1665-71	78
1217	Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype. 2012 , 60, E87-95	80
1216	B-crystallin is a useful marker for triple negative and basal breast cancers. 2012 , 61, 378-86	25
1215	PARP inhibitors: mechanism of action and their potential role in the prevention and treatment of cancer. 2012 , 72, 1579-90	25
1214	Molecular Classification of Breast Cancer. 2012 , 5, 701-17	5
1213	Targeting the subtypes of breast cancer: rethinking investigational drugs. 2012 , 21, 191-204	1
1212	Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer. 2012 , 73, 998-1004	28
1211	Predictive value of breast cancer molecular subtypes in Chinese patients with four or more positive nodes after postmastectomy radiotherapy. 2012 , 21, 657-61	30
1210	Characterization of basal-like breast cancer: an update. 2012 , 18, 104-111	12
1209	Triple negative breast carcinoma: the good, the bad and the ugly. 2012 , 18, 210-216	1
1208	Molecular advances in salivary gland pathology and their practical application. 2012 , 18, 388-396	9
1207	Practical implications of gene-expression-based assays for breast oncologists. 2011 , 9, 48-57	205
1206	Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. 2012 , 29, 1536-42	13
1205	P-cadherin expression and basal-like subtype in breast cancers. 2012 , 29, 2606-12	15

1204	Expression of SIRT1 is associated with lymph node metastasis and poor prognosis in both operable triple-negative and non-triple-negative breast cancer. 2012 , 29, 3240-9			57
1203	Novel model for basaloid triple-negative breast cancer: behavior in vivo and response to therapy. 2012 , 14, 926-42			24
1202	Descripci3n de una cohorte de pacientes con c3ncer de mama triple-negativo subtipo basal-like, atendidas en el Instituto Nacional de Cancerolog3a y en el Hospital de San Jos3 durante el periodo 2006-2008. 2012 , 16, 91-99			
1201	Triple-negative breast cancer: epidemiological considerations and recommendations. 2012 , 23 Suppl 6, vi7-12			324
1200	Breast cancer proteome takes more than two to tango on TRAIL: beat them at their own game. 2012 , 245, 763-77			6
1199	Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. 2012 , 12, 18			23
1198	Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer. 2012 , 10 Suppl 1, S4			23
1197	CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. 2012 , 14, R48			290
1196	Age of 40 years or younger is an independent risk factor for locoregional failure in early breast cancer: a single-institutional analysis in saudi arabia. <i>Journal of Oncology</i> , 2012 , 2012, 370385	4-5		10
1195	Update on triple-negative breast cancer: prognosis and management strategies. 2012 , 4, 511-20			76
1194	Triple Negative Breast Cancer - An Overview. 2013 , 2013,			61
1193	Lymphangiogenesis assessed using three methods is related to tumour grade, breast cancer subtype and expression of basal marker. 2012 , 63, 165-71			4
1192	Morphology of the myoepithelial cell: immunohistochemical characterization from resting to motile phase. 2012 , 2012, 252034			19
1191	Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. 2012 , 226, 84-96			122
1190	Immunophenotypic and genomic characterization of papillary carcinomas of the breast. 2012 , 226, 427-441			65
1189	Validation of an immunohistochemical signature predictive of 8-year outcome for patients with breast carcinoma. 2012 , 131, E236-43			20
1188	Targeted therapy for triple-negative breast cancer: where are we?. 2012 , 131, 2471-7			63
1187	Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma: a critical review. 2012 , 5, 345-66			19

1186	Metaplastic and medullary mammary carcinomas do not express mammaglobin. 2012 , 137, 747-52	11
1185	HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. 2012 , 118, 4354-62	113
1184	Triple negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy. 2012 , 118, 3893-8	20
1183	Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index. 2012 , 118, 4385-93	24
1182	Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis. 2012 , 118, 5198-209	45
1181	Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. 2012 , 118, 5463-72	343
1180	Serological analysis of SEREX-defined medullary breast carcinoma-associated antigens. 2012 , 30, 519-27	6
1179	Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. 2012 , 132, 793-805	205
1178	Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. 2012 , 134, 561-7	54
1177	Image analysis tools for evaluation of microscopic views of immunohistochemically stained specimen in medical research-a review. 2012 , 36, 2621-31	75
1176	EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. 2012 , 29, 401-5	59
1175	Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. 2012 , 29, 547-53	10
1174	Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study. 2012 , 14, 430-6	14
1173	Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer. 2012 , 36, 1189-94	47
1172	Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients. 2012 , 69, 923-30	9
1171	Importance of assessing CK19 immunostaining in core biopsies in patients subjected to sentinel node study by OSNA. 2012 , 460, 569-75	34
1170	Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment. 2012 , 138, 837-42	21
1169	Immunohistochemical study of metaplastic carcinoma and central acellular carcinoma of the breast: central acellular carcinoma is related to metaplastic carcinoma. 2012 , 45, 14-21	6

1168	Egyptian male breast carcinoma: patients hormonal profile, management and outcome. 2012 , 11, 89-98	
1167	Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. 2012 , 132, 937-45	27
1166	A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. 2012 , 133, 37-47	88
1165	Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. 2012 , 133, 437-45	22
1164	A CD44 ⁺ /CD24 ⁺ phenotype is a poor prognostic marker in early invasive breast cancer. 2012 , 133, 979-95	79
1163	Molecular insights on basal-like breast cancer. 2012 , 134, 21-30	64
1162	Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy. 2012 , 134, 199-205	64
1161	A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. 2012 , 60, 854-63	18
1160	Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. 2012 , 24, 183-9	44
1159	Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. 2012 , 11, 522-4	13
1158	Taxane resistance in breast cancer: a closed HER2 circuit?. 2012 , 1825, 197-206	20
1157	Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. 2012 , 21, 50-7	141
1156	Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design. 2012 , 21, 20-6	24
1155	High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients. 2012 , 21, 380-3	11
1154	Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. 2012 , 60, E115-30	42
1153	Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer type. 2012 , 61, 365-77	37
1152	Cytokeratin 7: a re-evaluation of the 'tried and true' in triple-negative breast cancers. 2012 , 61, 660-6	12
1151	Variable performance of commercial epidermal growth factor receptor antibodies in detection of basal-like breast cancer. 2012 , 61, 518-9	1

1150	Triple-negative breast cancer: making the most of a misnomer. 2012 , 8, 145-55	9
1149	Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India. 2012 , 120, 1008-19	13
1148	Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. 2012 , 103, 1679-87	41
1147	Hypoxia-inducible factor 1 α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. 2012 , 14, R6	155
1146	Race and the prognostic influence of p53 in women with breast cancer. 2012 , 19, 2334-44	8
1145	HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients. 2012 , 19, 1831-40	40
1144	ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. 2012 , 32, 166-215	65
1143	Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results. 2012 , 19, 54-9	6
1142	Treatment of Metastatic Triple-Negative Breast Cancer. 2012 , 4, 10-21	
1141	Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers. 2012 , 69, 223-45	51
1140	Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. 2012 , 69, 533-46	21
1139	Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. 2012 , 132, 131-42	91
1138	Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. 2012 , 131, 159-67	146
1137	A retrospective review of the metabolic syndrome in women diagnosed with breast cancer and correlation with estrogen receptor. 2012 , 131, 325-31	20
1136	Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. 2012 , 131, 1061-6	176
1135	Fine-needle aspiration cytology of triple-negative basal-like breast cancer. 2013 , 41, 283-7	2
1134	Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas. 2013 , 8, 80	19
1133	Is mammary not otherwise specified-type sarcoma with CD10 expression a distinct entity? A rare case report with immunohistochemical and ultrastructural study. 2013 , 8, 14	9

1132	Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas. 2013 , 209, 296-301	15
1131	GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. 2013 , 44, 1341-9	150
1130	Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. 2013 , 44, 959-65	110
1129	Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer. 2013 , 63, 713-25	18
1128	A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. 2013 , 26, 1438-50	47
1127	Demethoxycurcumin inhibits energy metabolic and oncogenic signaling pathways through AMPK activation in triple-negative breast cancer cells. 2013 , 61, 6366-75	48
1126	Molecularly targeted therapies for metastatic triple-negative breast cancer. 2013 , 138, 21-35	109
1125	CX3CL1 expression is associated with poor outcome in breast cancer patients. 2013 , 140, 495-504	35
1124	Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer. 2013 , 13, 175	36
1123	Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series. 2013 , 13, 15	34
1122	A new genome-driven integrated classification of breast cancer and its implications. 2013 , 32, 617-28	212
1121	Clinicopathological features of breast cancer with different molecular subtypes in Chinese women. 2013 , 33, 117-121	14
1120	Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer. 2013 , 30, 612	13
1119	Salivary duct carcinoma: new developments--morphological variants including pure in situ high grade lesions; proposed molecular classification. 2013 , 7 Suppl 1, S48-58	86
1118	Vimentin as a poor prognostic factor for triple-negative breast cancer. 2013 , 139, 739-46	87
1117	The complex genetic landscape of familial breast cancer. 2013 , 132, 845-63	94
1116	HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. 2013 , 139, 741-50	38
1115	Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. 2013 , 140, 195-205	35

1114	The management of early-stage and metastatic triple-negative breast cancer: a review. 2013 , 27, 737-49, viii	64
1113	Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. 2013 , 71, 1183-90	28
1112	Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. 2013 , 138, 47-57	72
1111	Breast Cancer Metastasis and Drug Resistance. 2013 ,	5
1110	Breast Cancer Heterogeneity in Primary and Metastatic Disease. 2013 , 65-95	1
1109	Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. 2013 , 109, 1886-94	34
1108	The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. 2013 , 138, 783-94	58
1107	Calretinin expression in high-grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis. 2013 , 44, 2743-50	17
1106	Triple-negative breast cancer and the need for new therapeutic targets. 2013 , 183, 1064-1074	110
1105	Advances in molecular and clinical subtyping of breast cancer and their implications for therapy. 2013 , 22, 823-40	22
1104	MicroRNA signatures in hereditary breast cancer. 2013 , 142, 19-30	28
1103	Multifocal breast cancer documented in large-format histology sections: long-term follow-up results by molecular phenotypes. 2013 , 119, 1132-9	23
1102	Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes. 2013 , 22, 1066-71	7
1101	Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. 2013 , 22, 650-6	55
1100	The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value. 2013 , 13, 146-52	17
1099	Appraising iniparib, the PARP inhibitor that never was--what must we learn?. 2013 , 10, 688-96	66
1098	Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. 2013 , 183, 1113-1124	157
1097	Breast carcinoma: is molecular evaluation a necessary part of current pathological analysis?. 2013 , 30, 321-8	6

1096	Three molecular classifications surrogate to four immunohistochemical markers in 374 invasive breast carcinomas with long follow-up: which is better?. 2013 , 209, 337-44		1
1095	Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas. 2013 , 44, 1241-50		51
1094	Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 5505-12	12.9	443
1093	PIK3CA mutations are frequently observed in BRCA1 but not BRCA2-associated male breast cancer. 2013 , 15, R69		18
1092	High-risk human papillomavirus (HPV) DNA sequences in metaplastic breast carcinomas of Mexican women. 2013 , 13, 445		22
1091	Association between mammographic density and basal-like and luminal A breast cancer subtypes. 2013 , 15, R76		27
1090	Family history and risk of ductal carcinoma in situ and triple negative breast cancer in a Han Chinese population: a case-control study. 2013 , 11, 248		9
1089	Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series. 2013 , 15, R84		65
1088	Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. 2013 , 13, 403		36
1087	Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics. 2013 , 140, 475-84		19
1086	Pregnancy-related characteristics and breast cancer risk. 2013 , 24, 1675-85		20
1085	Fibrotic focus in breast carcinomas: relationship with prognostic parameters and biomarkers. 2013 , 20, 2842-9		33
1084	Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?. 2013 , 20, 2866-72		34
1083	Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence. 2013 , 20, 1886-92		16
1082	Cancers du sein T1a,b N0 M0 (RPC 2013). 2013 , 15, 637-670		4
1081	Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. 2013 , 2, 31		58
1080	Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers. 2013 , 142, 311-22		17
1079	Breast adenomyoepithelioma: a case report with malignant proliferation of epithelial and myoepithelial elements. 2013 , 11, 285		18

1078	Epigenetic modifications in breast cancer and their role in personalized medicine. 2013 , 183, 1052-1063	58
1077	Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth?. 2013 , 22, 1026-33	34
1076	Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. 2013 , 95, 276-87	45
1075	Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype. 2013 , 20, 1505-13	26
1074	The classification of invasive carcinoma of the breast. 2013 , 13, 941-54	9
1073	TACE-dependent TGFβ shedding drives triple-negative breast cancer cell invasion. 2013 , 133, 2587-95	25
1072	Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. 2013 , 109, 444-51	64
1071	Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers. 2013 , 148, 298-306	40
1070	Breast Cancer. 2013 , 707-713	
1069	Lack of expression of the proteins GMPR2 and PPARβ are associated with the basal phenotype and patient outcome in breast cancer. 2013 , 137, 127-37	15
1068	Assessing the role of ultrasound in predicting the biological behavior of breast cancer. 2013 , 200, 284-90	54
1067	Expression of androgen receptors in triple negative breast carcinomas. 2013 , 115, 344-8	78
1066	Targeted therapy for breast cancer. 2013 , 183, 1096-1112	83
1065	P-cadherin and vimentin are useful basal markers in breast cancers. 2013 , 44, 2782-91	10
1064	Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour. 2013 , 22, 986-92	31
1063	Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancer. 2013 , 185, 697-703	29
1062	Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys. 2013 , 138, 298-306	5
1061	Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. 2013 , 34, 10160-71	95

1060	Molecular subtypes of ductal carcinoma in situ in African American and Caucasian American women: distribution and correlation with pathological features and outcome. 2013 , 37, 474-8	8
1059	A review of adenoid cystic carcinoma of the breast with emphasis on its molecular and genetic characteristics. 2013 , 44, 301-9	32
1058	Clinicopathologic features of ductal carcinoma in situ in young women with an emphasis on molecular subtype. 2013 , 44, 2487-93	13
1057	Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study. 2013 , 44, 2055-63	76
1056	The prognostic significance of metaplastic carcinoma of the breast (MCB)--a case controlled comparison study with infiltrating ductal carcinoma. 2013 , 22, 968-73	56
1055	Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. 2013 , 22, 282-8	47
1054	Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of st Gallen recommendations. 2013 , 13, 119-28	16
1053	Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts. 2013 , 108, 1042-51	49
1052	Shotgun proteomics of archival triple-negative breast cancer samples. 2013 , 7, 283-91	24
1051	Therapeutic targets in triple negative breast cancer. 2013 , 66, 530-42	104
1050	Pathology of invasive breast disease. 2013 , 93, 363-92	14
1049	Biomarkers for the clinical management of breast cancer: international perspective. 2013 , 133, 1-13	118
1048	Characteristics of basal cytokeratin expression in breast cancer. 2013 , 139, 23-37	28
1047	The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis. 2013 , 138, 59-67	21
1046	Emerging therapies for triple-negative breast cancer. 2013 , 2, 47-55	0
1045	Molecular mapping the presence of druggable targets in preinvasive and precursor breast lesions: a comprehensive review of biomarkers related to therapeutic interventions. 2013 , 1835, 230-42	4
1044	Curcumin-derivative nanomicelles for the treatment of triple negative breast cancer. 2013 , 21, 675-83	18
1043	Transducer of Cdc42-dependent actin assembly promotes breast cancer invasion and metastasis. 2013 , 32, 3080-90	31

1042	Molecular and clinicopathological markers of prognosis in breast cancer. 2013 , 13, 481-98	4
1041	Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 'years' follow-up. 2013 , 140, 93-104	41
1040	Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. 2013 , 26, 955-66	63
1039	c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer. 2013 , 100, 490-6	38
1038	p130Cas alters the differentiation potential of mammary luminal progenitors by deregulating c-Kit activity. 2013 , 31, 1422-33	12
1037	St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial. 2013 , 13, 558	32
1036	Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. 2013 , 138, 81-90	104
1035	Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. 2013 , 20, 1059-66	48
1034	Targeted approaches to triple-negative breast cancer: current practice and future directions. 2013 , 20, 605-12	15
1033	Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. 2013 , 26, 485-95	64
1032	Genetic and Genomic Factors in Breast Cancer. 2013 , 29-47	
1031	TMPRSS4 as a poor prognostic factor for triple-negative breast cancer. 2013 , 14, 14659-68	23
1030	MicroRNAs and triple negative breast cancer. 2013 , 14, 22202-20	59
1029	Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. 2013 , 86, 20120601	74
1028	Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines. 2013 , 14, 7959-78	43
1027	Updates in the treatment of basal/triple-negative breast cancer. 2013 , 25, 40-8	32
1026	Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. 2013 , 36, 224-31	91
1025	Ductal carcinoma in situ: morphology-based knowledge and molecular advances. 2013 , 20, 205-16	14

1024	A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338. 2013 , 36, 540-4	15
1023	Stromal EGF and igf-I together modulate plasticity of disseminated triple-negative breast tumors. 2013 , 3, 922-35	32
1022	Salivary gland-like tumors of the breast express basal-type immunohistochemical markers. 2013 , 21, 283-6	19
1021	14-3-3 β stabilizes a complex of soluble actin and intermediate filament to enable breast tumor invasion. 2013 , 110, E3937-44	42
1020	Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. <i>Clinical Cancer Research</i> , 2013 , 19, 291-303	12.9 34
1019	TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers. 2013 , 33, 557-70	60
1018	[Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives]. 2013 , 100, 453-64	14
1017	ADAM-17: a novel therapeutic target for triple negative breast cancer. 2013 , 24, 362-369	41
1016	Are mammaglobin and GCDFP-15 sensitive markers for diagnosis of metastatic basal-like triple negative breast carcinomas?. 2014 , 30, 18-22	1
1015	Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women. 2013 , 2013, 675051	11
1014	Molecular Biology of Breast Cancer in the Horn of Africa: Case Series A Pilot Study of Breast Cancer from Eritrea. 2013 , 2013, 1-7	4
1013	Epidemiological and clinical profile of triple negative breast cancer at a cancer hospital in North India. 2013 , 34, 89-95	15
1012	Genomic approaches in breast cancer research. 2013 , 12, 391-6	13
1011	Treatment of estrogen receptor-positive breast cancer. 2013 , 20, 596-604	142
1010	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. 2013 , 5, 169-81	121
1009	Focusing on breast cancer overdiagnosis and overtreatment: the promise of molecular medicine. 2013 , 19, 127-9	5
1008	Triple-negative breast cancer: molecular characterization and targeted therapies. 2013 , 2, 417-430	1
1007	Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer. 2013 , 66, 291-6	13

1006	Estrogen receptor [putting a positive into triple negative breast cancer?. 2013 , 16, 117-23		6
1005	Tight Junctions in Cancer Metastasis. 2013 ,		3
1004	Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. 2013 , 15, R98		69
1003	Expression of cell metabolism-related genes in different molecular subtypes of triple-negative breast cancer. 2013 , 99, 555-564		5
1002	The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients. 2013 , 11, 293		8
1001	Differential expression of testin and survivin in breast cancer subtypes. 2013 , 30, 824-32		10
1000	Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression. 2013 , 43, 785-92		14
999	Low methylation levels of the SFRP1 gene are associated with the basal-like subtype of breast cancer. 2013 , 29, 1946-54		13
998	Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells. 2013 , 29, 819-25		54
997	A Case of Aggressive Primary Squamous Cell Carcinoma of the Breast with the Overexpression of Epidermal Growth Factor Receptor. 2013 , 38, 785-789		
996	Comparison of nuclear grade and immunohistochemical features in situ and invasive components of ductal carcinoma of breast. 2013 , 35, 97-102		9
995	Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer. 2013 , 99, 545-554		4
994	A recombined fusion protein PTD-Grb2-SH2 inhibits the proliferation of breast cancer cells in vitro. 2013 , 42, 1061-9		5
993	Distinct effects of EGFR ligands on human mammary epithelial cell differentiation. <i>PLoS ONE</i> , 2013 , 8, e75907	3.7	16
992	Prognostic factors of young women (≤5 years) with node positive breast cancer: possible influence on post-therapeutic follow-up. 2013 , 100, 22-9		3
991	Phosphoproteomics for the Mapping of Altered Cell Signaling Networks in Breast Cancer. 2013 ,		1
990	A microRNA signature associated with early recurrence in breast cancer. <i>PLoS ONE</i> , 2014 , 9, e91884	3.7	64
989	The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFR β closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. <i>PLoS ONE</i> , 2014 , 9, e102176	3.7	37

988	A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer. <i>PLoS ONE</i> , 2014 , 9, e112765	3-7	27
987	Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. <i>PLoS ONE</i> , 2014 , 9, e114900	3-7	48
986	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. 2014 , 5, 745-53		32
985	Optimizing chemotherapy in triple-negative breast cancer: the role of platinum. 2014 , e37-42		16
984	Should triple-negative breast cancer (TNBC) subtype affect local-regional therapy decision making?. 2014 , e32-6		10
983	Resistance to HER2-targeted therapies: a potential role for FOXM1. 2014 , 3, 423-431		13
982	Microarray big data integrated analysis to identify robust diagnostic signature for triple negative breast cancer. 2014 ,		1
981	NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas. 2014 , 67, 768-71		18
980	FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer. 2014 , 21 Suppl 4, S758-66		31
979	Prognosis in very young women with triple-negative breast cancer: retrospective study of 216 cases. 2014 , 31, 222		12
978	Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer. 2014 , 14, 959		23
977	PIAS1 expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. 2014 , 67, 301-6		9
976	Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. 2014 , 15, 1571-82		16
975	Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. 2014 , 13, 316-28		57
974	Successes and limitations of targeted cancer therapy in breast cancer. 2014 , 41, 15-35		23
973	cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?. 2014 , 18, 999-1009		19
972	Folate receptor β associated with triple-negative breast cancer and poor prognosis. 2014 , 138, 890-5		92
971	Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma. 2014 , 138, 175-81		8

970	Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer. 2014 , 2014, 141864		11
969	Relationship between the prognostic and predictive value of the intrinsic subtypes and a validated gene profile predictive of loco-regional control and benefit from post-mastectomy radiotherapy in patients with high-risk breast cancer. 2014 , 53, 1337-46		28
968	Standard of care and promising new agents for triple negative metastatic breast cancer. <i>Cancers</i> , 2014 , 6, 2187-223	6.6	32
967	Triple-negative breast cancer: An institutional analysis. 2014 , 51, 163-6		21
966	Computational analysis of mRNA expression profiles identifies the ITG family and PIK3R3 as crucial genes for regulating triple negative breast cancer cell migration. 2014 , 2014, 536591		12
965	Integrated microarray analytics for the discovery of gene signatures for triple-negative breast cancer. 2014 ,		1
964	Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. 2014 , 7, ra29		93
963	Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. 2014 , 20, 358-63		8
962	Differentiation and histogenesis of syringomatous tumour of the nipple and low-grade adenosquamous carcinoma: evidence for a common origin. 2014 , 65, 9-23		29
961	Molecular subtypes of breast cancer in South Asian population by immunohistochemical profile and Her2neu gene amplification by FISH technique: association with other clinicopathologic parameters. 2014 , 20, 578-85		23
960	Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations. 2014 , 110, 1045-52		26
959	Molecular phenotype of the foci in multifocal invasive breast carcinomas: intertumoral heterogeneity is related to shorter survival and may influence the choice of therapy. 2014 , 120, 26-34		30
958	Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. 2014 , 101, 925-38		30
957	Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. 2014 , 111, 2351-60		17
956	Molecular classification of metaplastic carcinoma using surrogate immunohistochemical staining. 2014 , 81, 69-77		3
955	Enhanced down-regulation of ALCAM/CD166 in African-American Breast Cancer. 2014 , 14, 715		12
954	Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. 2014 , 14, 908		33
953	Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. 2014 , 16, 423		16

952	DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. 2014 , 16, 450	64
951	Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer. 2014 , 16, 466	24
950	Correlation of clinicopathologic parameters and immunohistochemical features of triple-negative invasive lobular carcinoma. 2014 , 22, e18-26	8
949	Triple-negative breast carcinoma in African American and Caucasian women: clinicopathology, immunomarkers, and outcome. 2014 , 22, 17-23	10
948	The role of Ki-67 in the proliferation and prognosis of breast cancer molecular classification subtypes. 2014 , 25, 950-7	24
947	Expression of topoisomerase II- β in triple negative breast cancer. 2014 , 22, 182-7	18
946	Triple-negative, basal marker-expressing, and high-grade breast carcinomas are characterized by high lymphatic vessel density and the expression of podoplanin in stromal fibroblasts. 2014 , 22, 10-6	12
945	Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features. 2014 , 138, 37-43	34
944	Theranostic and molecular classification of breast cancer. 2014 , 138, 44-56	35
943	Omics Approaches in Breast Cancer. 2014 ,	8
942	Breast Cancer Genomics. 2014 , 53-103	
941	A Novel Subset of Human Tumors That Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate Cancers. 2014 , 13, 89-100	13
940	Clinical Significance of Androgen Receptor, CK-5/6, KI-67 and Molecular Subtypes in Breast Cancer. 2014 , 10, 201-208	4
939	High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis. 2014 , 7, 1475-80	114
938	Baseline staging tests based on molecular subtype is necessary for newly diagnosed breast cancer. 2014 , 33, 28	17
937	The role of platinum therapy in triple-negative breast cancer. 2014 , 3, 377-385	1
936	How to identify patients with increased risk of breast cancer relapse?. 2014 , 22, 488-97	2
935	Clinicopathological and molecular significance of Sumoylation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women. 2014 , 210, 10-7	12

934	Expression of cancer stem cell markers in basal and penta-negative breast carcinomas--a study of a series of triple-negative tumors. 2014 , 210, 432-9	13
933	Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. 2014 , 27, 352-60	102
932	Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells. 2014 , 21, 75-85	19
931	CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy. 2014 , 45, 35-45	24
930	Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. 2014 , 16, 386-94	14
929	Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. 2014 , 143, 385-92	43
928	Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing. 2014 , 143, 57-68	25
927	Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. 2014 , 21, 1561-8	47
926	Complexity in regulation of microRNA machinery components in invasive breast carcinoma. 2014 , 20, 697-705	23
925	Helix-loop-helix protein inhibitor of differentiation 4 (ID4) expression is an indicator of poor survival in Nigerian breast cancer women. 2014 , 6, 129-137	2
924	Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1-T2 breast cancer and 1-3 positive lymph nodes. 2014 , 21, 1569-74	29
923	Descriptive analysis of molecular subtypes in Tunisian breast cancer. 2014 , 10, e69-74	17
922	Low concordance of biomarkers in histopathological and cytological material from breast cancer. 2014 , 64, 971-80	14
921	Predicting prognostic factors of breast cancer using shear wave elastography. 2014 , 40, 269-74	40
920	The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. 2014 , 15, 681-700	40
919	Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. 2014 , 35, 7733-41	70
918	YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK. 2014 , 171, 4010-25	22
917	MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. 2014 , 134, 2424-36	59

916	Analysis of a new histological and molecular-based classification of canine mammary neoplasia. 2014 , 51, 549-59	45
915	Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. 2014 , 18, 863-81	30
914	Immunohistochemistry-based subtyping of breast carcinoma in Egyptian women: a clinicopathologic study on 125 patients. 2014 , 18, 21-6	9
913	Increased SOX2 expression in less differentiated breast carcinomas and their lymph node metastases. 2014 , 64, 494-503	28
912	Time for more optimism in metastatic breast cancer?. 2014 , 40, 220-8	44
911	Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. 2014 , 31, 801	45
910	P16 but not retinoblastoma expression is related to clinical outcome in no-special-type triple-negative breast carcinomas. 2014 , 27, 204-13	9
909	Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study. 2014 , 25, 259-65	61
908	Targeting multiple pathways in breast cancer. 2014 , 3, 87-101	0
907	Breast-Cancer Subtyping in Clinical Practice: Clinicopathologic Features and Outcomes. 2014 , 30, 260-264	1
906	Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. 2014 , 14, 468-74	25
905	Deconstructing breast cancer heterogeneity: clinical implications for women with Basal-like tumors. 2014 , 41, 639-46	4
904	Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell. 2014 , 20, 704-15	24
903	Label-free proteomic analysis of breast cancer molecular subtypes. 2014 , 13, 4752-72	21
902	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis. 2014 , 40, 1048-55	27
901	Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. 2014 , 110, 1497-505	227
900	Breast cancer subtypes and previously established genetic risk factors: a bayesian approach. 2014 , 23, 84-97	29
899	Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). <i>Cancer Letters</i> , 2014 , 353, 153-9	9.9 87

898	Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. 2014 , 13, 1356-68	40
897	Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. 2014 , 25, 1570-7	75
896	The dog as a natural animal model for study of the mammary myoepithelial basal cell lineage and its role in mammary carcinogenesis. 2014 , 151, 166-80	31
895	Predicting response and survival in chemotherapy-treated triple-negative breast cancer. 2014 , 111, 1532-41	82
894	Therapeutic antibodies in breast cancer. 2014 , 41, 576-88	3
893	Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast. 2014 , 31, 172	11
892	Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. 2014 , 14, 102	22
891	alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. 2014 , 14, 28	10
890	Fibromatosis-like metaplastic carcinoma of the breast has a claudin-low immunohistochemical phenotype. 2014 , 465, 185-91	16
889	Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. 2014 , 146, 25-40	20
888	Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers. 2014 , 146, 175-82	18
887	Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. 2014 , 6, 12	60
886	Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers. 2014 , 21, 2218-28	44
885	Molecular Heterogeneity of Triple Negative Breast Cancer. 2014 , 6, 154-158	43
884	Can molecular subtyping replace axillary nodal status as prognostic marker in breast cancer?. 2014 , 5, 282-9	5
883	Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. 2014 , 14, 141	19
882	Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice. 2014 , 14, 266	10
881	Identification of breast cancer patients with a high risk of developing brain metastases: a single-institutional retrospective analysis. 2014 , 14, 289	16

880	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. 2014 , 14, 302	37
879	Effect of niclosamide on basal-like breast cancers. 2014 , 13, 800-11	62
878	Comparison of frequencies and prognostic effect of molecular subtypes between young and elderly breast cancer patients. 2014 , 8, 1014-25	34
877	Efficacy of biological agents in metastatic triple-negative breast cancer. 2014 , 40, 605-13	34
876	Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas. 2014 , 116, 740-6	4
875	Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. 2014 , 23, 346-51	18
874	Clinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis. 2014 , 19, 173-81	8
873	YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer. 2014 , 32, 1437-50	30
872	High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. 2014 , 31, 57	60
871	Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. 2014 , 21, 283-9	25
870	The omics of triple-negative breast cancers. 2014 , 60, 122-33	44
869	Luminal (Her2 negative) prognostic index and survival of breast cancer patients. 2014 , 38, 286-90	9
868	Molecular classification of breast cancer. 2014 , 465, 1-14	106
867	Basal-like and triple-negative breast cancers: searching for positives among many negatives. 2014 , 23, 567-77	65
866	Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition. 2014 , 90, 226-34	47
865	Primary relapse site pattern in women with triple-negative breast cancer. 2014 , 210, 571-5	10
864	PELO negatively regulates HER receptor signalling and metastasis. 2014 , 33, 1190-7	6
863	Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library. 2014 , 21, 738-47	1

862	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. 2014 , 33, 148-56		67
861	Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways. 2014 , 16, 437		10
860	Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. 2014 , 16, 432		137
859	Dysregulation of microRNA expression drives aberrant DNA hypermethylation in basal-like breast cancer. 2014 , 44, 563-72		62
858	Metaplastic carcinoma of the breast: an immunohistochemical study. 2014 , 9, 139		36
857	Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer. 2014 , 114, 153-9		3
856	Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social. 2015 , 83, 193-198		2
855	Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. 2015 , 17, 80		5
854	B-crystallin Expression in Breast Cancer is Associated with Brain Metastasis. <i>Npj Breast Cancer</i> , 2015 , 1,	7.8	22
853	Forkhead box C1 promoter upstream transcript, a novel long non-coding RNA, regulates proliferation and migration in basal-like breast cancer. 2015 , 11, 3155-9		25
852	Evaluation of p40 as a Myoepithelial Marker in Different Breast Lesions. 2015 , 82, 166-71		8
851	Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer. 2015 , 13, 254		12
850	Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy. 2015 , 4, 386		21
849	MYC is expressed in the stromal and epithelial cells of primary breast carcinoma and paired nodal metastases. 2015 , 3, 506-514		1
848	Effect of Ki-67 on Immunohistochemical Classification of Luminal A to Luminal B Subtypes of Breast Carcinoma. 2015 , 21, 465-72		7
847	Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteria. 2015 , 4, 528		7
846	Quantification of length-bias in screening trials with covariate-dependent test sensitivity. 2015 , 57, 777-96		2
845	Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women. 2015 , 123, 688-96		9

844	Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances. 2015 , 7, 797-816		39
843	The clinical significance of standardized uptake value in breast cancer measured using 18F-fluorodeoxyglucose positron emission tomography/computed tomography. 2015 , 36, 790-4		6
842	Breast Cancer Molecular Subtypes and Oxidative DNA Damage. 2015 , 23, 696-703		10
841	Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes. 2015 , 22, 306-13		11
840	MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer. 2015 , 1, 60-71		
839	Comparisons of the Clinicopathological Characteristics and the Expression of Tumor Biomarkers among Luminal, HER2-Enriched and Triple Negative Breast Cancer. 2015 , 03,		1
838	The association of subtypes of breast cancer with tumour characteristics and reproductive factors in 1326 Mexican women. 2015 , 19, 462-6		1
837	Invasive ductal carcinoma of no special type and its corresponding lymph node metastasis: do they have the same immunophenotypic profile?. 2015 , 66, 30-7		4
836	Adjuvant chemotherapy may improve survival of patients with luminal A breast cancer and positive lymph nodes. 2015 , 14, 8563-73		4
835	MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer. 2015 , 16, 28347-76		46
834	Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients. 2015 , 30, e190-9		11
833	Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients. <i>PLoS ONE</i> , 2015 , 10, e0128368	3-7	38
832	Clinicopathological Features and Prognosis of Metaplastic Breast Carcinoma: Experience of a Major Chinese Cancer Center. <i>PLoS ONE</i> , 2015 , 10, e0131409	3-7	40
831	Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen. <i>PLoS ONE</i> , 2015 , 10, e0136829	3-7	57
830	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. 2015 , 6, 12890-908		80
829	Criteria for prediction of metastatic axillary lymph nodes in early-stage breast cancer. 2015 , 37, 308-13		9
828	Biomarkers in triple negative breast cancer: A review. 2015 , 6, 252-63		65
827	Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay. 2015 , 107,		37

826	Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. 2015 , 25, 3314-21		26
825	Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 88-104	7	50
824	Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. 2015 , 43, 42-60		104
823	Clinicopathological study of centrally necrotizing carcinoma of the breast. 2015 , 15, 282		5
822	The fate of chemoresistance in triple negative breast cancer (TNBC). 2015 , 3, 257-75		216
821	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. 2015 , 1, 18-32		18
820	CD10 Immunohistochemical Expression in Apocrine Lesions of the Breast. 2015 , 82, 259-63		4
819	Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6. 2015 , 47, 122-32		23
818	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. 2015 , 7, 232-241		
817	Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells. 2015 , 46, 878-84		34
816	The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. 2015 , 484, 16-28		35
815	A histomorphologic predictive model for axillary lymph node metastasis in preoperative breast cancer core needle biopsy according to intrinsic subtypes. 2015 , 46, 246-54		9
814	Breast Cancers with Brain Metastases. 2015 , 113-119		
813	Mining cancer gene expression databases for latent information on intronic microRNAs. 2015 , 9, 473-87		4
812	Bcl2 and Ki67 refine prognostication in luminal breast cancers. 2015 , 149, 631-43		13
811	Metabolic Signatures of Human Breast Cancer. 2015 , 2,		42
810	BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy. 2015 , 36, 4243-52		27
809	Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma. 2015 , 32, 275		21

808	Genetic variation in cell cycle regulatory gene AURKA and association with intrinsic breast cancer subtype. 2015 , 54, 1668-77	13
807	Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast. 2015 , 63, 408-16	15
806	Regulation of C-X-C chemokine gene expression by keratin 17 and hnRNP K in skin tumor keratinocytes. 2015 , 208, 613-27	46
805	p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy. 2015 , 24, 294-7	18
804	Greater absolute risk for all subtypes of breast cancer in the US than Malaysia. 2015 , 149, 285-91	10
803	Breast. 2015 , 183-215	
802	The origin of breast tumor heterogeneity. 2015 , 34, 5309-16	90
801	Genetic variation in estrogen and progesterone pathway genes and breast cancer risk: an exploration of tumor subtype-specific effects. 2015 , 26, 121-31	12
800	Radiation therapy in the locoregional treatment of triple-negative breast cancer. 2015 , 16, e113-22	64
799	Targeted Therapies in Triple-Negative Breast Cancer. 2015 , 10, 159-66	44
798	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. 2015 , 20, 713-8	11
797	Over-expression of EPS15 is a favorable prognostic factor in breast cancer. 2015 , 11, 2978-85	6
796	The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors. 2015 , 16, 1535-47	13
795	Molecular and diagnostic features of apocrine breast lesions. 2015 , 15, 1011-22	11
794	[Molecular taxonomy of luminal breast cancer in 2015]. 2015 , 102, S34-46	5
793	Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer. 2015 , 15, 498-504	36
792	An overview of triple negative breast cancer for surgical oncologists. 2015 , 24, 276-83	21
791	Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database. 2015 , 93, 622-30	59

790	The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. 2015 , 211, 740-7	25
789	Subclonal diversification of primary breast cancer revealed by multiregion sequencing. 2015 , 21, 751-9	521
788	PEA-15 facilitates EGFR dephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cells. 2015 , 589, 1033-9	10
787	Kindlin-2 interacts with and stabilizes EGFR and is required for EGF-induced breast cancer cell migration. <i>Cancer Letters</i> , 2015 , 361, 271-81	9.9 40
786	Cell signaling events differentiate ER-negative subtypes from ER-positive breast cancer. 2015 , 32, 142	4
785	Therapies for triple negative breast cancer. 2015 , 16, 983-98	60
784	Retrospective analysis of metastatic behaviour of breast cancer subtypes. 2015 , 150, 547-57	104
783	Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment. 2015 , 15, 109	9
782	Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. 2015 , 17, 43	171
781	Quantification of HER family receptors in breast cancer. 2015 , 17, 53	30
780	Role of Poly ADP-Ribose Polymerase (PARP) Inhibitors in Triple-Negative Breast Cancer (TNBC). 2015 , 73-80	
779	A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. 2015 , 16, 678-83	22
778	Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. 2015 , 8, 237-51	100
777	Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer. 2015 , 150, 479-86	44
776	Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer. 2015 , 27, 1315-24	11
775	Transgelin: a potentially useful diagnostic marker differentially expressed in triple-negative and non-triple-negative breast cancers. 2015 , 46, 876-83	13
774	4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival. 2015 , 153, 647-58	37
773	CDK7-dependent transcriptional addiction in triple-negative breast cancer. 2015 , 163, 174-86	268

772	Heat Shock Proteins in Triple-Negative Breast Cancer (TNBC) Treatment. 2015 , 129-149		1
771	A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. 2015 , 15, 14		25
770	A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer. 2015 , 4, e992222		32
769	Reliability of Prognostic and Predictive Factors Evaluated by Needle Core Biopsies of Large Breast Invasive Tumors. 2015 , 144, 555-62		8
768	Heterogeneity between triple negative breast cancer cells due to differential activation of Wnt and PI3K/AKT pathways. 2015 , 339, 67-80		14
767	Advances in small-molecule drug discovery for triple-negative breast cancer. 2015 , 7, 2019-39		11
766	Breast cancer survival in African-American women by hormone receptor subtypes. 2015 , 153, 211-8		17
765	Precision Molecular Pathology of Breast Cancer. 2015 ,		3
764	Heat Shock Protein-Based Therapies. 2015 ,		4
763	Microvascular proliferation in luminal A and basal-like breast cancer subtypes. 2015 , 68, 891-7		16
762	Clinical implications of molecular heterogeneity in triple negative breast cancer. 2015 , 24 Suppl 2, S36-40		76
761	Epidermal growth factor-stimulated Akt phosphorylation requires clathrin or ErbB2 but not receptor endocytosis. 2015 , 26, 3504-19		51
760	CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping. <i>Clinical Cancer Research</i> , 2015 , 21, 1779-81	12.9	14
759	Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers. 2015 , 15, 506		11
758	Molecular Classification of Breast Cancer. 2015 , 137-155		
757	FOXA2 mRNA expression is associated with relapse in patients with Triple-Negative/Basal-like breast carcinoma. 2015 , 153, 465-74		18
756	[Prevalence of breast cancer sub-types by immunohistochemistry in patients in the Regional General Hospital 72, Instituto Mexicano del Seguro Social]. 2015 , 83, 193-8		3
755	Basal Protein Expression Is Associated With Worse Outcome and Trastuzumab Resistance in HER2+ Invasive Breast Cancer. 2015 , 15, 448-457.e2		8

754	Targeting Mdmx to treat breast cancers with wild-type p53. 2015 , 6, e1821	28
753	Screening mammography-detected ductal carcinoma in situ: mammographic features based on breast cancer subtypes. 2015 , 39, 983-6	10
752	Secretary breast carcinoma in a 41-year-old man with long-term follow-up: a special report. 2015 , 11, 1767-73	2
751	Single-nucleotide polymorphisms in DNA bypass polymerase genes and association with breast cancer and breast cancer subtypes among African Americans and Whites. 2015 , 149, 181-90	7
750	The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis. 2015 , 141, 505-14	4
749	Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer. 2015 , 111, 198-202	7
748	Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer. 2015 , 136, 204-11	48
747	Prediction of individual response to anticancer therapy: historical and future perspectives. 2015 , 72, 729-57	33
746	Prognostic evaluation of feline mammary carcinomas: a review of the literature. 2015 , 52, 46-60	53
745	Triple-negative breast cancer: investigating potential molecular therapeutic target. 2015 , 19, 55-75	39
744	IMMUNOHISTOCHEMICAL DIFFERENTIATION OF TRIPLE NEGATIVE BREAST CANCER. 2016 , 55, 3-8	2
743	Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. 2016 , 7, 73618-73637	43
742	MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition. 2016 , 63, 44-56	11
741	Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment. 2016 , 7, 49349-49367	69
740	The expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients. 2016 , 9, 5751-5759	18
739	Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer. 2016 , 7, 167-73	68
738	Immunohistochemical characteristics of basal-like breast cancer. 2016 , 20, 436-443	20
737	Patterns of distant metastasis in Chinese women according to breast cancer subtypes. 2016 , 7, 47975-47984	18

736	Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers. 2016 , 7, 69903-69915	40
735	Overexpression of seven in absentia homolog 2 protein in human breast cancer tissues is associated with the promotion of tumor cell malignant behavior in in vitro. 2016 , 36, 1301-12	4
734	Triple-negative breast cancer: treatment challenges and solutions. 2016 , 8, 93-107	146
733	Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. 2016 , 7, 1281-94	190
732	Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. 2016 , 7, 57633-57650	54
731	Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. 2016 , 138, 2274-80	36
730	Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival. 2016 , 68, 702-12	14
729	Do platinum salts fit all triple negative breast cancers?. 2016 , 48, 34-41	38
728	Alcohol consumption and risk of breast cancer by molecular subtype: Prospective analysis of the nurses' health study after 26 years of follow-up. 2016 , 138, 1094-101	20
727	Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers. 2016 , 138, 2510-21	28
726	Prognostic analysis of triple-negative breast cancer patients treated with adjuvant chemotherapy of fluorouracil, epirubicin and cyclophosphamide. 2016 , 11, 2320-2326	4
725	Triple-Negative Breast Cancer. 2016 , 71-80	5
724	Hyaluronan synthase 2 is an adverse prognostic marker in androgen receptor-negative breast cancer. 2016 , 69, 1055-1062	4
723	Novel Immunohistochemical Based Biomarkers in Breast Cancer. 2016 , 99-119	
722	Biological Subtypes and Distant Relapse Pattern in Breast Cancer Patients After Curative Surgery (Study of Anatolian Society of Medical Oncology). 2016 , 11, 248-252	13
721	IHC-breast cancer subtypes of invasive ductal carcinoma with predominant intraductal component as an insignificant prognostic factor: A register-based study from Korea. 2016 , 7, 52-57	0
720	Breast Cancer Subtypes in Patients Aged 70 Years and Older. 2016 , 34, 197-204	9
719	Active smoking and risk of Luminal and Basal-like breast cancer subtypes in the Carolina Breast Cancer Study. 2016 , 27, 775-86	16

718	"Triple negative breast cancer": Translational research and the (re)assembling of diseases in post-genomic medicine. 2016 , 59, 20-34	11
717	Tyrosine Kinase Inhibitors. 2016 , 617-631	
716	Personalized Treatment of Breast Cancer. 2016 ,	2
715	Aberrant keratin 7 and 20 expression in triple-negative carcinoma of the breast. 2016 , 20, 36-9	2
714	Estrogen receptor beta modulates breast cancer cells functional properties, signaling and expression of matrix molecules. 2016 , 56, 4-23	54
713	Prognostic significance of inflammatory factors expression by stroma from breast carcinomas. 2016 , 37, 768-776	22
712	Development of a new tri-block copolymer with a functional end and its feasibility for treatment of metastatic breast cancer. 2016 , 144, 73-80	17
711	The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells. 2016 , 107, 282-290	43
710	Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer. 2016 , 24, 238-45	39
709	The Molecular Basis of Breast Cancer Subtypes. 2016 , 111-116	0
708	Genetics of triple-negative breast cancer: Implications for patient care. 2016 , 40, 130-140	17
707	Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy. 2016 , 50, 168-174	9
706	Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update. 2016 , 140, 806-14	70
705	Protein Tyrosine Phosphatases in Cancer. 2016 ,	3
704	The Role of TCPTP in Cancer. 2016 , 145-168	3
703	Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. 2016 , 16, 587	22
702	The Pathobiology of Breast Cancer. 2016 ,	4
701	Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications. 2016 , 37, 14479-14499	5

700	Triple-Negative/Basal-Like Breast Carcinomas. 2016 , 431-443		
699	Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers. 2016 , 12, 1240-1256		13
698	Biology and Management of Patients With Triple-Negative Breast Cancer. 2016 , 21, 1050-62		131
697	Tumors of the Mammary Gland. 2016 , 723-765		12
696	Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. <i>Scientific Reports</i> , 2016 , 6, 30091	4.9	15
695	Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy. <i>Scientific Reports</i> , 2016 , 6, 30934	4.9	24
694	Investigation of breast cancer sub-populations in black and white women in South Africa. 2016 , 160, 531-537		10
693	The Apocrine Profile of Triple-negative Breast Carcinomas in Patients Aged 45 Years or Younger: favorable but rare features. 2016 , 38, 512-517		3
692	A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. 2016 , 10, 25-36		100
691	uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. 2016 , 16, 615		19
690	MicroRNA-205 directly targets Krüppel-like factor 12 and is involved in invasion and apoptosis in basal-like breast carcinoma. 2016 , 49, 720-34		23
689	Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies. 2016 , 138, 2346-56		70
688	Snail-induced epithelial-to-mesenchymal transition of MCF-7 breast cancer cells: systems analysis of molecular changes and their effect on radiation and drug sensitivity. 2016 , 16, 236		31
687	Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment. 2016 , 17, 698-707		28
686	Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 4687-97	12.9	36
685	Prognostic value of ERBB4 expression in patients with triple negative breast cancer. 2016 , 16, 138		28
684	Surgery and radiation therapy of triple-negative breast cancers: From biology to clinics. 2016 , 28, 148-55		15
683	The Challenge to Overcome Triple-Negative Breast Cancer Heterogeneity. 2016 , 247-261		

682	Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization. 2016 , 27, 44-51	30
681	Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial. 2016 , 16, 349-355	25
680	Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model. 2016 , 16, 191	20
679	SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. 2016 , 18, 2	25
678	Ēatenin regulates c-Myc and CDKN1A expression in breast cancer cells. 2016 , 55, 431-9	37
677	Clinicopathological features and prognosis of triple-negative breast cancer: a comparison between younger (. 2016 , 25, 1065-1075	9
676	CD73-adenosine: a next-generation target in immuno-oncology. 2016 , 8, 145-63	82
675	A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines. 2016 , 48, 385-98	9
674	Breast cancer subtypes: morphologic and biologic characterization. 2016 , 12, 103-19	19
673	Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer. 2016 , 114, 14-20	37
672	Applications of molecular diagnostics for personalized treatment of head and neck cancer: state of the art. 2016 , 16, 205-21	9
671	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. 2016 , 47, 52-63	214
670	N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. 2016 , 16, 23-30	31
669	Clinical application of a color map pattern on shear-wave elastography for invasive breast cancer. 2016 , 25, 44-8	8
668	Healthy dietary patterns and risk of breast cancer by molecular subtype. 2016 , 155, 579-88	37
667	Immunohistochemistry for Triple-Negative Breast Cancer. 2016 , 1406, 39-51	2
666	High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer. <i>Cancer Letters</i> , 2016 , 382, 77-85	9.9 24
665	c-Met and ERĒ expression differences in basal-like and non-basal-like triple-negative breast cancer. 2016 , 37, 11385-95	8

664	Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer. 2016 , 23, 1104-10	94
663	Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer. 2016 , 46, 821-6	22
662	An overview of triple-negative breast cancer. 2016 , 293, 247-69	268
661	Comprehensive profiling of biological processes reveals two major prognostic subtypes in breast cancer. 2016 , 37, 3365-70	
660	Weibull regression with Bayesian variable selection to identify prognostic tumour markers of breast cancer survival. 2017 , 26, 414-436	17
659	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017 , 23, 649-657	12.9 75
658	Oncoplastic surgery for inner quadrant breast cancer: fish-hook incision rotation flap. 2017 , 87, E129-E133	7
657	Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. 2017 , 162, 1-10	27
656	BMI, reproductive factors, and breast cancer molecular subtypes: A case-control study and meta-analysis. 2017 , 27, 143-151	37
655	First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. 2017 , 17, 3	20
654	FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis. 2017 , 162, 243-253	12
653	Pipetting-driven microfluidic immunohistochemistry to facilitate enhanced immunoreaction and effective use of antibodies. 2017 , 17, 702-709	13
652	17 β -Estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib. 2017 , 37, 1212-1218	25
651	Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. 2017 , 10,	24
650	Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer. 2017 , 28, 43-53	27
649	Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor. 2017 , 36, 3618-3628	10
648	Basal markers and prognosis in luminal breast cancer. 2017 , 163, 207-217	5
647	Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors. 2017 , 6, e1305531	35

646	Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas. 2017 , 71, 446-452	15
645	Picrasidine G decreases viability of MDA-MB 468 EGFR-overexpressing triple-negative breast cancer cells through inhibition of EGFR/STAT3 signaling pathway. 2017 , 27, 2608-2612	18
644	FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer. 2017 , 79, 1205-1213	16
643	Strong association of epidermal growth factor receptor status with breast cancer FDG uptake. 2017 , 44, 1438-1447	9
642	Canine Mixed Mammary Tumour as a Model for Human Breast Cancer with Osseous Metaplasia. 2017 , 156, 352-365	11
641	Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. <i>Scientific Reports</i> , 2017 , 7, 1089	4.9 13
640	Basal-like breast cancer: molecular profiles, clinical features and survival outcomes. 2017 , 10, 19	42
639	Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy. 2017 , 108, 1520-1529	13
638	Novel therapeutic strategies in the treatment of triple-negative breast cancer. 2017 , 9, 493-511	44
637	Raman-Encoded Molecular Imaging with Topically Applied SERS Nanoparticles for Intraoperative Guidance of Lumpectomy. 2017 , 77, 4506-4516	52
636	Association of long-chain acyl-coenzyme A synthetase 5 expression in human breast cancer by estrogen receptor status and its clinical significance. 2017 , 37, 3253-3260	25
635	Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. 2017 , 22, 1086-1093	53
634	FBP1 expression is associated with basal-like breast carcinoma. 2017 , 13, 3046-3056	7
633	Breast cancer biomarkers at Niger delta university hospital: Comparisons with national and international trends and clinical significance. 2017 , 24, 191-196	3
632	Expression of unusual immunohistochemical markers in mucinous breast carcinoma. 2017 , 119, 327-336	4
631	Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC). 2017 , 96, e6561	36
630	Metaplastic Breast Cancer. 2017 , 327-337	1
629	First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF- κ B Activity As Novel Anticancer Agents. 2017 , 60, 2853-2868	17

628	Down regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast Cancer. <i>Scientific Reports</i> , 2017 , 7, 44414	4.9	11
627	Increased Eps15 homology domain 1 and RAB11FIP3 expression regulate breast cancer progression via promoting epithelial growth factor receptor recycling. 2017 , 39, 1010428317691010		13
626	Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival. 2017 , 32, 18-25		13
625	Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes. 2017 , 10, 904-910		17
624	Utility of Sox10 labeling in metastatic breast carcinomas. 2017 , 67, 205-210		34
623	DIP2C expression in breast cancer and its clinical significance. 2017 , 213, 1394-1399		6
622	Deregulation of miR-126-3p in basal-like breast cancers stroma and its clinical significance. 2017 , 213, 922-928		5
621	The stem cell factor (SCF)/c-KIT system in carcinogenesis of reproductive tissues: What does the hormonal regulation tell us?. <i>Cancer Letters</i> , 2017 , 405, 10-21	9.9	10
620	Integrated diagnostic network construction reveals a 4-gene panel and 5 cancer hallmarks driving breast cancer heterogeneity. <i>Scientific Reports</i> , 2017 , 7, 6827	4.9	17
619	Assessment of Ki67 expression for breast cancer subtype classification and prognosis in the Nurses' Health Study. 2017 , 166, 613-622		20
618	Local therapy for triple-negative breast cancer: a comprehensive review. 2017 , 13, 1721-1730		8
617	Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study. 2017 , 84, 34-43		14
616	NanoString-based breast cancer risk prediction for women with sclerosing adenosis. 2017 , 166, 641-650		6
615	Silencing of Glut1 induces chemoresistance via modulation of Akt/GSK-3 β /E-catenin/survivin signaling pathway in breast cancer cells. 2017 , 636, 110-122		17
614	Transforming Growth Factor-beta Regulation of Ephrin Type-A Receptor 4 Signaling in Breast Cancer Cellular Migration. <i>Scientific Reports</i> , 2017 , 7, 14976	4.9	18
613	Immunohistochemical characterization of the molecular subtypes of invasive breast carcinoma in a series of Egyptian female patients with clinicopathologic correlation. 2017 , 37, 48-55		
612	Fundamental Pathways in Breast Cancer 1: Signaling from the Membrane. 2017 , 3-12		1
611	Circulating miRNA in Early Diagnosis. 2017 , 875-881		

610 Managing BRCA Mutation Carriers. **2017,**

609 Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. **2017, 16, 57** 120

608 Lymphocyte-predominant triple-negative breast carcinomas in premenopausal patients: Lower expression of basal immunohistochemical markers. **2017, 31, 34-39** 5

607 Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients. **2017, 56, 59-67** 14

606 Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells. **2017, 56, 1383-1394** 10

605 Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer. **2017, 62, 23-32** 25

604 High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. *Clinical Cancer Research*, **2017, 23, 946-953** 12.9 38

603 Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients. **2017, 25, 230-237** 4

602 Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor. **2017, 70, 185-194** 10

601 Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy. **2017, 13, 329-336** 7

600 Triple-negative breast cancer and its association with obesity. **2017, 7, 935-942** 22

599 CD44/CD24 phenotype predicts a poor prognosis in triple-negative breast cancer. **2017, 14, 5890-5898** 35

598 Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer. **2017, 17, 604** 11

597 Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells. **2017, 50, 132-137** 81

596 Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review. **2017, 10, 2009-2016** 3

595 Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer. *Cancers*, **2017, 9,** 6.6 32

594 AR Signaling in Breast Cancer. *Cancers*, **2017, 9,** 6.6 57

593 The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis. **2017, 8, 187** 60

592	New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. <i>PLoS ONE</i> , 2017 , 12, e0184680	3-7	46
591	BRCA2 carriers with male breast cancer show elevated tumour methylation. 2017 , 17, 641		4
590	The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. 2017 , 19, 99		38
589	Pathway-based classification of breast cancer subtypes. 2017 , 22, 1697-1712		11
588	Triple-negative breast cancer: is there a treatment on the horizon?. 2017 , 8, 1913-1924		176
587	Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. 2017 , 8, 5309-5322		24
586	Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer. 2017 , 12, 7225-7237		5
585	Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer. 2017 , 8, 124-130		16
584	RNA interference-mediated silencing of ppGalNAc-T1 and ppGalNAc-T2 inhibits invasion and increases chemosensitivity potentially by reducing terminal α ,3 sialylation and MMP14 expression in triple-negative breast cancer cells. 2017 , 15, 3724-3734		2
583	Prevalence of biological types of breast cancer and their influence on disease staging and therapeutic management - a single-center study. 2017 , 68, 16-25		3
582	Mammography and ultrasound effective features in differentiating basal-like and normal-like subtypes of triple negative breast cancer. 2017 , 8, 79670-79679		2
581	Molecular Testing in Breast Cancer. 2017 , 257-269		
580	Adenoid cystic carcinomas of the salivary gland, lacrimal gland, and breast are morphologically and genetically similar but have distinct microRNA expression profiles. 2018 , 31, 1211-1225		20
579	Update on the Treatment of Early-Stage Triple-Negative Breast Cancer. 2018 , 19, 22		41
578	Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at. 2018 , 27, 644-652		4
577	Prognostic significance of CD117 expression and missense mutations in triple-negative breast cancer. 2018 , 15, 6161-6170		9
576	The importance of EGFR as a biomarker in molecular apocrine breast cancer. 2018 , 77, 1-10		8
575	Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. 2018 , 85, 23-34		45

574	Involvement of both caspase-8 and Noxa-activated pathways in endoplasmic reticulum stress-induced apoptosis in triple-negative breast tumor cells. 2018 , 9, 134	11
573	Pathologic Evaluation of Triple-Negative Breast Cancer. 2018 , 1-22	2
572	Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer. 2018 , 19, 335-345	10
571	The combined pN stage and breast cancer subtypes in breast cancer: a better discriminator of outcome can be used to refine the 8th AJCC staging manual. 2018 , 25, 315-324	5
570	Breast Conserving Therapy for Invasive Breast Cancers. 2018 , 693-705.e6	1
569	microRNA as a systemic intervention in the specific breast cancer subtypes with C-MYC impacts; introducing subtype-based appraisal tool. 2018 , 233, 5655-5669	11
568	Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer. 2018 , 26, 1-5	1
567	Influence of intra-tumoral heterogeneity on the evaluation of BCL2, E-cadherin, EGFR, EMMPRIN, and Ki-67 expression in tissue microarrays from breast cancer. 2018 , 57, 102-106	8
566	Discovery of internalizing antibodies to basal breast cancer cells. 2018 , 31, 17-28	2
565	High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer. 2018 , 18, 223	14
564	Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa. 2018 , 18, 40	32
563	Frequency of breast cancer subtypes among African American women in the AMBER consortium. 2018 , 20, 12	21
562	Functional and genomic characterisation of a xenograft model system for the study of metastasis in triple-negative breast cancer. 2018 , 11,	14
561	Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers. 2018 , 18, e1123-e1132	18
560	Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. 2018 , 24, 505-511	28
559	Immunohistochemical Analysis of the Expression of Breast Markers in Basal-like Breast Carcinomas Defined as Triple Negative Cancers Expressing Keratin 5. 2018 , 24, 259-267	7
558	Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients. 2018 , 22, 79-90	8
557	Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group. 2018 , 18, 88-94	12

556	Canine invasive mammary carcinomas as models of human breast cancer. Part 2: immunophenotypes and prognostic significance. 2018 , 167, 459-468	38
555	Acute phase dynamics of circulating tumor cells after paclitaxel and doxorubicin chemotherapy in breast cancer mouse models. 2018 , 167, 439-450	9
554	Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer. 2018 , 641, 248-258	30
553	Male breast cancer: correlation between immunohistochemical subtyping and PAM50 intrinsic subtypes, and the subsequent clinical outcomes. 2018 , 31, 299-306	9
552	Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes. 2018 , 18, e123-e133	18
551	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. 2018 , 24, 701-716	13
550	Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials. 2018 , 57, 135-140	4
549	Extracellular vesicles compartment in liquid biopsies: Clinical application. 2018 , 60, 27-37	50
548	Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. 2018 , 444, 197-206	11
547	Serum endocan level and its prognostic significance in breast cancer patients. 2018 , 4, 15-18	3
546	Chondroitin sulfate-mediated N-cadherin/E-catenin signaling is associated with basal-like breast cancer cell invasion. 2018 , 293, 444-465	37
545	Advanced glycation end products promote triple negative breast cancer cells via ERK and NF- κ B pathway. 2018 , 495, 2195-2201	16
544	Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up. 2018 , 168, 107-115	10
543	Triple negative breast cancer in Asia: An insider's view. 2018 , 62, 29-38	108
542	Molecular Subtypes and Local-Regional Control of Breast Cancer. 2018 , 27, 95-120	180
541	Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. 2018 , 38, 65-77	10
540	Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?. 2018 , 97, e12690	6
539	Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells. 2018 , 52, 828-840	11

538	Practical consensus recommendations on management of triple-negative metastatic breast cancer. 2018 , 7, 127-131		3
537	Sleep and Breast Cancer in the Western New York Exposures and Breast Cancer (WEB) Study. 2018 , 14, 81-86		8
536	FOXC1, the new player in the cancer sandbox. 2018 , 9, 8165-8178		31
535	Endocrine and Cell Surface Receptor Signaling in Breast Carcinogenesis. 2018 ,		2
534	Implications of nestin in breast cancer pathogenesis (Review). 2018 , 53, 477-487		4
533	Oestrogen Inhibits VEGF Expression And Angiogenesis In Triple-Negative Breast Cancer By Activating GPER-1. 2018 , 9, 3802-3811		10
532	ME1 promotes basal-like breast cancer progression and associates with poor prognosis. <i>Scientific Reports</i> , 2018 , 8, 16743	4.9	17
531	Breast Cancer Outcomes in a Racially and Ethnically Diverse Cohort of Insured Women. 2018 , 28, 565-574		7
530	Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis. 2018 , 10, 177-194		9
529	Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer. 2018 , 8, 6386-6399		18
528	Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants. <i>Cancers</i> , 2018 , 10,	6.6	67
527	UCBG 2-08: 5-year efficacy results from the UNICANCER-PACS08 randomised phase III trial of adjuvant treatment with FEC100 and then either docetaxel or ixabepilone in patients with early-stage, poor prognosis breast cancer. 2018 , 103, 184-194		4
526	Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer. 2018 , 12, 3085-3093		4
525	Formin Proteins FHOD1 and INF2 in Triple-Negative Breast Cancer: Association With Basal Markers and Functional Activities. 2018 , 12, 1178223418792247		11
524	Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. 2018 , 9, 26406-26416		76
523	Identification of a Subtype of Poorly Differentiated Invasive Ductal Carcinoma of the Breast Based on Vimentin and E-cadherin Expression. 2018 , 40, 779-786		1
522	Prognostic significance of p16 & p53 immunohistochemical expression in triple negative breast cancer. 2018 , 18, 9		19
521	The downregulation of WWOX induces epithelial-mesenchymal transition and enhances stemness and chemoresistance in breast cancer. 2018 , 243, 1066-1073		8

520	The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer. 2018 , 9, 296-303		35
519	Identification of Key Genes and Pathways in Triple-Negative Breast Cancer by Integrated Bioinformatics Analysis. 2018 , 2018, 2760918		28
518	TGF- β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. 2018 , 502, 160-165		58
517	Modulation of Molecular Biomarker Expression in Response to Chemotherapy in Invasive Ductal Carcinoma. 2018 , 2018, 7154708		4
516	Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. 2018 , 171, 675-683		9
515	Inhibition of growth hormone receptor by Somavert reduces expression of GPER and prevents growth stimulation of triple-negative breast cancer by 17 β -estradiol. 2018 , 15, 9559-9566		6
514	High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors. <i>PLoS ONE</i> , 2018 , 13, e0199254	3-7	8
513	Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features. <i>PLoS ONE</i> , 2018 , 13, e0197827	3-7	43
512	miRNA-135b Contributes to Molecular Heterogeneity: Different Expression Profile in Versus Phenotypes. 2018 , 15, 536-548		13
511	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018 , 24, 5820-5829	12.9	47
510	Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: clinicopathologic significance in South-Asian population. 2018 , 11, 372		15
509	Molecular features of adenoid cystic carcinoma with an emphasis on microRNA expression. 2018 , 126 Suppl 140, 7-57		3
508	Characterization of FGD5 Expression in Primary Breast Cancers and Lymph Node Metastases. 2018 , 66, 787-799		8
507	Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile. 2018 , 473, 275-283		5
506	Role of BRCA Mutations in the Modulation of Response to Platinum Therapy. <i>Frontiers in Oncology</i> , 2018 , 8, 16	5-3	61
505	ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation. 2018 , 24, 630-641		53
504	CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer. 2018 , 71, 1007-1014		9
503	Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer. 2018 , 36, 378-388		7

502	Probing the Anticancer Action of Novel Ferrocene Analogues of MNK Inhibitors. 2018 , 23,		13
501	Computational Design of Multi-Target Drugs Against Breast Cancer. 2018 , 443-458		1
500	The prognostic value of androgen receptors in breast cancer subtypes. 2018 , 172, 283-296		17
499	miR-328-5p inhibits MDA-MB-231 breast cancer cell proliferation by targeting RAGE. 2018 , 39, 2906-2914		25
498	Subtyping Of Triple Negative Breast Carcinoma On The Basis Of RTK Expression. 2018 , 9, 2589-2602		2
497	Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1. <i>Clinical Cancer Research</i> , 2018 , 24, 4566-4578	12.9	24
496	ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer. 2018 , 82, 1733-1741		6
495	Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers. 2019 , 38, 140-150		37
494	CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients. 2019 , 144, 631-640		12
493	Ethanol Extracts of Dietary Herb, , Exhibit Anticancer Potential in Human Breast Cancer Cells. 2019 , 18, 1534735419866924		4
492	Depletion of the Transcriptional Coactivator Amplified in Breast Cancer 1 (AIB1) Uncovers Functionally Distinct Subpopulations in Triple-Negative Breast Cancer. 2019 , 21, 963-973		1
491	Practical Breast Pathology. 2019 ,		
490	Invasive Carcinoma of the Breast: Special Types. 2019 , 39-71		
489	Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. 2019 , 19, 695		2
488	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. <i>Molecular Cancer Research</i> , 2019 , 17, 2063-2076	6.6	12
487	MMP11 expression in intratumoral inflammatory cells in breast cancer. 2019 , 75, 916-930		14
486	Liver- and Microbiome-derived Bile Acids Accumulate in Human Breast Tumors and Inhibit Growth and Improve Patient Survival. <i>Clinical Cancer Research</i> , 2019 , 25, 5972-5983	12.9	18
485	Matrix-producing Carcinoma as an Aggressive Triple-negative Breast Cancer: Clinicopathological Features and Response to Neoadjuvant Chemotherapy. 2019 , 39, 3863-3869		7

484	Inhibition of super enhancer downregulates the expression of KLF5 in basal-like breast cancers. <i>International Journal of Biological Sciences</i> , 2019 , 15, 1733-1742	11.2	17
483	Surface active flexible palladium nano-thin-film electrode development for biosensing. 2019 , 107, 107461		3
482	Correlation between microRNA-21, microRNA-206 and estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 in breast cancer. 2019 , 71, 52-57		5
481	Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance. 2019 , 19, 1085		6
480	WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. 2019 , 17, 109		26
479	Clinical outcomes of an intraoperative surgical margin assessment using the fresh frozen section method in patients with invasive breast cancer undergoing breast-conserving surgery - a single center analysis. <i>Scientific Reports</i> , 2019 , 9, 13441	4.9	14
478	The Molecular Mechanism of Epithelial-Mesenchymal Transition for Breast Carcinogenesis. 2019 , 9,		10
477	Spontaneous pathological complete regression of high-grade triple-negative breast cancer with axillary metastasis. 2019 , 70, 139-143		5
476	Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite. 2019 , 86, 395-405		48
475	Estrogen Signaling in ER β -Negative Breast Cancer: ER β and GPER. 2018 , 9, 781		21
474	In vitro cytotoxicity and in vivo zebrafish toxicity evaluation of Ru(ii)/2-mercaptopyrimidine complexes. 2019 , 48, 6026-6039		21
473	Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 135, 66-75	7	17
472	HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women. 2019 , 19, 1		11
471	The exosomal compartment protects epidermal growth factor receptor from small molecule inhibitors. 2019 , 510, 42-47		5
470	Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. 2019 , 176, 709-716		21
469	Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides. 2019 , 20, 102003		22
468	Personalized medicine in breast cancer: pharmacogenomics approaches. 2019 , 12, 59-73		24
467	PLA Electrospun Scaffolds for Three-Dimensional Triple-Negative Breast Cancer Cell Culture. 2019 , 11,		20

466	Array comparative genomic hybridization analysis discloses chromosome copy number alterations as indicators of patient outcome in lymph node-negative breast cancer. 2019 , 19, 521	6
465	Loss of PICH promotes chromosome instability and cell death in triple-negative breast cancer. 2019 , 10, 428	9
464	Identification of differentially expressed genes between triple and non-triple-negative breast cancer using bioinformatics analysis. 2019 , 26, 784-791	13
463	Integrated omics-based pathway analyses uncover CYP epoxygenase-associated networks as theranostic targets for metastatic triple negative breast cancer. 2019 , 38, 187	8
462	Predicting breast cancer metastasis by using serum biomarkers and clinicopathological data with machine learning technologies. 2019 , 128, 79-86	37
461	A guide to hyaluronan and related enzymes in breast cancer: biological significance and diagnostic value. 2019 , 286, 3057-3074	12
460	Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells. 2019 , 45, 1334-1342	3
459	Studies on the Affinity-based Biosensors for Electrochemical Detection of HER2 Cancer Biomarker. 2019 , 31, 1125-1134	5
458	Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple-negative breast cancer cell lines. 2019 , 54, 1345-1356	4
457	SOX10, GATA3, GCDP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2019 , 43, 293-302	6.7 24
456	Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies. 2019 , 21, 40	28
455	The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer. 2019 , 20,	7
454	Identification of key pathways and hub genes in basal-like breast cancer using bioinformatics analysis. 2019 , 12, 1319-1331	33
453	High Response to Cetuximab in a Patient With -Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer.. 2019 , 3, 1-8	1
452	Reclassification of early stage breast cancer into treatment groups by combining the use of immunohistochemistry and microarray analysis. 2019 , 115,	4
451	Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer. 2019 , 15, 1433-1442	3
450	Application of Single-Cell Omics in Breast Cancer. 2019 , 69-103	4
449	Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. <i>Cancers</i> , 2019 , 11,	6.6 75

448	Understanding the tumour micro-environment communication network from an NOS2/COX2 perspective. 2019 , 176, 155-176		14
447	Screening of fetal chromosomal aneuploidy diseases using noninvasive prenatal testing in twin pregnancies. 2019 , 19, 189-196		13
446	Immunological therapy: A novel thriving area for triple-negative breast cancer treatment. <i>Cancer Letters</i> , 2019 , 442, 409-428	9.9	26
445	Single Cell Omics of Breast Cancer: An Update on Characterization and Diagnosis. 2019 , 34, 3-18		10
444	PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. 2019 , 174, 571-584		32
443	Tumor grade and molecular subtypes on local control in breast cancer radiotherapy: Does fractionation really matter? A retrospective control study group. 2019 , 15, 7-12		2
442	Microvessel density in breast cancer: the impact of field area on prognostic informativeness. 2019 , 72, 304-310		4
441	Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. 2019 , 173, 489-497		57
440	Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers. 2019 , 84, 231-238		10
439	Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40-44 years. 2019 , 26, 386-396		6
438	Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy. 2019 , 174, 1-13		12
437	A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer. 2019 , 174, 143-155		8
436	Epigenetic Silencing of Tracks the Acquisition of the Notch1-EGFR Signaling in a Xenograft Model of CD44/CD24/CD90 Myoepithelial Cells. <i>Molecular Cancer Research</i> , 2019 , 17, 628-641	6.6	2
435	Fresh Cut Versus Stored Cut Paraffin-embedded Tissue: Effect on Immunohistochemical Staining for Common Breast Cancer Markers. 2019 , 27, 231-237		5
434	Double-positive in triple-negative? How significant is basal cytokeratin expression in breast cancer?. 2020 , 76, 63-70		2
433	Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer. 2020 , 20, 80-86		9
432	Dermoglandular rotation flap with subaxillary advancement flap as an oncoplastic technique for breast cancer. 2020 , 26, 420-426		1
431	Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. 2020 , 179, 557-564		5

430	Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling. 2020 , 315, 108872	15
429	Beclin 1 Promotes Endosome Recruitment of Hepatocyte Growth Factor Tyrosine Kinase Substrate to Suppress Tumor Proliferation. 2020 , 80, 249-262	13
428	MiR-210 Is Overexpressed in Tumor-infiltrating Plasma Cells in Triple-negative Breast Cancer. 2020 , 68, 25-32	4
427	Storage Conditions and Immunoreactivity of Breast Cancer Subtyping Markers in Tissue Microarray Sections. 2020 , 28, 267-273	6
426	Prospective study of a diabetes risk reduction diet and the risk of breast cancer. 2020 , 112, 1492-1503	12
425	Advances in the Molecular Taxonomy of Breast Cancer. 2020 , 51, 777-783	7
424	Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions. 2020 , 19, 1533033820943246	4
423	ELP-dependent expression of promotes resistance to EGFR inhibition in triple-negative breast cancer cells. 2020 , 13,	5
422	Sinonasal analogue HPV related breast multiphenotypic carcinoma, a report of a case with the first description in the breast. 2020 , 15, 137	1
421	Effects of curcumin complexes on MDA-MB-231 breast cancer cell proliferation. 2020 , 57, 445-455	14
420	EGFR Expression in HER2-Driven Breast Cancer Cells. 2020 , 21,	4
419	Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome. 2020 , 11, 7246-7252	0
418	Variability in hospital treatment costs: a time-driven activity-based costing approach for early-stage invasive breast cancer patients. 2020 , 10, e035389	2
417	The impact of gene polymorphisms on the response and toxicity derived from neoadjuvant chemotherapy for breast cancer. 2020 , 9, 925-935	1
416	Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment. 2020 , 17, 1597-1613	9
415	Relationships between Breast Feeding and Breast Cancer Subtypes: Lessons Learned from Studies in Humans and in Mice. 2020 , 80, 4871-4877	7
414	Breast Cancer Stem Cells: Biomarkers, Identification and Isolation Methods, Regulating Mechanisms, Cellular Origin, and Beyond. <i>Cancers</i> , 2020 , 12,	6.6 15
413	miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker. 2020 , 14, 1178223420977845	

4 ¹²	Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis. <i>Journal of Oncology</i> , 2020 , 2020, 8880727	4.5	
4 ¹¹	LHRH-Conjugated Drugs as Targeted Therapeutic Agents for the Specific Targeting and Localized Treatment of Triple Negative Breast Cancer. <i>Scientific Reports</i> , 2020 , 10, 8212	4.9	18
4 ¹⁰	Focus on Triple-Negative Breast Cancer: Potassium Channel Expression and Clinical Correlates. 2020 , 11, 725		1
4 ⁰⁹	The Clinicopathological Significance of Basal Markers in Early-Stage Invasive Carcinoma of No Special Type of the Breast. 2020 , 36, 195-204		
4 ⁰⁸	Tumor Necrosis Factor Blockade: An Opportunity to Tackle Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 584	5.3	23
4 ⁰⁷	EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both and. 2020 , 9, e01135		10
4 ⁰⁶	Breast Cancer Health Disparities in Hispanics/Latinas. 2020 , 12, 175-184		1
4 ⁰⁵	Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. 2020 , 25, e1481-e1491		27
4 ⁰⁴	Triple-negative breast cancer molecular subtyping and treatment progress. 2020 , 22, 61		249
4 ⁰³	PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR. 2020 , 21, 2209-2219		5
4 ⁰²	High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers. 2020 , 102, 13-22		5
4 ⁰¹	Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5. <i>Clinical Cancer Research</i> , 2020 , 26, 5682-5688	12.9	3
4 ⁰⁰	Neoadjuvant chemotherapy modifies serum pyrrolidone carboxypeptidase specific activity in women with breast cancer and influences circulating levels of GnRH and gonadotropins. 2020 , 182, 751-760		4
399	KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene. 2020 , 22, 66		5
398	A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. 2020 , 326, 628-647		56
397	The evolving management of metastatic triple negative breast cancer. 2020 , 47, 229-237		12
396	Early stage triple negative breast cancer: Management and future directions. 2020 , 47, 201-208		5
395	The Usefulness of Bayesian Network in Assessing the Risk of Triple-Negative Breast Cancer. 2020 , 27, e282-e291		1

394	Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study. 2020 , 44, 100556	1
393	Prevalence of Molecular Subtypes of Breast Cancer: A Single Institutional Experience of 2062 Patients. 2020 , 16, 39-43	13
392	Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphology. 2020 , 38, 1316-1325	2
391	TTF-1/p63-Positive Poorly Differentiated NSCLC: A Histogenetic Hypothesis from the Basal Reserve Cell of the Terminal Respiratory Unit. 2020 , 10,	5
390	Comprehensive Proteomic Characterization Reveals Subclass-Specific Molecular Aberrations within Triple-negative Breast Cancer. 2020 , 23, 100868	8
389	Failure of sentinel lymph node mapping in breast cancer patients qualified for treatment sparing axillary lymph nodes-Clinical importance and management strategy-One-center analysis. 2020 , 26, 873-881	3
388	Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer. 2020 , 12, 1758835919897546	11
387	Prognostic significance of immunohistochemical markers and histological classification in malignant canine mammary tumours. 2020 , 18, 753-762	7
386	Spatiotemporal Regulation of p63 by TGF β Regulated miRNAs Is Essential for Cancer Metastasis. 2020 , 80, 2833-2847	9
385	Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer. 2020 , 77, 936-948	11
384	Best Foot Forward: Neoadjuvant Systemic Therapy as Standard of Care in Triple-Negative and HER2-Positive Breast Cancer. 2020 , 40, 1-16	5
383	Are Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers Really Different?. <i>Journal of Oncology</i> , 2020 , 2020, 4061063	4-5 2
382	Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. 2020 , 17,	63
381	Pathology of triple negative breast cancer. 2021 , 72, 136-145	27
380	Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy. 2021 , 21, 37-44	9
379	Epidemiology of Basal-like and Luminal Breast Cancers among Black Women in the AMBER Consortium. 2021 , 30, 71-79	5
378	Triple-negative breast cancer: new treatment strategies in the era of precision medicine. 2021 , 64, 372-388	5
377	One-year conditional survival of dogs and cats with invasive mammary carcinomas: A concept inspired from human breast cancer. 2021 , 19, 140-151	4

376	Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. 2021 , 2021, 6668573		3
375	Defining Breast Cancer. 2021 , 1-31		
374	Extensive Pulmonary Metastases of Intracranial Anaplastic Meningioma: Case Report. 2021 , 11, 102-106		
373	[Triple-negative breast cancer. Modern molecular genetic concepts and their clinical significance]. 2021 , 83, 46-51		
372	Molecular Classification of Breast Cancer. 2021 , 33-38		
371	Local Treatment of Triple-Negative Breast Cancer. 2021 , 27, 32-40		0
370	Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities. 2021 , 57,		15
369	Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 575317	5.3	1
368	Unfavorable Prognostic Effects of the Stem Cell Pluripotency Factor Sox2 in Feline Invasive Mammary Carcinomas. 2020 , 7, 622019		0
367	The action of hyaluronan in functional properties, morphology and expression of matrix effectors in mammary cancer cells depends on its molecular size. 2021 , 288, 4291-4310		8
366	Resveratrol Mediates the Apoptosis of Triple Negative Breast Cancer Cells by Reducing POLD1 Expression. <i>Frontiers in Oncology</i> , 2021 , 11, 569295	5.3	7
365	Immunohistochemical and clinicopathologic features of estrogen receptor-negative, progesterone receptor-positive, HER-2 negative breast carcinomas. <i>Revista Da Associação Médica Brasileira</i> , 2021 , 67, 265-270	1.4	
364	Genomic Assays in Node Positive Breast Cancer Patients: A Review. <i>Frontiers in Oncology</i> , 2020 , 10, 609199		5
363	Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer. 2021 , 66, 785-793		0
362	The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell Features. <i>Cancers</i> , 2021 , 13,	6.6	2
361	Overview of recent advances in metastatic triple negative breast cancer. 2021 , 12, 164-182		9
360	The prognostic and predictive significance of cytokeratin 5/6 and epidermal growth factor receptor in metastatic triple-negative breast cancer treated with maintenance capecitabine.. 2021 , 10, 1193-1203		
359	High Intrinsic Expression of P-glycoprotein and Breast Cancer Resistance Protein in Canine Mammary Carcinomas Regardless of Immunophenotype and Outcome. 2021 , 11,		1

358	Sous-types moléculaires de cancers du sein : quels enjeux pour faire évoluer le dépistage en France. 2021 , 31, 6-12		
357	Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. 2021 , 34, 1282-1296		7
356	Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma. <i>Pharmaceutics</i> , 2021 , 13,	6.4	2
355	Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers. 2021 , 7,		1
354	Annexin A1 Is Required for Efficient Tumor Initiation and Cancer Stem Cell Maintenance in a Model of Human Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
353	Cooperative regulation of coupled oncoprotein translation and stability in triple-negative breast cancer by EGFR and CDK12.		
352	ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer. 2021 , 149, 200-213		1
351	Highly Integrated Cell-Imprinted Biomimetic Interface for All-in-One Diagnosis of Heterogeneous Circulating Tumor Cells. 2021 , 13, 19603-19612		0
350	Genetic Association of CYP1B1 4326 C>G Polymorphism with Disease-Free Survival in TNBC Patients Undergoing TAC Chemotherapy Regimen. 2021 , 22, 1319-1324		1
349	Impaired Expression of Cytoplasmic Actins Leads to Chromosomal Instability of MDA-MB-231 Basal-Like Mammary Gland Cancer Cell Line. 2021 , 26,		0
348	Inhibition of aquaporins as a potential adjunct to breast cancer cryotherapy. 2021 , 21, 458		1
347	Long Non-Coding RNA Expression in Laser Micro-Dissected Luminal A and Triple Negative Breast Cancer Tissue Samples-A Pilot Study. 2021 , 57,		1
346	Nanodiamonds and their potential applications in breast cancer therapy: a narrative review. 2021 , 1		0
345	Synthesis and Structural Characterization of Half-Sandwich AreneRuthenium(II) Complexes with Bis(imidazol-1-yl)methane, Imidazole and Benzimidazole. 2021 , 9, 34		1
344	A network approach reveals driver genes associated with survival of patients with triple-negative breast cancer. 2021 , 24, 102451		1
343	Vitamin D receptor (VDR) expression in different molecular subtypes of canine mammary carcinoma. 2021 , 17, 197		0
342	Sugar-Sweetened Beverages, Artificially Sweetened Beverages, and Breast Cancer Risk: Results From 2 Prospective US Cohorts. 2021 , 151, 2768-2779		2
341	Natural Killer Cell Dysfunction in Obese Patients with Breast Cancer: A Review of a Triad and Its Implications. 2021 , 2021, 9972927		1

340	Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation, and androgen receptor in metaplastic breast cancer and their prognostic impact. 2021 , 60, 1233-1239		0
339	Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
338	Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer. 2021 , 12, 684		4
337	Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. 2021 , 13, 5223-5237		6
336	Healthful and Unhealthful Plant-Based Diets and Risk of Breast Cancer in U.S. Women: Results from the Nurses' Health Studies. 2021 , 30, 1921-1931		3
335	AGR2 and AGR3 play an important role in the clinical characterization and prognosis of basal like breast cancer. 2021 ,		2
334	Androgen receptor expression and prognosis in Hispanic/Latino women with triple negative breast cancer.. 2022 , 55, 96-104		
333	Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma. 2021 , 8,		0
332	Development of the predictive model for I stage breast cancer. 2021 , 17, 14-22		
331	Synergistic apoptotic effect of miR-183-5p and Polo-Like kinase 1 inhibitor NMS-P937 in breast cancer cells. 2021 ,		0
330	Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications. 2021 , 1		0
329	(Mango): A Promising Medicinal Plant for Breast Cancer Therapy and Understanding Its Potential Mechanisms of Action. 2021 , 13, 471-503		3
328	Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 114	7.8	2
327	Basal-like breast cancer with low TGF β and high TNF β pathway activity is rich in activated memory CD4 T cells and has a good prognosis. <i>International Journal of Biological Sciences</i> , 2021 , 17, 670-682	11.2	4
326	Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment. 2021 , 13, 31-44		0
325	Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients. 2020 , 9, 2427-2434		5
324	Molecular Pathology of Breast Cancer. 2013 , 95-128		3
323	Familial Breast Cancer and Genetic Predisposition in Breast Cancer. 2015 , 15-37		2

322	A practical guide to constructing and using tissue microarrays. 2011 , 675, 363-73	6
321	Introduction to omics. 2010 , 593, 1-23	2
320	Biology and Treatment of Basal-Like Breast Cancer. 2013 , 91-109	2
319	Canine and Feline Spontaneous Mammary Tumours as Models of Human Breast Cancer. 2020 , 173-207	2
318	Pathology of BRCA Tumors. 2017 , 89-117	1
317	Molecular Diagnosis of Metastasizing Breast Cancer Based Upon Liquid Biopsy. 2014 , 425-459	1
316	Immunohistochemistry and Molecular Biology of Breast Cancers: Old and New Prognostic Factors. 2011 , 119-148	3
315	Familial Breast Cancer. 2006 , 241-248	1
314	Predictive and Prognostic Marker Testing in Breast Pathology: Immunophenotypic Subclasses of Disease. 2012 , 151-172	1
313	Diagnostic Immunohistology of the Breast. 2012 , 189-232	2
312	Triple-Negative and Basal-like Carcinoma. 2012 , 446-478	1
311	Apocrine Carcinoma of the Breast. 2012 , 502-511	2
310	Rare Breast Carcinomas. 2012 , 573-595	1
309	Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions. 2009 , 133, 1822-5	7
308	Ki-67 Expression is a Significant Prognostic Factor Only When Progesterone Receptor Expression is Low in Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer. <i>Journal of Oncology</i> , 2019 , 2019, 7386734	4.5 8
307	T-cell Receptors Derived from Breast Cancer-Infiltrating T Lymphocytes Mediate Antitumor Reactivity. 2020 , 8, 530-543	18
306	Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population. 2014 , 17, 249	26
305	AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. 2006 , 116, 261-70	237

304	Is the small heat shock protein alphaB-crystallin an oncogene?. 2006 , 116, 30-2		40
303	IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. 2007 , 117, 3988-4002		604
302	Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. 2010 , 120, 3843-54		167
301	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. 2011 , 121, 2750-67		3125
300	Insight into the heterogeneity of breast cancer through next-generation sequencing. 2011 , 121, 3810-8		180
299	Breast cancer - one term, many entities?. 2011 , 121, 3789-96		152
298	Triple-Negative Breast Cancer: Current State of the Art. 2010 , 96, 875-888		48
297	Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. <i>PLoS ONE</i> , 2009 , 4, e6146	3-7	537
296	Comparison of breast cancer to healthy control tissue discovers novel markers with potential for prognosis and early detection. <i>PLoS ONE</i> , 2010 , 5, e9122	3-7	15
295	NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. <i>PLoS ONE</i> , 2011 , 6, e22666	3-7	77
294	In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas. <i>PLoS ONE</i> , 2012 , 7, e43110	3-7	31
293	Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. <i>PLoS ONE</i> , 2012 , 7, e45684	3-7	15
292	Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. <i>PLoS ONE</i> , 2012 , 7, e45831	3-7	61
291	TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. <i>PLoS ONE</i> , 2013 , 8, e63737	3-7	93
290	Assessing interactions between common genetic variant on 2q35 and hormone receptor status with breast cancer risk: evidence based on 26 studies. <i>PLoS ONE</i> , 2013 , 8, e69056	3-7	4
289	Assessing interactions between the association of common genetic variant at 1p11 (rs11249433) and hormone receptor status with breast cancer risk. <i>PLoS ONE</i> , 2013 , 8, e72487	3-7	3
288	Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. <i>PLoS ONE</i> , 2013 , 8, e75038	3-7	104
287	Plasma membrane proteomics of human breast cancer cell lines identifies potential targets for breast cancer diagnosis and treatment. <i>PLoS ONE</i> , 2014 , 9, e102341	3-7	33

286	The differences in ultrasound and clinicopathological features between basal-like and normal-like subtypes of triple negative breast cancer. <i>PLoS ONE</i> , 2015 , 10, e0114820	3.7	9
285	LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition. <i>PLoS ONE</i> , 2015 , 10, e0118002	3.7	49
284	Differentially expressed microRNAs in postpartum breast cancer in Hispanic women. <i>PLoS ONE</i> , 2015 , 10, e0124340	3.7	20
283	Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. <i>PLoS ONE</i> , 2015 , 10, e0125232	3.7	16
282	Expression of HIF-1 α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy. <i>PLoS ONE</i> , 2015 , 10, e0129356	3.7	21
281	Strong Expression of Hypoxia-Inducible Factor-1 α [HIF-1 α] Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer. <i>PLoS ONE</i> , 2016 , 11, e0146823	3.7	31
280	Claudin-Low Breast Cancer; Clinical & Pathological Characteristics. <i>PLoS ONE</i> , 2017 , 12, e0168669	3.7	75
279	Competing risks in low-risk breast cancer. 2013 , 32-9		2
278	Role of Taxanes in Triple-Negative Breast Cancer: A Study From Tertiary Cancer Center in South India. 2017 , 8, 110-116		3
277	Androgen excess in breast cancer development: implications for prevention and treatment. 2019 , 26, R81-R94		19
276	Estrogen Receptor- α and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. 2015 , 20, 373-90		5
275	Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial. 2016 , 7, 60647-60656		45
274	DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer. 2017 , 8, 62834-62841		11
273	Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion. 2013 , 4, 1449-60		38
272	FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. 2016 , 7, 75729-75738		6
271	Kindlin-2 interacts with E-catenin and YB-1 to enhance EGFR transcription during glioma progression. 2016 , 7, 74872-74885		22
270	Common profiles of Notch signaling differentiate disease-free survival in luminal type A and triple negative breast cancer. 2017 , 8, 6013-6032		15
269	The prognostic value of node status in different breast cancer subtypes. 2017 , 8, 4563-4571		13

268	Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. 2017 , 8, 22218-22234	33
267	Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance. 2017 , 8, 17819-17832	30
266	microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. 2014 , 5, 1174-84	121
265	Post-operative radiotherapy is beneficial for T1/T2 triple negative breast cancer patients with four or more positive lymph nodes. 2017 , 8, 42917-42925	6
264	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. 2017 , 8, 70481-70495	10
263	Fatty acid synthase expression and its association with clinico-histopathological features in triple-negative breast cancer. 2017 , 8, 74391-74405	24
262	Transcriptional signature of lymphoblastoid cell lines of , and non- high risk breast cancer families. 2017 , 8, 78691-78712	6
261	The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. 2017 , 8, 76974-76986	24
260	A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. 2017 , 8, 104894-104912	20
259	Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study. 2017 , 8, 84349-84359	3
258	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. 2014 , 5, 9952-65	52
257	Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity. 2018 , 9, 30115-30123	3
256	Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. 2015 , 6, 5547-66	36
255	Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR. 2015 , 6, 11150-61	58
254	Identification and evaluation of network modules for the prognosis of basal-like breast cancer. 2015 , 6, 17713-24	3
253	Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. 2015 , 6, 27923-37	19
252	Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer. 2015 , 6, 36625-42	39
251	Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy. 2015 , 6, 43135-43	25

250	Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2. 2015 , 6, 32856-67	15
249	Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. 2016 , 7, 9135-49	27
248	ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer. 2016 , 7, 15811-27	13
247	Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup. 2013 , 4, 231-41	17
246	Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1). 2013 , 4, 329-45	42
245	Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer. 2016 , 7, 41559-41574	10
244	FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance. 2016 , 7, 52597-52612	31
243	Downregulation of hexokinase 2 improves radiosensitivity of breast cancer.. 2019 , 8, 290-297	4
242	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. 2017 , 14, 181-195	19
241	Prognostic Value of BCL2 in Women Patients with Invasive Breast Cancer. 2018 , 19, 3557-3564	1
240	Establishment and Characterization of Canine Mammary Gland Carcinoma Cell Lines With Vasculogenic Mimicry Ability and. 2020 , 7, 583874	5
239	Recent advances in managing triple-negative breast cancers. 2009 , 1,	1
238	[Effects of Astragalus injection on proliferation of basal-like breast cancer cell line MDA-MB-468]. 2008 , 6, 399-404	7
237	[Effects of Astragalus injection and its ingredients on proliferation and Akt phosphorylation of breast cancer cell lines]. 2009 , 7, 1174-80	12
236	[Effects of Astragalus polysaccharide on proliferation and Akt phosphorylation of the basal-like breast cancer cell line]. 2011 , 9, 1339-46	18
235	Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells. 2020 , 19, 3950-3958	5
234	INVESTIGATION OF THE PROGNOSIS OF BREAST CANCER FROM THE VIEW POINT OF PRESENTATION OF ESTROGEN RECEPTOR AND HER2 IN IMMUNOHISTOCHEMICAL STAINING. 2007 , 68, 2171-2177	3
233	Basal-like phenotype in a breast carcinoma case series from Sudan: prevalence and clinical/pathological correlations. 2011 , 2011, 806831	11

232	A study of triple negative breast cancer at a tertiary cancer care center in southern India. 2014 , 4, 933-7	13
231	Triple-negative breast cancers: Are they always different from nontriple-negative breast cancers? An experience from a tertiary center in India. 2017 , 54, 658-663	6
230	Impact of St. Gallen surrogate classification for intrinsic breast cancer sub-types on disease features, recurrence, and survival in South Indian patients. 2020 , 57, 49-54	6
229	Interobserver Variability of Ki-67 Measurement in Breast Cancer. 2016 , 50, 129-37	14
228	Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes. 2017 , 49, 484-493	9
227	The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes. 2019 , 51, 706-717	2
226	Hydrophobic Fractionation Enhances Novel Protein Detection by Mass Spectrometry in Triple Negative Breast Cancer. 2010 , 3, 1-10	3
225	Clinicopathological Feature and Recurrence Pattern of Triple Negative Breast Cancer. 2010 , 79, 14	7
224	Triple Negative Breast Cancer Treatment: Use of Platinum and Platinum Analogs. 2012 , 03, 777-781	2
223	Inverted Apical CD24 and Weak EZH2 Expressions Are Phenotypic Characteristics of Pure Invasive Micropapillary Carcinoma of the Breast. 2013 , 03, 85-95	1
222	Crosstalk between integrin and receptor tyrosine kinase signaling in breast carcinoma progression. 2010 , 43, 311-8	64
221	Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells. 2015 , 48, 342-7	7
220	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. 2009 , 153, 13-7	36
219	Carcinoma of the Breast With Medullary-like Features: Diagnostic Challenges and Relationship With BRCA1 and EZH2 Functions. 2009 , 133, 1822-1825	18
218	Basal-like breast carcinoma: from expression profiling to routine practice. 2009 , 133, 860-8	58
217	Basal-like breast carcinoma: a phenotypically distinct entity. 2010 , 134, 130-3	34
216	Immunohistochemical and clinicopathologic characteristics of invasive ductal carcinoma of breast with micropapillary carcinoma component. 2005 , 129, 1277-82	52
215	Application of immunohistochemistry to breast lesions. 2008 , 132, 349-58	46

214	Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ. 2013 , 68, 638-43	11
213	Immunohistochemical profile of high-grade ductal carcinoma in situ of the breast. 2013 , 68, 674-8	6
212	The prognostic value of promoter methylation in early stage triple negative breast cancer. 2014 , 3, 1-11	40
211	Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases. 2012 , 13, 5081-6	17
210	Clinical significance of basal-like breast cancer in Chinese women in Heilongjiang province. 2012 , 13, 2735-8	4
209	Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience. 2013 , 14, 6013-7	14
208	Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer. 2013 , 14, 3223-8	12
207	Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India. 2014 , 15, 10577-83	18
206	Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand. 2014 , 15, 1187-92	13
205	Outcomes of triple-negative versus non-triple-negative breast cancers managed with breast-conserving therapy. 2014 , 15, 2577-81	13
204	Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients. 2016 , 17, 1973-8	12
203	MicroRNA and histopathological characterization of pure mucinous breast carcinoma. 2013 , 10, 22-7	11
202	Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. 2016 , 8, e924	37
201	Immunohistochemical profile and morphology in triple - negative breast cancers. 2013 , 7, 1361-5	22
200	A Comparison of Clinical Features, Pathology and Outcomes in Various Subtypes of Breast Cancer in Indian Women. 2015 , 9, PC01-4	9
199	Clinicopathological Study of Triple Negative Breast Cancers. 2016 , 10, EC05-EC09	3
198	Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. 2021 ,	3
197	Expression of the Markers for the Mammary Stem Cells and the Cellular Lineages of the Mammary Gland on Ductal Carcinoma In Situ. 2006 , 9, 184	

- 196 Genetic Markers in Breast Tumors with Hereditary Predisposition. **2008**, 85-105
- 195 Well-circumscribed solid malignancies. **2008**, 63-72
- 194 Molecular Signatures of Drug Resistance. **2009**, 271-294
- 193 Molecular Pathology of Breast Cancer. **2009**, 360-378
- 192 Interval Breast Cancer. **2009**, 657-666
- 191 Clinicopathologic Characteristics and Prognosis of Early Stage Triple Negative Breast Cancer: Comparison with Non-triple Negative Group. **2009**, 77, 37 2
- 190 Critical Roles of Tumorigenic and Migrating Cancer Stem/Progenitor Cells in Cancer Progression and their Therapeutic Implications. **2009**, 287-308
- 189 Gene Expression Profiling in Breast Cancer. **2009**, 123-136
- 188 The Genetics of Breast Cancer. **2009**, 39-54
- 187 Évaluation immunohistochimique du risque métastatique dans les cancers du sein débutants sur microbiopsies. **2009**, 193, 2045-2061
- 186 [Gene expression based multigene prognostic and predictive tests in breast cancer]. **2009**, 53, 351-9
- 185 Biology, Metastatic Patterns, and Treatment of Patients With Triple-Negative Breast Cancer. **2009**, 3, 39-47
- 184 Response to Paclitaxel in Node-positive Triple Negative Breast Cancer. **2010**, 79, 173
- 183 References. **2011**, 249-347
- 182 Malignant disease of the breast. **2011**, 707-749
- 181 Invasive Carcinoma. **2011**, 227-259 1
- 180 Familial Breast Cancer. **2011**, 279-286
- 179 Triple Negative Breast Carcinoma: A Comparative Study between Breast Lesion and Lymph Node Metastases: A Preliminary Study. **2011**, 2011, 1-6 0

- 178 Targeting triple-negative sporadic and hereditary BRCA-related metastatic breast cancer. **2011**, 050-066
- 177 Molecular subtypes and emerging therapeutic opportunities. **2011**, 24-36
- 176 Targeted therapies: EGFR inhibitors. **2011**, 70-80
- 175 Comment augmenter la performance des médicaments anti-HER?. **2012**, 529-551
- 174 Molecular Classification of Breast Carcinoma. **2012**, 365-379
- 173 Protéomique et cancer du sein: Techniques et perspectives. **2012**, 291-307
- 172 Mieux faire que les facteurs histopronostiques classiques TN et grade histopronostique : biochimie et immunohistochimie?. **2012**, 113-115
- 171 Understanding Triple-Negative Breast Cancer. **2013**, 97-116
- 170 Tight Junctions in Breast Cancer: Multifaceted Players in Tumorigenesis and Progression. **2013**, 169-196
- 169 Triple Negative and Younger Cases in Breast Cancer Showed Higher Ki67 Proliferation Index, Nuclear Grade and Histological Grade. **2013**, 38, 721-725
- 168 Differential Expression of Glu-Tubulin in Basal-Like Phenotype Carcinoma of the Mammary Gland. **2013**, 02, 66-71
- 167 Analyses of the cytologic findings of triple-negative breast cancer. **2013**, 52, 1-7
- 166 The Histopathology of Breast Cancer. 19-34
- 165 Ki-67 and p53 as Prognostic Factors for Luminal Type Breast Cancer. **2013**, 1, 21-27 1
- 164 Omics Technologies Applied in Breast Cancer Research. **2014**, 3-15
- 163 Synthetic Sickness with Molecularly Targeted Agents Against the EGFR Pathway. **2015**, 381-412
- 162 Triple-Negative Breast Cancer: Subtypes with Clinical Implications. **2015**, 157-175
- 161 Molecular Pathology of Lobular Carcinoma. **2015**, 95-105

- 160 Drug treatment for triple-negative metastatic breast cancer. **2015**, 4, 74
- 159 Clinical Applications for Immunohistochemistry of Breast Lesions. **2016**, 1406, 11-37
- 158 Evaluation of Patients for Metastases Prior to Primary Therapy. **2016**, 13-24
- 157 Breast Cancer Molecular Subtypes Among Moroccan Women. **2016**, 3, 47-54
- 156 Expression Profiling, mRNA. **2016**, 474-477
- 155 Basal-Like Carcinoma. **2016**, 324-331
- 154 Molecular Classification of Breast Cancer. **2016**, 203-219 ○
- 153 Risikoadaptierte Diagnostik und Therapie. **2017**, 43-53
- 152 A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran. **2017**, In Press,
- 151 Reparameterization of PAM50 expression identifies novel breast tumor dimensions and leads to discovery of a breast cancer susceptibility locus at 12q15.
- 150 The Effect of Histone Hyperacetylation on Viability of Basal-Like Breast Cancer Cells MDA-MB-231. **2017**, 5, ○
- 149 Respuesta al Tratamiento Neoadyuvante en pacientes con Cáncer de Mama en SOLCA-Guayaquil.. 253-258
- 148 Basic Molecular Pathology in Breast Carcinoma. **2018**, 357-372 ○
- 147 Necessity of In Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients with Equivocal HER2 Immunohistochemistry Results. **2018**, 6, 1-10
- 146 COMPARISON OF CLINICO-PATHOLOGICAL FEATURES AND PROGNOSIS OF TRIPLE-NEGATIVE AND NON-TRIPLE-NEGATIVE FEMALE BREAST CANCER PATIENTS. **2018**, 7, 3412-3418
- 145 IMMEDIATE AND LONG-TERM OUTCOMES OF DRUG TREATMENT IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER. **2018**, 8, 68-77 1
- 144 Evaluation of Patients for Metastases Prior to Primary Therapy. **2019**, 11-23
- 143 Tyrosine Kinase Inhibitors. **2019**, 529-539

- 142 Morphological and pathological features of basal-like breast cancer.. **2019**, 8, S503-S509 1
- 141 Modelo predictivo de met stasis en ganglios axilares no centinela en c ncer de mama. Variables emergentes. Estudio MOTTO, parte I. **2019**, 32, 127-132
- 140 Molecular Characterisation of Carcinoma Breast Using Surrogate IHC Markers-ER/PR, HER-2, CK5/6, EGFR, Ki-67. **2019**, 8, 3464-3468
- 139 Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer. **2020**, 11, 169-179 0
- 138 Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma. **2021**, 228, 153677 1
- 137 Pathological Aspects for Diagnosis. **2022**, 47-67
- 136 Molecular Basis of Breast Cancer. **2022**, 3-15
- 135 SOX10 is a highly specific biomarker of basal-like breast cancer. **2021**, 1 1
- 134 A clinicopathological study of triple-negative breast carcinoma in a patient cohort from a tertiary care center in Sri Lanka. **2020**, 63, 388-396
- 133 Bioinformatics analysis of key genes in triple negative breast cancer and validation of oncogene PLK1. **2020**, 8, 1637 3
- 132 Biological characteristics of breast cancers in a teaching hospital in Northwestern Nigeria. **2020**, 23, 211
- 131 Secretory carcinoma of breast: A diagnostic dilemma. **2020**, 63, S143-S145 1
- 130 Hereditary Breast and Ovarian Cancer Syndrome (BRCA) Gene: Concept, Pathways, Therapeutics, and Future. **2020**, 41, 9-14
- 129 Surrogate molecular classification of breast carcinoma: A classification in need or a dilemma indeed. **2020**, 4, 79
- 128 ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells.
- 127 Biological rationale for patient-specific treatment of breast cancer. Analysis of new data for breast cancer. **2020**, 15, 30-49 1
- 126 Breast cancer with HER 2 overexpressed. From laboratory to clinical practice. **2006**, 205-220
- 125 Targeted Therapy For Breast Cancer. **2008**, 309-342

124	Classification moléculaire des cancers du sein. Implications pratiques. 2007 , 289-295	
123	Artichoke extracts in cancer therapy: do the extraction conditions affect the anticancer activity?. 2020 , 6,	0
122	18F-fluorodeoxyglucose uptake on PET/computed tomography in association with androgen receptor expression and other clinicopathologic factors in surgically resected triple-negative breast cancer. 2021 , 42, 101-106	0
121	Differential expression between African-ancestry and White patients diagnosed with Triple-Negative Breast Cancer: EGFR, Myc, Bcl2 and E-Catenin as ancestry-associated markers.	
120	The breast. 571-687	1
119	Prevalence, morphologic features and proliferation indices of breast carcinoma molecular classes using immunohistochemical surrogate markers. 2009 , 2, 444-55	63
118	Understanding and treating triple-negative breast cancer. 2008 , 22, 1233-9; discussion 1239-40, 1243	167
117	p16INK4a expression in basal-like breast carcinoma. 2010 , 3, 600-7	18
116	The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. 2010 , 4, 35-41	389
115	New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. 2010 , 25, 1057-73	37
114	Absence of microsatellite instability in mucinous carcinomas of the breast. 2010 , 4, 22-31	11
113	Toponostics of invasive ductal breast carcinoma: combination of spatial protein expression imaging and quantitative proteome signature analysis. 2011 , 4, 454-67	7
112	The nuclear epidermal growth factor receptor signaling network and its role in cancer. 2011 , 12, 419-32	143
111	[Molecular classification of breast cancer in Morocco]. 2012 , 13, 91	6
110	YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression. 2007 , 2, 49-65	34
109	How transferable are recommendations of the era of treating conventionally defined breast cancer for the era of molecularly characterised breast cancer?. 2012 , 1, 156-8	
108	Correlations of ALDH1 expression with molecular subtypes and ABCG2 in breast cancer. 2012 , 1, 12-9	6
107	Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype. 2014 , 7, 5203-9	13

106	Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer. 2014 , 26, 550-7	3
105	Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer. 2015 , 5, 375-85	11
104	Large palpable ductal carcinoma in situ is Her-2 positive with high nuclear grade. 2015 , 8, 3963-70	2
103	Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine. 2015 , 5, 2330-43	17
102	HER2 status in molecular apocrine breast cancer: associations with clinical, pathological, and molecular features. 2015 , 8, 8008-17	8
101	Breast cancer intrinsic subtype classification, clinical use and future trends. 2015 , 5, 2929-43	296
100	[[18F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. 2016 , 6, 94-101	27
99	Breed- and age-related differences in canine mammary tumors. 2016 , 80, 146-55	4
98	A perspective on anti-EGFR therapies targeting triple-negative breast cancer. 2016 , 6, 1609-23	115
97	Breast cancer molecular subtypes: from TNBC to QNBC. 2016 , 6, 1864-1872	57
96	Role of the androgen receptor in triple-negative breast cancer. 2016 , 14, 186-93	59
95	Treatment Outcomes and Clinicopathologic Characteristics of Triple-Negative Breast Cancer: A Report from Cancer Institute of Iran. 2017 , 11, 37-42	3
94	The addition of calcitriol or its synthetic analog EB1089 to lapatinib and neratinib treatment inhibits cell growth and promotes apoptosis in breast cancer cells. 2017 , 7, 1486-1500	10
93	The Association between Molecular Subtypes of Breast Cancer with Histological Grade and Lymph Node Metastases in Indonesian Woman. 2018 , 19, 1263-1268	4
92	Molecular Subtypes of Breast Cancers from Myanmar Women: A Study of 91 Cases at Two Pathology Centers. 2017 , 18, 1617-1621	2
91	Renalase overexpression in ER-positive breast cancer. 2018 , 11, 1297-1307	3
90	Molecular classification predicts survival for breast cancer patients in Vietnam: a single institutional retrospective analysis. 2021 , 14, 322-337	1
89	The matricellular protein CCN6 differentially regulates mitochondrial metabolism in normal epithelium and in metaplastic breast carcinomas. 2021 , 1	

88	Metaplastic breast carcinoma:series of cases and literature review. 31,		
87	Triple-negative breast cancer and basal-like subtype : Pathology and targeted therapy. 2021 , 68, 213-219		2
86	MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade.. <i>Nature Communications</i> , 2022 , 13, 245	17.4	2
85	Biomarkers in Breast Carcinomas. 2022 , 309-333		
84	Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	1
83	Regulation of the tumor suppressor PTEN in triple-negative breast cancer.. <i>Cancer Letters</i> , 2021 , 527, 41-48	9.9	5
82	Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer.. <i>International Journal of Biological Sciences</i> , 2022 , 18, 2104-2115	11.2	0
81	Predicting HER2 Status in Breast Cancer on Ultrasound Images Using Deep Learning Method.. <i>Frontiers in Oncology</i> , 2022 , 12, 829041	5.3	0
80	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.. <i>Nature Communications</i> , 2022 , 13, 896	17.4	4
79	TrMab-6 Exerts Antitumor Activity in Mouse Xenograft Models of Breast Cancers.. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2022 , 41, 32-38	1.9	
78	Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors.. <i>Scientific Reports</i> , 2022 , 12, 4696	4.9	0
77	NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells.. <i>Cancers</i> , 2022 , 14,	6.6	1
76	A Novel Subset of Triple-Negative Breast Cancers with Unique Histology and Immunohistochemical Expression.. <i>Iranian Journal of Pathology</i> , 2022 , 17, 217-224	1.2	
75	PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas.. <i>Cancer Genetics</i> , 2022 , 264-265, 8-15	2.3	
74	Ligand-mediated nanomedicines against breast cancer: a review.. <i>Nanomedicine</i> , 2022 ,	5.6	0
73	Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients.. <i>Journal of Oncology</i> , 2022 , 2022, 1525245	4.5	2
72	Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 44	22.4	2
71	Data_Sheet_1.PDF. 2020 ,		

70	Does focal heterogeneity affect survival in postoperative ipsilateral multifocal and multicentric breast cancers?. <i>Revista Da Associação Médica Brasileira</i> , 2022 , 68, 405-412	1.4	
69	Targeting biologically specific molecules in triple negative breast cancer (TNBC). 2022 , 177-200		
68	Novel biomarkers in triple-negative breast cancer - role and perspective. 2022 , 29-60		
67	Role of immune system in TNBC. 2022 , 121-148		
66	Conventional adjuvant chemotherapy in combination with surgery, radiotherapy, and other specific targets. 2022 , 95-120		4
65	MYB RNA In Situ Hybridization Is a Useful Diagnostic Tool to Distinguish Breast Adenoid Cystic Carcinoma From Other Triple-negative Breast Carcinomas.. <i>American Journal of Surgical Pathology</i> , 2022 ,	6.7	1
64	Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies. <i>Frontiers in Oncology</i> , 2022 , 12,	5.3	0
63	Role of Lipoproteins in the Pathophysiology of Breast Cancer. <i>Membranes</i> , 2022 , 12, 532	3.8	1
62	The prognostic significance of immunophenotypes in canine malignant mammary tumors. <i>Arquivo Brasileiro De Medicina Veterinaria E Zootecnia</i> , 2022 , 74, 299-309	0.3	0
61	Cytokeratins 5 and 17 maintain an aggressive epithelial state in basal-like breast cancer. <i>Molecular Cancer Research</i> ,	6.6	
60	Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. <i>Cancer Letters</i> , 2022 , 215775	9.9	0
59	Breast. 2022 , 253-292		
58	Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers. <i>PLoS ONE</i> , 2022 , 17, e0270139	3.7	
57	A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm. <i>Frontiers in Oncology</i> , 12,	5.3	2
56	Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2022 , 12, 941	3.6	0
55	Intra- and Peritumoral Radiomics Model Based on Early DCE-MRI for Preoperative Prediction of Molecular Subtypes in Invasive Ductal Breast Carcinoma: A Multitask Machine Learning Study. <i>Frontiers in Oncology</i> , 12,	5.3	1
54	Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2022 , 8,	7.8	0
53	The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 176, 103757	7	1

52	The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.	
51	HER2-low breast cancer shows a lower immune response compared to HER2-negative cases. 2022 , 12,	2
50	Evaluation of CD44+/CD24- and Aldehyde Dehydrogenase Enzyme Markers in Cancer Stem Cells as Prognostic Indicators for Triple-Negative Breast Cancer. 2022 ,	
49	Distinctive gene expression patterns in pregnancy-associated breast cancer. 13,	1
48	Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features. 2022 , 23, 617-624	0
47	CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer. 13,	3
46	Identifying Phenotypic Concepts Discriminating Molecular Breast Cancer Sub-Types. 2022 , 276-286	0
45	Prognostic value of neutrophil-to-lymphocyte ratio for patients with triple-negative breast cancer: A meta-analysis. 2022 , 101, e29887	0
44	Clustering Molecular Subtypes in Breast Cancer, Immunohistochemical Parameters and Risk of Axillary Nodal Involvement. 2022 , 12, 1404	1
43	Disease Behavior and Treatment Response of Special Histological Types of Triple-Negative Breast Cancer. 2022 ,	0
42	A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer.	0
41	Can EGFR be a therapeutic target in breast cancer?. 2022 , 1877, 188789	1
40	Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. 2022 , 22,	1
39	Copper chelation inhibits TGF- β pathways and suppresses epithelial-mesenchymal transition in cancer.	0
38	A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer. 2022 , 12,	1
37	Intestinal Microbiota Influence Doxorubicin Responsiveness in Triple-Negative Breast Cancer. 2022 , 14, 4849	0
36	A genomic and transcriptomic study toward breast cancer. 13,	0
35	Chemopreventive and anti-tumor potential of vitamin E in preclinical breast cancer studies: a systematic review. 2022 ,	2

34	Circular RNAs: New layer of complexity evading breast cancer heterogeneity. 2023 , 8, 60-74	0
33	Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine.	0
32	Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer. 2023 , 13,	1
31	Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes. 2022 , 14, 5668	1
30	Triple-Negative/Basal-Like Breast Carcinomas. 2022 , 445-462	0
29	Long term trends of breast cancer incidence according to proliferation status. 2022 , 22,	0
28	Update on triple-negative breast cancers [highlighting subtyping update and treatment implication. 2023 , 82, 17-35	2
27	Breast lesions with myoepithelial phenotype. 2023 , 82, 53-69	1
26	A Clinical Cognizance of Molecular and Pathological Diagnostic Approach of TNBC. 2023 , 26-46	0
25	Hormone Receptors and HER-2 Status as Surrogates for Breast Cancer Molecular Subtypes Prognosticate for Disease Control in Node Negative Asian Patients Treated with Breast Conservation Therapy. 2011 , 40, 90-96	0
24	Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts.	0
23	Retarding breast tumor growth with nanoparticle-facilitated intravenous delivery of BRCA1 and BRCA2 tumor suppressor genes. 2023 , 13,	0
22	EGF-conjugated bio-safe luteolin gold nanoparticles induce cellular toxicity and cell death mediated by site-specific rapid uptake in human triple negative breast cancer cells. 2023 , 80, 104148	0
21	An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?. 2023 , 10, 19	0
20	Circulating Tumor Cells in Breast Cancer. 2023 ,	0
19	Sialyl LewisX/A and Cytokeratin Crosstalk in Triple Negative Breast Cancer. 2023 , 15, 731	0
18	Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis. 2023 , 13, 372	0
17	Could be FOXO3a, miR-96-5p and miR-182-5p useful for Brazilian women with luminal A and triple negative breast cancers prognosis and target therapy?. 2023 , 78, 100155	0

- 16 YAP transduction drives triple-negative breast cancer aggressiveness through modulating the EGFR-AKT axis in patient-derived xenograft cells. **2023**, 40, ○
- 15 Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. **2023**, 212, 115545 ○
- 14 Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis. **2023**, 22, ○
- 13 Statistical mining of triple-negative breast cancer-specific nanobodies among huge libraries from immunized alpacas. ○
- 12 In silico investigation of a novel anti EGFR Scfv LL 24 fusion protein induces apoptosis in malignant cells. ○
- 11 Clinical application of noninvasive prenatal testing in twin pregnancies: a single-center experience. 1-6 ○
- 10 Special Studies. **2013**, 279-304 ○
- 9 Invasive Breast Carcinomas. **2013**, 147-212 ○
- 8 The Normal Breast. **2013**, 1-14 ○
- 7 Comparative analysis of clinicopathological characteristics of central necrotizing breast cancer and basal cell-like breast cancer. 13, ○
- 6 Statistical mining of triple-negative breast cancer-specific nanobodies among huge libraries from immunized alpacas. ○
- 5 TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin. ○
- 4 Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival. ○
- 3 Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC). ○
- 2 Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy. **2023**, 12, 1156 ○
- 1 Diffusion-time dependent diffusion MRI: effect of diffusion-time on microstructural mapping and prediction of prognostic features in breast cancer. ○